Management of Tuberculosis: a handbook for clinicians by Street, Alan et al.

ManageMent of 
tuberculosis
A handbook for clinicians
Editors
Alan Street
Emma McBryde
Justin Denholm
Damon Eisen
First published 2012
This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 
Unported License. To view a copy of this license, visit http://creativecommons.org/
licenses/by-nc/3.0/ or send a letter to Creative Commons, 444 Castro Street, Suite 900, 
Mountain View, California, 94041, USA.
ISBN 978-1-105-69598-8
Disclaimer
Information in this publication has been obtained from the authors from sources believed 
to be reliable and up to date at the time of preparation. However, the editors and 
publisher are not responsible for errors or omissions or for any consequences from 
application of the information in this book, and make no warranty, express or implied, 
with respect to the currency, accuracy or completeness of the contents. Application of 
this information in particular clinical situations remains the responsibility of the medical 
practitioner.
Publisher and distributor:
Victorian Infectious Diseases Service
Royal Melbourne Hospital, Main Building
Grattan Street, Parkville, Victoria 3050
Australia
Telephone: (03) 9342 7212
Facsimile: (03) 9342 7277
Website: www.vids.org.au
iii
Preface
In the early 2000s, Dr Allen Yung wrote TB management guidelines for use by 
Victorian Infectious Diseases Service (VIDS) doctors in the clinic and on the 
ward at The Royal Melbourne Hospital (RMH). They reflected Allen’s unparal-
leled clinical experience in the clinical management of TB, chiefly at Fairfield 
Hospital and in the latter years of his career at RMH. These guidelines bore the 
hallmarks of all of Allen’s published material: they were carefully thought out 
and organised, approached problems from the doctor’s and patient’s perspective, 
were pitched at junior doctors (but consultants found them very useful as well!), 
and contained a wealth of information and advice that was often not readily 
available in published texts. But first and foremost, the guidelines were practical, 
and they became an indispensable guide to the busy clinician faced with the 
common and uncommon issues that arise in the course of TB management.
The time has come to update Allen’s original guidelines. The aim of providing 
useful, practical information – the essence of the original document – remains 
the same, but all chapters have been updated, and new information has been 
included about many topics. To highlight a few important areas, there is now a 
substantial section devoted to TB interferon gamma release assays (IGRA), 
including advantages and limitations of these tests and practical advice about 
management of patients with discordant IGRA/tuberculin skin test results. The 
chapter on drug-resistant TB has been completely revised, and includes informa-
tion about the threat of XDR-TB. A new chapter discusses diagnosis and man-
agement of HIV infection and TB, a section has been added about use of BCG for 
treatment of bladder cancer, and non-tuberculous mycobacterial infections have 
been consolidated into a single chapter. (We did not include M. leprae because 
comprehensive guidelines exist elsewhere for this specialised infection.)
The target audience for this clinical handbook remains doctors working in RMH 
and some of the information about public health aspects of management reflects 
practice in Victoria. We hope, however, that these guidelines could be useful to 
other doctors working in tuberculosis clinics in Australia. Naturally, some of the 
material in the handbook will not be applicable to all settings, such as resource-
poor countries.
This handbook is not intended to be a comprehensive document and we have not 
included an extensive list of references as this information can be readily found 
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in specialised TB texts and in international TB guidelines. In the same vein, we 
have deliberately chosen not to assign an evidence ranking to each of the recom-
mendations. The main focus of the handbook is on clinical management of TB 
(and other mycobacterial infections); other important areas such as diagnosis, 
microbiology, public health aspects, TB in poor countries and paediatric TB are 
not covered in detail. Finally, readers should bear in mind that because of the 
inevitable delay between the writing and publication of this handbook, it is 
possible that some of our management recommendations may need to be 
modified in the light of recently published information.
Our thanks go to all the contributors who gave so willingly of their time and 
effort, and who have been so patiently waiting for their words to see the light of 
day!
Alan Street
Emma McBryde
Justin Denholm
Damon Eisen
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1.1 Initial or intensive (‘bactericidal’) phase of treatment
Antituberculous treatment is almost always commenced without knowing the 
antibiotic susceptibilities of the causal organism. The initial regimen usually 
comprises four drugs (see Table 1.1.1).
1.1.1 HRZE regimen (the standard four-drug regimen)
Drugs: isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)
●● Isoniazid is the most effective bactericidal drug.
●● Rifampicin and pyrazinamide are the most important sterilising drugs 
and are thought to act by killing different populations of semi-dormant 
organisms (persisters).
●● Isoniazid and rifampicin are the most effective drugs at preventing the 
emergence of resistance to other drugs.
●● Pyrazinamide has good activity against intracellular organisms and is most 
active in the first 2 months of treatment; it enables the total duration of 
treatment to be shortened to 6 months (for fully drug-sensitive infections).
●● Ethambutol is a bacteriostatic drug that is given to prevent the emergence 
of resistance.
Duration of initial (intensive or bactericidal) phase
Minimum duration is 2 months (or 8 weeks). Pyrazinamide should be continued 
until sputum is acid-fast bacillus (AFB) smear-negative or for 2 months, which-
ever is longer.
2 Management of tuberculosis
Streptomycin can be administered instead of ethambutol but is now difficult to 
obtain and is rarely used.
1.1.2 HRZ regimen
Drugs: Three drugs: isoniazid (H), rifampicin (R) and pyrazinamide (Z)
Ethambutol is given to prevent the emergence of additional resistance in the 
event that isoniazid resistance is already present. Ethambutol is almost always 
included in the initial regimen because more than 90% of TB in Victoria occurs 
in individuals born in countries with a high TB incidence and in whom the rate 
of isoniazid resistance is 5–10% (or higher). Ethambutol is omitted from the 
initial regimen if the TB isolate is known to be fully susceptible to first-line 
agents before treatment has been started.
Omission of ethambutol can also be considered if the patient meets the following 
conditions (indicating a 5% or less likelihood of isoniazid resistance):
●● age >  75 and likely to have acquired TB infection before TB treatment 
became available (early 1950s)
●● no previous treatment with antituberculous medications
●● birth in Australia, UK, Western Europe or North America, and no pro-
longed residence in TB-endemic country
●● no exposure to a drug-resistant case
●● not HIV-infected.
The reason for wanting to omit ethambutol is to avoid the potential for ocular 
toxicity, especially in elderly patients. However, if there is any doubt, err on the 
side of caution and use ethambutol.
Ethambutol should not be given to children who are too young to be monitored 
for visual toxic effects. Ethambutol should also be avoided in patients with 
Table 1.1.1 Initial dosing of antituberculosis therapy (daily regimen)
Drug Dose
Isoniazid 10 mg/kg (up to 300 mg) orally, daily
Rifampicin 10 mg/kg (up to 600 mg) orally, daily
Ethambutol 15 mg/kg (up to 1200 mg) orally, daily
Pyrazinamide 25–40 mg/kg (up to 2 g) orally, daily
+ Pyridoxine 25 mg orally, daily
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impaired renal function. If ethambutol is not used in adults, moxifloxacin should 
be included in the regimen.
1.1.3 HRE regimen
Drugs: Three drugs: isoniazid (H), rifampicin (R) and ethambutol (E)
Pyrazinamide should be routinely included in the regimen to enable short-course 
(6 months) therapy to be given, but very occasionally it may have to be omitted 
(e.g. in a patient unable to tolerate pyrazinamide or in a patient with poorly con-
trolled gout), in which case treatment duration has to be extended to 9 months 
(see below).
1.1.4 Moxifloxacin
Moxifloxacin is not part of standard regimens, but has excellent in vitro activity 
and is already used to treat patients with multidrug-resistant TB. Preliminary 
clinical data indicate that it is as effective as ethambutol in the initial phase of 
standard treatment with a four-drug regimen and that its bactericidal activity is 
similar to that of rifampicin and isoniazid. For fully drug-sensitive infections, 
moxifloxacin is indicated in initial regimens for patients unable to take etham-
butol. It may also be an effective substitute if either isoniazid or rifampicin 
cannot be used, but further data are needed before this can be recommended 
more firmly. Large ongoing randomised controlled trials are investigating its role 
in abbreviated, 4-month treatment regimens.
1.1.5 Regimens for suspected or proven multidrug-resistant TB
The standard HRZE regimen will provide adequate initial treatment for 
 isoniazid-resistant infections, but not for multidrug-resistant TB (MDR-TB). 
Fortunately, MDR-TB is still rare (1–2% of notified cases in Victoria and in Aus-
tralia, although it is likely that this figure will increase in the future), so empiri-
cal MDR-TB coverage only has to be considered under special circumstances. For 
further details regarding indications and regimens for empirical MDR-TB treat-
ment, see Chapter 3, Evaluation and treatment of drug-resistant tuberculosis.
1.1.6 Starting treatment in older patients
Older patients (arbitrarily those aged >  70 years) often experience nausea or 
vomiting when antituberculous therapy is started. Tolerability can be improved if 
the drugs are introduced gradually, with a 1–2 day interval between the addition 
of each agent (given at full dose). Ethambutol is least likely to cause GI intolerance, 
so it can be started together with isoniazid, followed by rifampicin then pyrazina-
mide. This strategy does not increase the risk of inducing drug resistance.
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1.2 Continuation (‘sterilisation’) phase of treatment
Quadruple therapy is continued until susceptibility results are known. Ethambu-
tol should be discontinued before the end of the 2-month initial phase if the 
isolate is fully sensitive to all first-line drugs, providing the patient has responded 
satisfactorily and has been adherent with therapy. Pyrazinamide should be con-
tinued for a minimum of 2 months, and beyond this time if susceptibility results 
are still pending or the patient remains sputum smear positive. In the continua-
tion (‘sterilisation’) phase the regimen can be simplified.
1.2.1 M. tuberculosis fully sensitive to all first-line drugs
If the isolate is sensitive to all four drugs, pyrazinamide and ethambutol are 
ceased, and double therapy with rifampicin and isoniazid is continued to 
complete a 6-month course of treatment (unless there is an indication to treat for 
longer than 6 months – see below).
This regimen in shorthand is 2 HRZE/ 4 HR (the regimen 2 HRZ/ 4 HR is also 
acceptable when ethambutol is not used in the initial phase, as discussed above).
This standard regimen (2 HRZE/ 4 HR or 2 HRZ/ 4 HR) should be used in all 
patients with fully sensitive M. tuberculosis. It has the ability:
1. to cure patients rapidly
2. to cure the great majority of patients with bacilli initially resistant to 
isoniazid
3. to prevent therapeutic failure due to the emergence of acquired resistance.
For M. tuberculosis resistant to one or more first-line drugs refer to Chapter 3, 
Evaluation and treatment of drug-resistant tuberculosis.
Caveats to the standard 2 HRZE/ 4 HR (or 2 HRZ/ 4 HR) regimen
●● If pyrazinamide is not used in the initial phase, the total duration should 
be at least 9 months; the regimen in shorthand is 2 HRE/ 7 HR. (The term 
‘short course’ therapy implies a duration of 6 months; it can be used only 
if pyrazinamide is included in the initial 2 months of treatment.)
●● Isoniazid should be used for the full duration of any treatment regimen 
unless there are specific reasons against it, such as adverse effects or bac-
terial resistance.
●● Rifampicin is an essential drug for any regimen less than 12 months.
●● In the standard regimen the 6-month course should be regarded as a min-
imum period. A 7-month continuation phase should be given in patients 
with cavitary disease and who have positive sputum 2 months into initial 
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treatment. Patients not treated with pyrazinamide in the initial regimen 
should also have a 7-month continuation phase.
1.2.2 Duration of treatment of extra-pulmonary TB due to fully sensitive 
M. tuberculosis
Most forms of drug-sensitive extrapulmonary TB can be treated with a standard 
6-month short course regimen, unless the disease is extensive or complicated. 
Specific forms of extrapulmonary TB that require a longer course of treatment 
are:
●● disseminated (miliary) tuberculosis – 9 to 12 months
●● tuberculous meningitis – 12 months
●● skeletal tuberculosis – depending on the extent of disease, 6 to 9 months.
1.2.3 If no M. tuberculosis is cultured
Sometimes the diagnosis of TB is not confirmed by a positive culture, for example 
if:
●● specimens have not been sent for TB culture (e.g. excised lymph node 
tissue put in formalin)
●● few organisms are present
●● the tuberculous disease is inactive
●● the pre-treatment diagnosis of TB is wrong and the patient has another 
condition altogether
●● the patient has an atypical mycobacterial infection caused by a difficult-
to-culture organism.
If AFBs are visible in smears or tissue sections but are not cultured, one or more 
of the following molecular tests is recommended:
●● TB PCR
●● generic mycobacterial PCR – if non-tuberculous infection suspected
●● RNA polymerase B TB PCR (for rifampicin resistance mutations) – if 
MDR-TB suspected.
In patients with culture-negative pulmonary disease, the major indicators of 
response to empiric TB treatment are radiological and clinical.
If there is symptomatic and/or CXR improvement after 2 months of treatment 
with HRZE, this suggests that the disease is active, and treatment should be con-
tinued. The American Thoracic Society (ATS) guidelines recommend HR for 
only another 2 months (that is, a 4-month treatment course), but in VIDS we take 
6 Management of tuberculosis
a more conservative approach, treating for longer and also covering the possibil-
ity of isoniazid-resistant disease (but continuing isoniazid throughout). The 
regimen used in VIDS is:
2 HRZE/ 7 HRE
Failure of the CXR to improve is strongly suggestive that the abnormality is the 
result of either previous (not current) tuberculosis or another process. TB therapy 
can usually be stopped since the patient will have been adequately treated for 
latent TB at this stage.
1.3 Intermittent therapy
WHO and other international authorities recommend routine use of intermit-
tently administered, directly observed short course therapy (DOTS) for all tuber-
culosis cases. Practice in Australia varies from state to state: in Victoria, patients’ 
treatment is closely supervised by the TB Control Program and the treating clini-
cian, and DOTS is provided on a case-by-case basis for patients with anticipated 
or documented adherence problems.
Duration of therapy and treatment outcome are the same for DOTS as for daily 
therapy. In shorthand the standard DOTS regimen is 2 HRZE/ 4 H3R3. Twice-
weekly intermittent therapy is recommended in the United States but not in the 
WHO or UK National Institute of Health and Clinical Excellence (NICE) guide-
lines. Daily therapy is usually given initially, followed by a switch to intermittent 
therapy after 2 to 8 weeks.
The practice of giving one or two drugs daily and others intermittently (three 
times per week) is inadvisable and dangerous if the daily dose is not accompa-
nied by another drug also given daily, because of the risk of developing resistance 
to a single daily drug.
1.4 Patients with renal impairment
Isoniazid, rifampicin, pyrazinamide, prothionamide and ethionamide are elimi-
nated almost entirely by hepatic metabolism or by biliary excretion.
Isoniazid and rifampicin
Isoniazid and rifampicin are the safest antituberculous drugs in patients with 
renal impairment. Isoniazid can be given in standard doses in renal impairment, 
including dialysis patients. Some sources recommend dose reduction for 
rifampicin but the ATS 2003 guidelines support full-dose rifampicin and this is 
the practice in VIDS.
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Pyrazinamide
There is disagreement regarding pyrazinamide dosing in patients with moderate 
to severe renal impairment. British Thoracic Society (BTS) guidelines suggest 
that it can be given in standard dosage whereas the ATS guidelines suggest 
dosage reduction to 25–35 mg/kg three times a week if the GFR is < 30 mL/min. 
We suggest following the specific dosing recommendations in Therapeutic 
Guidelines: Antibiotic, which advise pyrazinamide dose reduction only with 
severe renal impairment (GFR < 10 mL/min) (see Table 1.4.1).
Streptomycin, amikacin and other aminoglycosides
Aminoglycosides are excreted exclusively by the kidneys. It is best to avoid these 
drugs altogether in patients with renal impairment, but if their use is absolutely 
essential, monitoring of levels is done to guide appropriate dosing.
Ethambutol
Ethambutol is excreted predominantly by the kidney. Although dosage can be 
adjusted according to degree of renal impairment (see Table 1.4.1), the availabil-
ity of moxifloxacin means that ethambutol should rarely need to be used in the 
setting of renal impairment.
Ethionamide/prothionamide
These drugs are metabolised and not renally excreted.
●● For GFR > 10 mL/min — no change in dose
●● For GFR < 10 mL/min — 5 mg/kg/day
1.5 Patients with pre-existing liver disease
●● Patients with pre-existing liver disease or abnormalities of liver function 
(e.g. due to chronic hepatitis B and C, alcohol or other forms of liver disease) 
are at increased risk of additional liver damage from antituberculous drugs.
●● Regular monitoring of LFTs and close clinical follow-up is required for 
these patients – weekly for 2 weeks then fortnightly for 2 months with 
subsequent monthly follow-up if stable.
●● Rifampicin, isoniazid and pyrazinamide are all potentially hepatotoxic.
●● Isoniazid and rifampicin can generally be used with careful monitoring 
(as discussed in more detail below), although the combination is best 
avoided in patients with severe liver disease.
●● Pyrazinamide has the highest rates of hepatotoxicity – it can also be used 
with careful monitoring but is best avoided in patients with severe liver 
disease.
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●● Drugs that can be used without additional monitoring in liver 
disease are aminoglycosides, capreomycin, cycloserine, ethambutol and 
fluoroquinolones.
1.5.1 Patients with pre-existing impaired liver function
●● If the LFTs are mildly abnormal and likely to be due to TB, disregard but 
monitor carefully.
●● If the abnormal LFTs are due to chronic liver disease, use either rifampicin 
or isoniazid at a lower dose initially (e.g. 450 mg and 200 mg respectively 
for adults with body weight ≥ 50 kg) with pyrazinamide and ethambutol. 
The other drug, i.e. either isoniazid or rifampicin, may be added after 1 or 
2 weeks if there is no deterioration of liver function and no symptoms of 
hepatitis.
●● Increases in aminotransferases are common. Drugs should be stopped if 
aminotransferases are > 5× the upper limit of normal, or ≥ 3× in the pres-
ence of symptoms. Otherwise, treatment can be continued, providing 
monitoring is more frequent and information about symptoms of hepati-
tis is reinforced.
●● More information about management of deterioration in liver function 
while on therapy is included in Chapter 2, Management of patients on 
treatment for tuberculosis.
1.5.2 Patients with pre-existing severe liver disease
●● The World Health Organization (WHO) suggests either 2 SHRE/ 6 HR or 
9 RE, or 2 SHE/ 10 HE (S = streptomycin) for patients with liver failure.
●● ATS guidelines suggest HRE for 9 months (with cessation of ethambutol if 
fully sensitive), and in patients with cirrhosis, RE with a fluoroquinolone 
or cycloserine for 12–18 months.
Both these regimens avoid pyrazinamide, but still entail administration of iso-
niazid and/or rifampicin.
If hepatotoxic medications must be avoided altogether (e.g. hepatic decompensa-
tion or severe LFT abnormalities), a suggested regimen is ethambutol plus moxi-
floxacin plus an injectable aminoglycoside plus (possibly) cycloserine.
1.6 Adjunctive use of corticosteroids in tuberculosis
Although corticosteroids are a well recognised risk factor for TB reactivation in 
patients with latent TB infection, they are also of proven benefit in some forms of 
TB when given as an adjunct to antituberculous therapy.
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1.6.1 Considerations before use
Exacerbation of underlying chronic hepatitis B and strongyloidiasis
These conditions share a common geographical distribution with TB. Unmoni-
tored corticosteroid use can lead to a flare of hepatitis B or to the development of 
disseminated strongyloidiasis. Hepatitis B surface antigen status should be 
known in all patients before use. Strongyloides serology should be requested in 
all refugees (if not done previously) and in overseas-born patients with unex-
plained gastrointestinal, skin or respiratory symptoms, or with unexplained 
eosinophilia.
Side-effects of corticosteroids
Diabetes mellitus, osteoporosis and gastrointestinal ulceration are some of the 
many side-effects of corticosteroids. Blood glucose levels should be checked peri-
odically, especially during the initial, higher-dose phase of treatment, and more 
intensively in those with pre-existing diabetes. The risk of osteoporosis is low 
with short-term corticosteroid therapy but vitamin D levels should be checked 
and corrected if low, and calcium intake should be optimised. Patients with a 
past history of peptic ulcer disease or those on regular NSAID treatment should 
be considered for gastro-protective therapy with a proton pump inhibitor.
1.6.2 Definite indications
Corticosteroids should be used as adjunctive therapy to antituberculous treat-
ment in the following situations.
Pericarditis
Adjunctive corticosteroid therapy for tuberculous pericarditis is recommended. 
Multiple smaller trials have demonstrated benefits including enhanced resolu-
tion of effusion and lower mortality, although not with clear statistical signifi-
cance. Meta-analysis of four of the trials showed benefits including reduced 
mortality and reduced requirement for repeat pericardiocentesis, again with very 
broad confidence intervals. The authors of the meta-analysis concluded that cor-
ticosteroids have an important clinical benefit although trials to date have been 
too small to demonstrate this effect beyond doubt. Corticosteroids have not been 
shown to prevent the later complication of constrictive pericarditis. Input from 
the cardiology and cardiothoracic surgical service should be requested in every 
patient with suspected tuberculous pericarditis.
Recommended dosing: prednisolone 60 mg daily for 4 weeks, 30 mg daily for 4 weeks, 
15 mg daily for 2 weeks, 5 mg daily for 2 weeks (total 12 week course)
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Meningitis (TBM) and intracerebral tuberculoma
Adjunctive corticosteroid therapy is of proven benefit in TBM. A 2008 meta-analy-
sis of seven trials including 1140 participants demonstrated a significantly reduced 
risk of death and disabling residual neurological deficit. This benefit was applied to 
all stages of TBM (Medical Research Council stage I–III). CNS damage in TBM 
results from occlusion of ventricular foramina (causing hydrocephalus), vasculitis 
of perforating blood vessels (causing cerebral infarction) and involvement of 
cranial nerves. Corticosteroids exert their beneficial effect by reducing the inflam-
mation in the sub-arachnoid space that is responsible for these complications.
In TBM patients administered corticosteroids, symptoms such as fever, headache, 
malaise and delirium may improve more rapidly, and CSF may normalise (in 
protein level and cell count) more quickly than otherwise. All these clinical and 
laboratory parameters may rebound when corticosteroids are discontinued, even 
when the dose has been carefully tapered. Despite an oft-cited concern that ster-
oid-induced suppression of meningeal inflammation could reduce CNS penetra-
tion of antituberculous drugs, there is no difference in CSF levels of 
commonly-used agents with or without concomitant corticosteroids.
Most experts would also advise routine use of adjunctive corticosteroids in 
patients with intracerebral tuberculoma, even though corticosteroids are not of 
proven benefit in this situation.
Recommended dosing: dexamethasone 12–16 mg daily for 3 weeks then tapered over the 
following 3 weeks or prednisolone 60 mg daily for 3 weeks then tapered over the following 
3 weeks (From Prasad & Singh, 2008)
HIV-associated immune reconstitution syndrome
HIV-infected patients who are being treated for TB can develop an exaggerated 
(‘paradoxical’) inflammatory reaction when antiretroviral therapy is commenced. 
Clinical complications such as worsening respiratory distress or increased intrac-
ranial pressure can develop as a result (see Chapter 6, HIV and tuberculosis). Risk 
factors are a short interval (< 4 weeks) between starting TB and HIV therapy, a low 
CD4 cell count (< 100 per microlitre) and disseminated disease. In a randomised 
controlled trial, corticosteroid therapy was shown to be effective treatment for 
this condition.
1.6.3 Possible indications
There is limited evidence for the benefit of corticosteroids as adjunctive therapy 
to antituberculous treatment in settings other than TBM and TB pericarditis. In 
these other settings, adjunctive corticosteroids are sometimes used in 
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exceptional circumstances, such as in the seriously ill patient where more rapid 
resolution of symptoms may be beneficial. A clinical decision about corticoster-
oid use in these settings should be made on a case-by-case basis.
Endobronchial tuberculosis
In paediatric patients, enlarged intrathoracic lymph nodes can compress bronchi 
leading to lobar or segmental collapse-consolidation and respiratory distress; 
this often improves with use of corticosteroids. Bronchial obstruction is also a 
complication of endobronchial TB, but there is no evidence of benefit for corti-
costeroid therapy in this situation.
Tuberculous pleural effusion
A 2007 meta-analysis reported that adjunctive use of corticosteroids in TB 
pleural effusion was associated with reduction in size of the effusion at 4 weeks, 
earlier resolution of symptoms and less residual pleural thickening, but the mag-
nitude of the benefit was small. Studies have not consistently demonstrated long-
term reduction in morbidity or preservation of respiratory function after 
completion of antituberculous treatment.
Extensive pulmonary disease
There have been numerous controlled studies of the possible role of corticoster-
oids in the treatment of pulmonary tuberculosis. Some have demonstrated 
benefits early in the course of disease treatment, including a more rapid clinical 
and radiological improvement, but this benefit is brief, with no demonstrated 
difference between steroid and control groups at 3–6 months. Studies have also 
described rebound worsening of clinical status with corticosteroid withdrawal. 
On the basis of this evidence, corticosteroids cannot be recommended for the 
sole indication of pulmonary disease. However, some experienced clinicians 
would use corticosteroids for the occasional patient who presents with extensive 
pulmonary disease, respiratory distress and severe systemic symptoms such as 
marked weight loss (‘galloping consumption’).
Ureteric tuberculosis
Renal tract tuberculosis involving the ureter can lead to obstruction, hydrone-
phrosis and renal insufficiency. Primary management of mechanical renal 
obstruction should be via early urological intervention with ureteric stenting 
or percutaneous nephrostomy. Older trials have demonstrated that corticoster-
oids can reduce ureteric stenosis and stricture in patients with ureteric tuber-
culosis, but their concurrent use with modern urological interventions has not 
been investigated.
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Other indications
Corticosteroids have been used in a variety of other forms of tuberculosis. 
Examples include gastrointestinal TB (to prevent stricture formation), vertebral 
TB with involvement of the epidural space (to reduce the risk of spinal cord or 
nerve root compression) and tuberculous arthritis (to prevent joint ankylosis). 
Despite a weak or non-existent supportive evidence base, there are some compel-
ling case reports in the literature and anecdotes from experienced clinicians that 
are hard to ignore, so corticosteroid use in these situations should not be dis-
missed entirely.
1.7 Interrupted or incomplete treatment
Accidental or necessary interruptions to TB treatment are common. After a 
patient has an interruption to TB treatment a decision must be made about the 
best course of further treatment. In some circumstances it may be possible to 
restart the interrupted regimen, whereas a completely new course of treatment is 
required in other instances.
A TB regimen can be considered as a requisite number of days (or doses) of 
therapy. If a treatment interruption of any length occurs, the usual course of 
action is to prolong the regimen to compensate for any missed doses.
There is no evidence basis for recommendations relating to treatment interrup-
tion, and the definition of a treatment interruption requiring intervention varies 
widely between guidelines. Factors related to the patient’s immune status and 
extent of disease must also be considered. The recommendations below are only 
for isolates treated with first-line agents. In some situations, these recommenda-
tions advocate a more cautious approach than that found in international guide-
lines, as described below.
1.7.1 Durations of interruptions of therapy requiring further intervention
●● Interruption for ≥ 14 days during initial phase of therapy
●● Interruption for ≥ 1 month during the continuation phase of therapy
1.7.2 Restarting a new treatment course
The TB treatment regimen should be restarted from the beginning, without com-
pensation for the duration of previous therapy taken, in the following situations:
●● Interruption of > 14 days in initial phase of therapy, or
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●● Interruption of > 2 months in continuation phase. (Note: This differs 
from WHO guidelines, which recommend only restarting in this situa-
tion if the patient was also smear positive before or after interruption.)
1.7.3 Recommencing the previous regimen
The TB treatment regimen can be recommenced in circumstances other than 
those listed above, the aim being to provide the patient with the same total 
number of doses of treatment that were originally planned.
For patients who interrupt therapy for less than 2 months in the continuation 
phase, the WHO recommendation would be for the patient to receive treatment 
for a total of 6 months (180 daily doses, or equivalent) by adding the lapsed period 
to the originally planned stopping date. However, our practice in this situation 
(not evidence-based) is often more conservative, and we may extend the continu-
ation phase to provide a total duration on antituberculous therapy of 9 months. 
We may also consider restarting rather than recommencing treatment in patients 
who were smear or culture positive at the time of the treatment discontinuation, 
in immunosuppressed patients, and in patients at higher risk of treatment failure 
(e.g. with extensive or cavitary disease, or severe underlying lung pathology such 
as silicosis), depending on factors such as whether treatment was ceased early in 
the continuation phase.
Key steps in restarting or recommencing treatment
●● Identify and address the issues that contributed to the interruption of 
treatment.
●● Obtain new sputum samples to determine smear status and to undertake 
repeat sensitivity testing.
●● Discuss arrangements for enhanced supervision or directly observed 
therapy (DOT) with the public health TB program and implement other 
measures to enhance adherence (e.g. support for financial, accommoda-
tion, transport, or substance abuse problems).
1.8 Indicators of treatment failure
1.8.1 Definition of treatment failure
Treatment failure, an entity distinct from disease relapse, is defined by failure of 
resolution or recrudescence of active disease while on therapy, rather than recur-
rence after completion of treatment.
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●● Positive TB cultures while on treatment any time after completion of the 
4th (ATS) or 5th (WHO) month of antituberculous therapy
or
●● Reversion from a negative culture to a positive culture while on treatment 
any time after completion of the 3rd month of antituberculous therapy.
In addition, treatment failure should be considered if cultures are pending and 
the individual has clinical deterioration or radiological deterioration suggestive 
of treatment failure. After 3 months of therapy containing HR, 90–95% of 
patients should be culture negative. Positive cultures after this time should lead 
to close monitoring for impending treatment failure.
1.8.2 Common causes of treatment failure
●● Drug resistant isolate
●● Poor medication compliance – the most common reason
●● Low drug levels. Consider:
– drug interactions
– poor absorption
– incorrect dose calculation
– dispensing or administration errors.
1.8.3 Management of treatment failure
●● Obtain repeat samples for culture and sensitivity testing. The laboratory 
should be requested to check susceptibility of the most recent isolate to 
second-line, as well as first-line, agents.
– Pulmonary TB: three consecutive daily sputum samples (spontaneous 
or induced); if unobtainable, organise bronchoscopy.
– Extrapulmonary TB: renewed attempts should be made to obtain appro-
priate specimens for AFB smear, culture and susceptibility testing.
●● If the patient is clinically stable, the current regimen may be continued 
until new susceptibility results are available to guide the choice of 
medications.
●● If the patient is clinically deteriorating the regimen should be modified as 
per the recommendations in Chapter 3, Evaluation and treatment of drug-
resistant tuberculosis.
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●● Directly observed therapy (DOT) should be instituted if the individual is 
not currently under this method of care – discuss with the public health 
TB program.
– Address social and other issues that may have contributed to treat-
ment failure.
– For drug-sensitive infections, extend duration of therapy to 6 months 
after culture conversion.
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2.1 Site of care and isolation
Commencement of therapy as an outpatient can be considered for patients who are 
non-infectious (e.g. lymph node TB or truly asymptomatic pulmonary TB) who are 
otherwise clinically stable and who have satisfactory social circumstances.
Patients with bacteriologically confirmed or clinically suspected active pulmo-
nary TB should be admitted to hospital and placed in a single TB isolation room 
maintained under negative pressure.
Patients moving outside the isolation room should wear N95 masks. Where 
possible investigative procedures for these patients should be scheduled at times 
when they can be performed rapidly and when patients are not held in crowded 
waiting areas for long periods.
The number of healthcare workers (HCW) or visitors entering an isolation room 
should be kept to a minimum. All persons entering an isolation room should 
wear an N95 mask.
TB patients should be educated about the mechanisms of TB transmission, and 
the need to cover their mouths and noses when coughing or sneezing to minimise 
the droplet spread of mycobacteria in expelled air.
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Most patients are no longer infectious 2 weeks after commencing an HRZ-con-
taining regimen as cough has usually lessened markedly and most of the bacilli 
are dead. However one should be more guarded with a patient who continues to 
have a hacking cough, has cavitary disease or has plentiful AFB on sputum 
smears. This applies particularly to the multidrug-resistant case. In practice, we 
tend to err on the side of caution and maintain isolation in hospital until the 
patient is discharged, unless the admission is prolonged.
2.2 Notification
All patients started on full antituberculous treatment, whether or not the diagno-
sis of TB has been confirmed at the time, must be notified to the relevant state or 
territory public health TB program. In Victoria this is the TB Control Program, 
Department of Health (DoH). Tuberculosis is a group B disease, requiring 
written notification within 5 days.
●● For some situations involving patients with smear positive pulmonary TB, 
contact tracing may be a matter of urgency, in which case notify the TB 
program by telephone (in Victoria, on 9096 5144 or 1300 651 160). Exam-
ples include:
– close contact with infants and young children
– recent travel on an international flight
– exposure in congregate settings, such as prison, nursing homes and 
other care facilities.
●● In Victoria, complete the Enhanced Notification of TB form – this is avail-
able online at <http://ideas.health.vic.gov.au/notifying/what-to-notify.asp>.
●● Copy notification form and file in the patient’s history.
●● Return the notification form – in Victoria to DoH by either:
– Mail (pre-printed envelopes available) to 
Communicable Diseases Control (Public Health Branch) 
Victorian Government Department of Human Services 
Reply Paid 65937 
Melbourne VIC 8060
– Fax to 1300 651 170.
2.3 Contact tracing
Tracing of the index patient’s community contacts is the responsibility of the 
relevant state or territory public health TB program, and should not be initiated 
by the hospital medical staff unless there is an untreated symptomatic contact 
who may need more urgent management. Concerned family, social or work 
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contacts who request ‘testing’ should be referred to the TB program public health 
nurse who has been assigned to the case.
In contrast to contacts in the community, if hospital staff or patients have occu-
pational exposure to a hospital patient with unrecognised TB before institution 
of airborne precautions, contact tracing is the responsibility of the hospital. It is 
usually carried out by infection control personnel, in consultation with relevant 
specialists such as infectious diseases or respiratory physicians or microbiolo-
gists. The relevant TB program should be notified of these measures.
Patients receiving treatment of latent TB do not need to be notified.
2.4 Before starting therapy
2.4.1 Educate patient and family
●● For non-English-speaking patients, use an interpreter in person – a tele-
phone interpreter is usually unsatisfactory.
●● Give information about TB – excellent prognosis with treatment, likeli-
hood of transmission (reassure if non-pulmonary TB), requirement for 
notification to public health authorities.
●● Provide detailed information about treatment (for inpatients, involve the 
ward pharmacist to reinforce explanations):
– importance of adherence
– specific dosing instructions (use aids such as tablet cards and sheets) 
– number of tablets, frequency, timing in relation to food
– side-effects – specifically hepatitis (describe symptoms, and instruct 
patient to stop all medications if they develop), eye toxicity (instruct 
patient to stop medications if altered colour vision or blurred vision 
develops), early GI upset, orange urine, arthralgias, allergy
– written information (for example DoH pamphlets in Victoria) about 
TB and TB drugs in appropriate language (if available).
●● Provide clinic/hospital contact details.
2.4.2 Check for drug interactions
Rifampicin
●● Oral contraceptive pill – advise patient to use an alternative contraceptive 
method.
●● Prednisolone – if being given for a pre-existing condition, a rule of thumb 
is to double the prednisolone dose (discuss with treating doctor or parent 
unit beforehand).
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●● Warfarin – increase frequency of INR monitoring until the warfarin dose 
is stabilised.
●● There are many other potentially important interactions – for details see 
texts such as UpToDate or consult ATS guidelines, and if in doubt, contact 
Pharmacy.
Isoniazid
●● Phenytoin – monitor levels.
2.4.3 Baseline laboratory tests
●● Full blood examination (FBE), urea and electrolytes (U&Es), and LFTs
●● HIV testing – after appropriate provision of information
●● Hepatitis B serology (HBsAg, anti-HBs, anti-HBc) and hepatitis C anti-
body for all overseas-born patients
●● 25-OH vitamin D level (and provide replacement if low)
●● Other immigrant and refugee health testing such as Strongyloides and 
schistosomiasis serology if not done previously, as appropriate.
2.4.4 Baseline visual acuity and colour vision
●● Before starting ethambutol, check and document baseline visual acuity 
and colour vision.
●● Refer to ophthalmology if there are pre-existing visual problems or a his-
tory of significant eye disease – otherwise, advice from our ophthalmolo-
gists is that formal monitoring by an ophthalmologist is not required, 
either at baseline or on treatment.
Table 2.5.1 Inpatient monitoring schedule.
Baseline Weekly On discharge
LFTs ✓ ✓ ✓
FBE ✓ ✓
U&Es ✓ If on amikacin ✓
ESR ✓
HIV ✓
HCV ✓
HBV ✓
Vitamin	D ✓
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2.5 Routine inpatient monitoring
A second CXR is not routinely necessary until 3 months after the initial one.
After 2 weeks of chemotherapy, sputum smear should be performed once a week 
if it continues to be positive.
Serum uric acid should be performed if arthralgia occurs while on pyrazinamide.
2.6 Discharge from hospital
The decision about when a patient with smear-positive pulmonary TB can be 
discharged from hospital is not always straightforward, and should be made on a 
case-by-case basis by the responsible consultant physician, with input from other 
specialists and public health authorities if necessary. There is no ‘magic formula’ 
that can be applied; in practice, patients usually meet the following criteria 
around 2 weeks after starting TB treatment, but some patients can be safely dis-
charged earlier than this while others will need a longer admission.
2.6.1 Ideal criteria to be met before patient is discharged
●● There is no uncontrolled associated illness or condition that is likely to 
impede progress.
●● Cough is controlled.
●● Sputum quantity is reduced and the patient understands the possibility of 
infecting contacts.
●● In patients with smear-positive pulmonary TB, there should be a reduc-
tion in the number (but not necessarily absence) of organisms seen on 
smears before discharge.
●● In patients with smear-positive pulmonary TB who will have contact in 
the home with children < 5 years of age or immunocompromised persons, 
or who are to be transferred to another short- or long-term care facility, 
smears should ideally be negative before discharge but factors such as 
duration of therapy (≥ 2 weeks) and resolution of cough may moderate 
this recommendation.
●● The patient has satisfactorily tolerated a drug regimen that can be man-
aged on an outpatient basis.
●● The patient understands the disease and the need for compliance.
●● Home conditions are satisfactory, and reliable home supervision is avail-
able, ideally with at least one family member or other appropriate person 
who appreciates the disease and the need for patient compliance.
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●● Follow-up arrangements have been made for routine clinical reviews and 
supply of drugs, and for visits by an appropriate nurse or health worker as 
necessary.
2.6.2 On discharge, the following steps should be taken
●● Inform the public health TB program (in Victoria, the TB Control Pro-
gram on 1300 651 160 or fax 1300 651 170).
●● Ring the referring doctor or local medical officer and inform of diagnosis, 
treatment, present state of health and plan of management.
●● Complete the discharge summary and ensure a copy is faxed to the refer-
ring doctor and to the public health TB program.
●● Make a follow-up appointment at the outpatient clinic (usually 2 to 4 
weeks after discharge), with an interpreter if needed.
●● Ensure that the patient has a sufficient supply of antituberculous drugs to 
last until the first follow-up appointment. This may require a specific note 
on the discharge summary prescription if the default hospital pharmacy 
practice is to dispense a fixed supply of medications (e.g. only for 5 days) 
at discharge.
●● Ensure full cooperation with the responsible person at home.
●● In patients with complicated or special management issues, ensure that 
the management plan is clearly outlined on the discharge information 
sheet, or preferably discuss the case with a TB Clinic consultant.
2.7 On-treatment review in the outpatient clinic
2.7.1 Frequency of review
If treatment has been commenced in the outpatient setting, patients should be 
reviewed 2 weeks after initiation, then monthly thereafter.
For patients who do not attend scheduled appointments, inform the TB 
program public health nurse, who will coordinate a response with the clinic 
staff – the patient should be contacted and given another appointment date 
and, if medications are running low, a prescription should be given via the 
public health nurse.
2.7.2 Clinical monitoring
Related to disease
●● Recurrence of cough
●● Recurrence of haemoptysis
●● Weight loss.
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Related to drugs
●● Fever and/or rash
●● Gastrointestinal symptoms
●● Joint pains
●● Jaundice
●● Visual symptoms – while on ethambutol ask patient about visual symp-
toms, and check visual acuity and colour vision at each visit.
2.7.3 Drug compliance
Check if the patient has been compliant with the medications if directly observed 
therapy is not administered. The quantity remaining in the bottles is an unrelia-
ble indicator. The urine colour should be red in those taking rifampicin. A urine 
test for isoniazid can also be done. If there is any doubt with compliance, discuss 
this with the TB program public health nurse, who will arrange for closer super-
vision in the community. In selected cases, directly observed therapy may be 
indicated.
2.7.4 Blood tests
Some TB clinicians choose to monitor LFTs in all patients on TB therapy, but this 
is not our practice at VIDS (in line with recommendations in international 
guidelines) and we restrict regular LFT monitoring to the following patients:
●● upper gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal 
pain)
●● older than 60 years
●● abnormal baseline LFTs
●● excess alcohol intake
●● concomitant hepatotoxic medication
●● chronic HBV infection
●● chronic HCV infection (5× increased risk of hepatitis)
●● HIV infection (4× increased risk – 14× if HCV coinfected)
●● pregnancy, and 3 months post-partum.
FBE and U&Es should be performed only if clinically indicated.
2.7.5 Microbiology
Pulmonary TB
●● Check sputum specimens monthly until smear and culture negativity is 
documented.
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●● If patients are unable to produce sputum, obtaining respiratory secretions 
(e.g. induced sputum) entails some inconvenience and discomfort and is 
only indicated if the patient has MDR-TB, or is otherwise not responding 
satisfactorily on clinical or radiological grounds. If the patient has a drug-
sensitive infection and is doing well, this is not necessary.
Extrapulmonary TB
●● If there is a delayed treatment response, obtain additional specimens if 
possible.
2.7.6 Radiology
For patients with pulmonary TB, CXR should be performed at 3 months, and on 
completion of therapy.
For patients with extrapulmonary TB, the need for radiological follow-up will 
depend on the site involved. For instance, routine assessment of radiologic 
progress is indicated for CNS tuberculoma, but not for lymph node disease.
2.7.7 Communication
Write to the local doctor and the public health TB program at least every 3 
months. In addition, if the patient has special problems the TB program nurse 
should be contacted (in Victoria, on 1300  651  160). In Victoria, a Treatment 
Outcome Form will be sent by the TB Control Program to the treating physician 
for completion at the close of treatment. Other units involved in care should also 
be updated on progress.
2.8 Post-treatment follow-up
2.8.1 Pulmonary tuberculosis
Although routine follow-up of patients after an uncomplicated course of treat-
ment for fully drug-sensitive pulmonary TB is no longer recommended in US 
and UK treatment guidelines, our practice in VIDS is to review patients at 6 
months, 12 months and 24 months, with a repeat CXR at each visit. A letter 
should be sent to the public health TB program when the patient is discharged 
from the clinic.
2.8.2 Extrapulmonary tuberculosis
The need for follow-up will depend on factors such as the site of disease and 
whether the treatment course was uneventful or not. Routine review of patients 
with lymph node TB and an uncomplicated treatment course is probably unnec-
essary (patients can be instructed to return if lymphadenopathy recurs), whereas 
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regular follow-up (including imaging, and liaison with other relevant hospital 
units) would be indicated for most patients with more complicated forms of TB, 
such as CNS and bone and joint disease.
2.8.3 Longer follow-up
The following patients may require longer-term follow-up:
●● Patients who have not been treated with a regimen that includes both 
rifampicin and isoniazid
●● Patients with silicosis
●● Patients who have not been satisfactorily compliant with treatment
●● Patients with drug-resistant tuberculosis
●● Patients requiring long-term steroid or immunosuppressive therapy
●● Patients with HIV.
2.9 When patients develop problems
2.9.1 Drug hypersensitivity reactions
●● Hypersensitivity reactions usually occur within the first 8 weeks of treat-
ment. The most common clinical features of hypersensitivity reactions 
are rash and fever. The rash is usually erythematous and itchy, and may be 
macular or papular.
●● Pyrazinamide often causes initial facial flushing or pruritus. These symp-
toms are transient and need not be regarded as reactions.
●● Generalised reactions also include fever, rigors, headache, myalgia, peri-
orbital swelling, conjunctivitis, generalised lymphadenopathy, hepatos-
plenomegaly and occasionally transient jaundice. Rarely exfoliative 
dermatitis or Stevens-Johnson syndrome may occur.
●● Hypotension or shock may occur if a large dose of a drug is given after a 
previous hypersensitivity reaction.
Management of hypersensitivity
●● Minor reactions such as a slight itch that do not distress the patient may 
be self-limiting. Treatment with an antihistamine may be all that is needed 
without stopping the antituberculous drugs.
●● If the reaction is more than trivial, all drug treatment should be stopped 
and corticosteroids may need to be used. 
●● For non-severe reactions, when the reaction has subsided attempt to iden-
tify the drug responsible by re-introducing the drugs singly, starting with 
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a low challenge dose. This is best done in hospital, and referral to Clinical 
Immunology is advised for all but the most straightforward cases.
●● The recommended sequence of daily challenging doses (in mg) in mild to 
moderate reactions is given in Table 2.9.1. It is not a desensitisation 
regimen.
●● Formal desensitisation is indicated if:
– the original reaction was severe
– a reaction occurs with the first challenge dose, as shown above, and it 
is decided that the drug must be used.
●● Desensitisation should not be performed on any patient who had hepati-
tis, haemolytic anaemia, purpura, nephritis, or ocular toxicities as mani-
festations of the drug hypersensitivity.
●● Desensitisation will require input from Clinical Immunology, but a sug-
gested approach is as follows:
– When starting to desensitise, it is usually safe to begin with one-tenth 
of the normal dose. Then the dose is increased by a tenth each day if 
tolerated.
– If the patient has a mild reaction to a dose, the same dose (instead of a 
higher dose) is given next day.
– If there is no reaction, the dose is to be increased again by a tenth each 
day.
– If a reaction is severe (which is unusual), a lower dose is used and then 
increased more gradually.
– If a reaction occurs with the second challenge dose, desensitisation 
can be started with the first challenge dose. Then the dose is increased 
by the amount equal to the first challenge dose each day.
●● A rapid oral desensitisation method for rifampicin and ethambutol was 
described by Matz et al. (1994).
Table 2.9.1 Recommended sequence of daily challenging doses
Drug Day 1 Day 2 Day 3
isoniazid 50 100 300
then rifampicin 75 150 450–600	(on	4th	day	if	required)
then pyrazinamide 250 500 full dose
then ethambutol 100 400 full dose
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2.9.2 Gastrointestinal symptoms
Almost any medication can cause upper gastrointestinal (GI) symptoms 
(anorexia, nausea, vomiting, epigastric discomfort) in susceptible individuals. 
Among first line antituberculous drugs, rifampicin is the most common cause, 
although pyrazinamide is responsible in some instances. However, rifampicin is 
the most important member of combination antituberculous therapy, so every 
effort should be made to continue this drug.
Because upper GI symptoms may be due to drug-related hepatitis, LFTs must be 
done in all individuals who present with such symptoms, and all medications 
should be ceased if transaminases are greater than 3 times the upper limit of 
normal, as discussed in the following section.
GI symptoms can often be controlled by advising the patient to take rifampicin 
with food (rather than on an empty stomach), and by use of symptom-relief med-
ications such as H2 blockers. If symptoms persist, or are severe to begin with, 
antituberculous drugs may need to be discontinued. If unrelated GI disease is 
suspected, appropriate referral for diagnostic investigation should be arranged.
If medications are ceased then restarted, gradual dose escalation of rifampicin 
after reintroduction of HZE should be tried. If the GI symptoms are caused by 
pyrazinamide, it is usually simplest to omit this medication and to extend the 
duration of treatment to 9 months (see Chapter 1).
2.9.3 Abnormal liver function tests
See also section 2.7.4 Blood tests (liver function tests) and Chapter 5, Diagnosis 
and management of latent TB infection.
●● Modest elevations of hepatic transaminases (AST/ALT) are not uncom-
mon in the pretreatment liver function tests of TB patients.
●● Minor transaminase elevations are also common in the early stages of TB 
treatment, but the risk of clinical hepatitis is much lower (see Table 2.9.3). 
●● Isoniazid and pyrazinamide are the most common causes of drug-induced 
hepatitis in patients on TB treatment. The risk of isoniazid hepatotoxicity 
increases with age. 
●● As discussed in section 2.7.3, in those whose initial LFTs are normal we do 
not routinely monitor LFTs unless the patient develops upper gastrointes-
tinal symptoms, is aged 60 or older, has chronic hepatitis B or C or another 
form of chronic liver disease, is a heavy drinker of alcohol, is HIV-infected, 
or is pregnant.
28 Management of tuberculosis
●● Although the specific cause of hepatitis cannot be determined by the pat-
tern of LFT abnormality in general, if the pattern is hepatocellular with 
enzymes elevated and out of proportion to bilirubin or alkaline phos-
phatase, the cause may be isoniazid, rifampicin, or pyrazinamide. 
Rifampicin is usually implicated if the pattern is cholestatic (elevated bili-
rubin or alkaline phosphatase out of proportion to enzyme elevations). 
Very rarely, ethambutol causes hepatitis with a hepatocellular pattern.
Management of abnormal LFTs
VIDS follows the recommendations of the ATS for management of abnormal 
LFTs during TB therapy (see Figure 2.9.1).
●● If the AST/ALT is < 2× the upper limit of normal, liver function should be 
repeated in 2 weeks:
– if transaminase levels remain < 2× the upper limit of normal, further 
repeat tests are only required for symptoms
– if the repeat test shows an AST/ALT level > 2× the upper limit of 
normal, management should be as below.
●● If the AST/ALT is 2–5× the upper limit of normal, and the patient is 
asymptomatic, treatment can be continued but liver function should be 
monitored weekly for 2 weeks then 2-weekly until normal.
●● If the AST/ALT level rises to > 5× the upper limit of normal or the biliru-
bin level rises and AST/ALT is > 3× the upper limit of normal, antituber-
culous therapy should be stopped.
Table 2.9.3 Risk of clinical hepatitis with antituberculous drugs
Type of Treatment Drugs Number of patients
Percentage with 
clinical hepatitis
Treatment of latent 
TB infection
isoniazid alone 38 257 0.6%
Multi-drug regimen isoniazid-containing 
regimens	without	
rifampicin
2 053 1.6%
Multi-drug regimen rifampicin-containing 
regimens	without	
isoniazid
1 264 1.1%
Multi-drug regimen rifampicin + isoniazid-
containing regimens
6 105 2.55%
(US series 3%)
(UK series 4%)
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●● If the patient is not unwell and the form of TB is non-infectious, no treat-
ment needs to be given until liver function normalises. This approach 
requires careful assessment to ensure patients conform to the above 
description.
●● If the individual has extensive pulmonary, or disseminated, TB, or is HIV-
positive, institution of a new regimen with less potential for hepatotoxicity 
(e.g. amikacin, ethambutol, moxifloxacin) may be indicated before liver 
enzymes normalise. This treatment should be given in hospital. If other 
reserve drugs are used, any potential hepatotoxicity should be considered.
●● Once liver function has returned to < 2× the upper limit of normal (or 
near to baseline levels if initially abnormal), full dosages of the original 
drugs can be reintroduced sequentially in the order rifampicin–isonia-
Figure 2.9.1 Monitoring for hepatotoxicity during treatment of TB disease. Dotted lines signify 
management according to physician’s discretion. ALT = alanine aminotransferase; AST = 
aspartate aminotransferase; HCV = hepatitis C virus; HepBsAg = hepatitis B surface antigen. 
Reprinted with permission of the American Thoracic Society. Copyright © 2012 American 
Thoracic Society. Saukkonen JJ, Cohn DL, Jasmer RM et al. 2006. Hepatotoxicity of 
antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine; 174:935–
52. Official Journal of the American Thoracic Society.
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zid–pyrazinamide with monitoring of the patient’s clinical condition and 
liver function. In VIDS, we usually start ethambutol at the same time as 
rifampicin, because it is such a rare cause of hepatitis and this approach 
minimises the amount of time on incompletely active TB treatment.
●● Rifampicin should be introduced first at full dose (450 mg (< 50 kg) or 
600  mg (≥  50  kg)). After 5–7 days without reaction LFTs should be 
checked. If the ALT/AST has not increased then isoniazid may be intro-
duced at full dose (300 mg/day). Again, after 5–7 days without reaction, 
LFTs should be checked. If the ALT/AST has not increased then pyrazina-
mide may be added at full dose (25 mg/kg/day).
●● If hepatotoxicity was prolonged or severe, or if the patient developed jaun-
dice, and reintroduction of isoniazid and rifampicin is tolerated, treat-
ment should be continued for 9 months without reintroduction of 
pyrazinamide. This also applies if pyrazinamide is found to be the offend-
ing drug.
●● If there is no further reaction standard chemotherapy can be continued 
and any alternative drugs introduced temporarily can then be withdrawn.
●● If there is further reaction the offending drug should be excluded and a 
suitable alternative regimen used. Such an alternative regimen should be 
on the advice of, and under the supervision of, an experienced physician.
●● A recent randomised controlled trial of three approaches to reintroduc-
tion of TB therapy in the setting of hepatotoxicity suggests that it may be 
safe to reintroduce rifampicin, isoniazid and pyrazinamide concurrently 
at full dose. This study compared the above ATS recommended approach 
with staggered reintroduction of isoniazid then rifampicin then pyrazina-
mide (as previously practised in VIDS and reflecting the BTS guidelines) 
and immediate reintroduction. There was no significant difference in the 
frequency of recurrent drug-induced hepatitis. This was a small (n = 175) 
single-centre study and requires replication and further consideration 
before the concurrent reintroduction of rifampicin, isoniazid and pyrazi-
namide can be recommended.
2.9.4 Visual disturbance
●● Visual impairment is a rare but serious adverse drug reaction in patients 
on TB medications. It is usually due to ethambutol, but it has also been 
reported with isoniazid. While it is exceedingly rare when ethambutol is 
given at the dose of 15 mg/kg/day, blindness has occurred with this dose 
(ocular toxicity is dosage related). The incidence of ocular toxicity is 
increased in those with impaired renal function.
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●● Visual impairment is due to retrobulbar neuritis. Onset is usually abrupt, 
but it may be insidious, occurring 3–6 months after commencement of 
drug. The manifestations are blurring of vision, decreased visual acuity, 
central scotoma and loss of ability to see green and sometimes red. Colour 
visual disturbance may be detectable when there is little or no decrease in 
visual acuity.
●● In many cases, if ethambutol is stopped promptly, vision slowly returns. 
Recovery may take 3–12 months. Sometimes, there is a period of worsening 
before improvement. Permanent and total visual loss has been reported, even 
with prompt cessation of ethambutol. In some case series this may occur in 
up to 50% of cases. Renal function should be checked pre-treatment, and 
ethambutol should be avoided in patients with impaired renal function.
●● The recommended dose and duration should not be exceeded. The maxi-
mum dose of ethambutol is 15 mg/kg.
●● Any history of eye disease should be recorded in the notes.
●● A pre-treatment record of visual acuity should be made by the Snellen test 
and colour vision documented using Ishihara plates. Ethambutol should 
not be given to those with pre-existing significant reduced visual acuity, 
as these patients may not notice further minor deterioration of vision.
●● The patient should be told that ethambutol may affect vision and that 
drugs should be stopped immediately should vision become impaired. To 
guard against lack of compliance the patient may be assured that this risk 
is very small.
●● This advice should be documented in the medical history, and the family 
doctor advised.
●● Ask patients on ethambutol about symptoms of visual disturbance at each 
outpatients visit. Patients complaining of visual disturbance during TB 
treatment should be referred to an ophthalmologist for detailed examina-
tion and treatment should be discontinued pending this examination.
●● Patients who are continuing on ethambutol beyond 2 months require 
monthly visual acuity and colour vision measurement. If progressive 
visual impairment is found, refer the patient immediately for formal oph-
thalmological assessment. Ethambutol is best avoided in children too 
young for objective eye tests, and also in adults with language or commu-
nication problems that would make assessment difficult.
2.9.5 Arthralgia/arthritis
Arthralgia occurs in some patients on pyrazinamide. It appears to be particularly 
problematic in African women. Arthralgia usually appears during the first 1–2 
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months of treatment. Unlike gout, it affects both large and small joints, most 
commonly shoulders, knees and fingers. Swelling, limitation of movement and 
tenderness are usually mild. It is commonly self-limiting and responds readily to 
symptomatic treatment. Sometimes it is necessary to cease pyrazinamide.
Symptoms are not correlated with serum measurements of uric acid, and treat-
ment with allopurinol is thought to be unhelpful.
2.9.6 Acute psychosis
Rifampicin and pyrazinamide are not associated with psychotic side-effects.
Isoniazid, in a standard dose of 5 mg/kg, has been identified as a triggering factor 
for the onset and relapse of schizophrenia. In healthy individuals psychosis due 
to isoniazid is very infrequent unless the dose is > 15 mg/kg. Resolution of psy-
chotic symptoms has been reported with cessation of isoniazid; however, antip-
sychotic medication and involvement of psychiatry services are important.
Isoniazid-induced encephalopathy (manifested with confusion) has occurred in 
dialysis patients. Observational reports have suggested that the co-administration 
of high-dose pyridoxine (100 mg daily) in renal patients receiving isoniazid may 
reduce this complication. Such patients are also prone to pellagra (diarrhoea, der-
matitis and dementia) owing to increased requirement and malnutrition-related 
deficiency of niacin. Isoniazid enhances the risk of pellagra by interfering with 
conversion of tryptophan to niacin. In the absence of typical dermatitis or diar-
rhoea, pellagra psychosis has been mistaken as cases of isoniazid-induced 
encephalopathy.
Neuropsychiatric complications of isoniazid occur more frequently in patients 
with predisposing factors: old age, diabetes, hepatic insufficiency, alcoholism, 
malnourishment, hyperthyroidism, slow acetylators, brain damage, past or 
family history of psychotic illness, high dose of isoniazid, concomitant adminis-
tration of monoamine oxidase inhibitors.
2.9.7 When lymph nodes enlarge
Tuberculous lymphadenitis under treatment often fluctuates markedly in its 
clinical course. In 25% of the patients the glands may enlarge or new ones may 
appear. This paradoxical response may occur after initial improvement, and in 
5–10% of the patients it may occur after the completion of treatment. The glands 
may become attached to the skin and discharge caseous material. Glandular 
enlargement in the chest may cause airway or superior mediastinal obstruction. 
In this situation corticosteroid therapy is indicated. Otherwise reassure the 
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patient that this event is common and does not signify failure of treatment. A 
case-controlled study showed no benefit of corticosteroid therapy for this para-
doxical reaction involving tuberculous lymph nodes (Hawkey et al. 2005).
Surgical treatment may occasionally be required for nodes that ‘point’ where dis-
charge of caseous material is imminent.
Recrudesent or enlarging lymph nodes in patients with tuberculosis is a well rec-
ognised phenomenon in HIV-positive patients, particularly in the setting of ini-
tiation of antiretroviral therapy when the CD4 cell count is low (see Chapter 6, 
HIV and tuberculosis).
2.9.8 When haemoptysis occurs
Haemoptysis may occur during treatment and after treatment is completed. 
It is usually not a sign of disease activity, but sputum specimens should still be 
sent for AFB smear and culture. If haemoptysis is persistent or recurrent one 
should exclude a coexistent carcinoma of the lung or bronchiectasis. If 
 haemoptysis is massive patients must be admitted to hospital for observation 
and management.
2.10 Usual response to treatment
2.10.1 Cough
Cough frequency declines rapidly following treatment - to 35% of initial cough 
counts within 2 weeks of initiation of treatment.
2.10.2 Fever
About 60% of febrile patients with TB became afebrile within 2 weeks with a 
mean of 16 days and median of 10 days. The remainder became afebrile more 
than 2 weeks after commencement of treatment; among this group the average 
time to defervesce can be as long as 1 month (Kiblawi et al. 1981).
2.10.3 Sputum smear
For drug-sensitive pulmonary TB, the median time to AFB sputum smear con-
version is 3–4 weeks, and 80% of patients will be smear negative after 2 months of 
treatment. The duration of smear positivity is associated with the degree of pre-
treatment smear positivity; for example, less than 5% of patients with grade 1+ or 
2+ smears will still have positive smears after 2 months, compared with up to 
50% of patients with initial grade 4+ smears. Smear positivity is also prolonged 
in patients with cavitary disease.
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The two most important factors to consider in patients with persistently positive 
smears, or in those exhibiting a clearcut fall and rise phenomenon, are emer-
gence of resistance and poor adherence.
The presence of AFB in sputum smears during treatment may occur in up to 
20% of patients after sputum culture has become negative. This phenomenon 
may be seen as early as after 4 weeks of treatment. Beyond 12 weeks of treat-
ment most persistently positive smears (about 2/3) are associated with negative 
cultures.
2.10.4 Sputum culture
Sputum culture usually becomes negative in patients being treated with both iso-
niazid and rifampicin:
●● at 1 month in > 50%
●● at the end of 2 months in 85%
●● at the end of 3 months in > 90%
Patients whose sputum has not converted by 3 months of treatment should be 
carefully re-evaluated.
●● Assess compliance. Consider directly observed therapy.
●● Check drug susceptibility tests (the results might have been missed).
●● Consider the possibility of non-tuberculous mycobacterial infection.
●● Do not change therapy unless the patient is clinically ill. It is preferable to 
wait for results of drug susceptibility tests before altering therapy.
●● If treatment is to be changed, never add one new drug at one time. Include 
at least 2 drugs to which the organisms are susceptible.
●● Evaluation should be performed at least monthly until sputum conversion 
occurs.
●● Patients in whom sputum culture results have not converted to negative 
after 5 to 6 months of therapy are considered treatment failure.
2.10.5 Radiological improvement
New infiltrates may develop within 3–5 weeks after commencement of treat-
ment. It does not mean failure of treatment at this stage. It may be an immuno-
logical phenomenon.
CXR usually shows improvement 1 to 3 months after initiation of treatment.
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Failure to show improvement after 3 months indicates wrong diagnosis or inad-
equate treatment.
CXR usually resolves or becomes stable in 90% at 6 months
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3.1 Definition of drug-resistant tuberculosis
Drug-resistant tuberculosis refers to a strain of M. tuberculosis that is resistant 
to at least one antituberculous drug. Multidrug-resistant tuberculosis 
(MDR-TB) strains are resistant to at least isoniazid and rifampicin. Extensively 
drug-resistant tuberculosis (XDR-TB) has recently been described and denotes 
MDR-TB that is also resistant to a f luoroquinolone agent and one or more sec-
ond-line injectable agents (amikacin, capreomycin or kanamycin). In this 
chapter, unless otherwise specified, drug-resistant TB refers to single, multi- 
and extensively drug-resistant TB, but the principal focus of this chapter will 
be MDR-TB.
In Australia, isoniazid (with or without streptomycin) resistance occurs in 7–10% 
of TB isolates. Local rates of MDR-TB have remained relatively stable at 0.5–2% 
for the past 10–15 years, but the global rate of MDR-TB is now estimated to be 
3.6%. Since almost all TB in Australia is imported, it is virtually inevitable that 
we will see an increase in MDR-TB cases in the coming years. Extensively drug-
resistant tuberculosis has not been reported in a previously untreated patient in 
Australia but is potentially only a jumbo jet flight away.
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3.2 Clinical and microbiological assessment of patients 
with drug-resistant TB
3.2.1 Risk factors
Clinical features at presentation do not distinguish patients with drug-sensitive 
from those with drug-resistant TB. However, the following features (some identi-
fied in overseas studies and not necessarily applicable in Australia) are risk 
factors for MDR-TB, and if present may prompt consideration of empirical use of 
second-line antituberculous medications in addition to the usual 4-drug regimen 
in some circumstances (discussed in more detail in section 3.4).
Epidemiological clues
●● Close contact with an individual with MDR-TB.
●● Birth in a country with a high prevalence of MDR-TB.
●● Previous treatment for tuberculosis, in particular if treatment was 
incomplete.
●● Previous hospitalisation in a hospital with an outbreak of a drug-resistant 
strain of TB, particularly if housed on the ward where the outbreak 
occurred.
Markers of non-response to standard TB treatment
●● Failure to defervesce after 2 weeks of treatment with a standard 4-drug 
regimen; however, persistent fever can also be caused by severe miliary 
disease or another concomitant infection, so this is not a specific sign of 
MDR-TB.
●● Persistent symptoms despite treatment, and detection of bacilli in sputum 
specimens.
●● Persistently positive culture after 3 months of initial treatment with iso-
niazid, rifampicin, pyrazinamide, and ethambutol – for fully drug-sensi-
tive TB, 80 to 90% of patients with positive pre-treatment sputum cultures 
should have converted to negative after 2 months of treatment, and nearly 
100% should have negative cultures within 5 to 6 months.
●● Reversion to a positive culture after having initially converted cultures 
from positive to negative.
In practice, the most useful epidemiological pointer to the presence of MDR-TB 
is the combination of previous treatment for TB and birth in a country with a 
high TB prevalence. The WHO undertakes ongoing global surveillance of TB 
drug resistance in selected countries and regions, and uses this data to provide 
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estimates of the rates of MDR-TB in newly diagnosed and re-treatment cases by 
country. For example, in the WHO’s latest report (2010) the estimated rates of 
MDR-TB in China are 5.7% for newly diagnosed and 25.6% for re-treatment 
cases. The latter figure is certainly high enough to warrant consideration of 
empirical MDR-TB treatment prior to results of susceptibility testing becoming 
available, and PCR testing for rifampicin resistance should be requested on 
clinical specimens (especially if AFB smear positive) or on primary cultures (see 
following section).
3.2.2 Sputum microscopy, culture and nucleic acid amplification testing
Clinical specimens are essential for confirmation of MDR-TB and for drug sus-
ceptibility testing (DST) and to document culture conversion.
The availability of nucleic acid amplification tests (NAAT) for rapid detection of 
multi-drug resistance can dramatically shorten the time to diagnosis and allow 
earlier institution of appropriate treatment. Assays such as Genotype MTBDR-
Plus and GeneXpert MTB/RIF are highly sensitive and specific for detection of 
rifampicin resistance in AFB smear-positive sputum specimens (sensitivity is 
lower in AFB smear-negative specimens), and give results in 1–2 days. These 
assays are being rolled out by WHO in high MDR-TB prevalence countries. In 
Victoria, the Mycobacterial Reference Laboratory offers molecular resistance 
testing, though not currently on a routine basis. We expect that the availability 
and use of these tests will increase in the coming years.
The presence of dead bacilli can produce ‘false positive’ smear results early in 
treatment and a similar phenomenon has been reported with NAATs. Up to 20% 
of patients (most commonly those with cavitary disease) who are initially smear- 
and culture-positive may continue to have positive smears after cultures become 
negative for up to 20 weeks after commencement of treatment.
3.3 Classifying drugs used to treat drug-resistant TB
For the purposes of treatment of drug-resistant tuberculosis (predominantly 
MDR-TB), WHO classifies antituberculous drugs into a hierarchy of 5 groups:
●● Group 1 – first-line oral agents (isoniazid, rifampicin, ethambutol and 
pyrazinamide).
●● Group 2 – injectable agents: aminoglycosides (streptomycin, kanamycin 
and amikacin) and cyclic polypeptides (capreomycin).
●● Group 3 – fluoroquinolones (potency based on descending order of in 
vitro activity: moxifloxacin > levofloxacin > ciprofloxacin = ofloxacin).
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●● Group 4 – oral bacteriostatic second-line agents: thioamides (e.g. pro-
thionamide and ethionamide); serine analogues (e.g. cycloserine and ter-
izidone); salicylic acid derivatives (e.g. para-aminosalicylic acid – PAS); 
thioacetazone.
●● Group 5 – agents with in vitro activity but with unclear efficacy (‘third-
line agents’): clofazimine, amoxycillin–clavulanic acid, clarithromycin, 
linezolid (other authorities also include imipenem and high dose isonia-
zid in this group, and possibly cotrimoxazole).
In Australia, the most widely used drugs in groups 2, 3 and 4 are amikacin, mox-
ifloxacin, prothionamide (not ethionamide), cycloserine and PAS. In Victoria, 
these drugs are now funded by DoH; clinicians are required to complete a DoH 
form (available from pharmacy) certifying that pre-specified criteria have been 
met. Prothionamide and PAS have to be prescribed through the Special Access 
Scheme: liaise with pharmacy about specific details.
Table 3.3.1 lists dosing and other information about the agents most commonly 
used for MDR-TB treatment.
3.4 Treatment of drug-resistant TB
3.4.1 General principles
●● Expert consultation must be sought for individuals with confirmed or 
suspected drug-resistant TB, especially MDR-TB and XDR-TB. Registrars 
should always discuss issues such as design of an initial regimen or man-
agement of drug toxicity with a consultant experienced in the manage-
ment of drug-resistant TB.
●● Use of standardised protocols for treatment of known or suspected 
MDR-TB and XDR-TB is often not possible because of factors such as the 
drug susceptibility results of an individual isolate, patient co-morbidities, 
and drug toxicity.
●● Patients with known or suspected pulmonary MDR-TB or XDR-TB 
should be hospitalised for isolation. Hospitalisation of other MDR-TB or 
XDR-TB patients is usually necessary in order to ensure compliance and 
to monitor drug intolerance and toxicity, drug levels and response.
●● Treat MDR-TB patients under directly observed therapy (DOT). Arrange-
ments will need to be discussed and post-discharge care coordinated with 
the public health TB program.
●● Intermittent therapy regimens should not be used for patients with 
MDR-TB or XDR-TB.
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●● Effective MDR-TB treatment requires the use of at least four active drugs 
(preferably five drugs in the initial phase) and prolonged therapy (for at 
least 18 months).
3.4.2 Selection of empiric regimen (susceptibilities pending)
Non-MDR-TB
Patients suspected on epidemiological grounds to have resistance to INH can be 
started on standard therapy with HRZE.
MDR-TB
If MDR-TB is anticipated or considered likely but results of susceptibility testing 
are not available, options are:
●● Start HRZE and await results of molecular and conventional drug suscep-
tibility testing
●● Start empiric regimen with MDR-TB activity, comprising HRZE plus 
moxifloxacin plus amikacin plus prothionamide. This will provide good 
activity against MDR-TB, except for the rare strains that are resistant to 
all first-line agents or for XDR-TB.
Because of the pill burden and risk of toxicity, the second approach is only indi-
cated in those with epidemiological risk factors for MDR-TB who are critically ill 
or whose condition is deteriorating on HRZE.
3.4.3 Specific treatment regimens according to resistance patterns
Perceived inconsistencies in recommended drug treatment regimens for drug-
resistant TB arise from:
●● Differing expert opinions in the management of drug-resistant TB, in 
particular MDR-TB, which are influenced by personal experience
●● Lack of rigorous randomised controlled trials in the treatment of MDR-TB
●● Technical difficulties in performing in vitro DST, especially for second-
line agents. Interpretation and application of DST requires experienced 
staff, local knowledge of drug usage, and appreciation of significant cross-
resistance patterns of TB strains. For example, susceptible and resistance 
results for isoniazid and rifampicin are reliable, while ‘susceptible’ results 
are more reliable than ‘resistant’ results for streptomycin and ethambutol. 
Rates of cross-resistance are 15–20% between isoniazid and ethionamide, 
20–60% between kanamycin and capreomycin, and 100% between ami-
kacin and kanamycin.
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The following are guidelines for the treatment of TB strains with specific resist-
ance patterns. For MDR-TB options are seldom clear-cut, as individuals often 
will have already received trials of some of the medications.
Non-MDR-TB
Management of these infections is usually straightforward. Treatment duration 
is generally longer than for drug-sensitive TB, but most patients can be treated 
with effective, well-tolerated regimens.
Isoniazid resistance (± streptomycin)
Resistance found after initiation of treatment with standard 4-drug regimen. 
Options are:
2 HRZE/ 4 RZE (US guidelines)
2 HRZE/ 7 RZE (VIDS preferred, if pyrazinamide tolerated)
2 HRZE/ 10 RE (UK guidelines)
Resistance known before initiation of treatment.  
Options are:
6 RZE (US guidelines)
9 RZE (VIDS preferred, if pyrazinamide tolerated)
2 RZE + injectable aminoglycoside/ 7 RE (UK guidelines)
2 RZE/ 10 RE
A fluoroquinolone may be added if there is extensive disease (US guidelines) but 
otherwise should not be part of standard management of these infections.
If the patient is HIV-positive or immunocompromised, a 9 or 12 month regimen 
is advisable, but this is not evidence-based.
In earlier studies where resistance testing was only performed following comple-
tion of treatment, isolated baseline INH resistance was shown to have minimal 
impact on cure rates with the standard 2HRZE/4HR regimen (95%, versus 98% 
with no resistance), but in developed countries where susceptibility testing is 
performed routinely, the finding of INH resistance should lead to a change to one 
of the regimens above.
The use of isoniazid in the treatment of isoniazid-resistant TB is controversial. 
Large populations of isoniazid-resistant organisms may contain some isoniazid-
susceptible organisms. Some feel that these susceptible organisms may be more 
virulent than the resistant bacilli, and continue isoniazid even when the laboratory 
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has reported isoniazid resistance. However, if other effective medications are 
included in the regimen, the addition of isoniazid has not been shown to improve 
the effectiveness of the regimen.
Isoniazid and ethambutol resistance
If initial standard treatment phase:
2 HRZE/ 7–10 RZQ1 ± IA2
If no initial treatment phase:
9–12 RZQ ± IA
Increasing experience with fluoroquinolones indicates they have similar activity 
to isoniazid against M. tuberculosis, hence use of an injectable agent is optional 
for this resistance pattern.
Rifampicin resistance
Options are:
2 H(R)ZE/ 16 HE (some US authorities recommend addition of fluoroquinolone, in which case 
duration of treatment could be shortened to 12 months)
2 H(R)ZEIA/ 10 HE
9 HZIA
Use of one of the regimens that includes an injectable agent is advised for patients 
with extensive disease.
MDR-TB
Management of these infections is challenging for doctor and patient alike. 
Treatment involves prolonged use of drugs that are unfamiliar to most clinicians, 
are not readily available, may be difficult to administer, and are often poorly tol-
erated. The treatment course must be supervised by an experienced physician, 
and close liaison with public health nurses is essential.
Choose drugs based on the hierarchical order of potency. Start with any remain-
ing Group 1 drugs to which the isolate is susceptible, then include one agent from 
each of Group 2 and Group 3, and if necessary use one or more agents from 
Groups 4 and 5 to achieve the aim of using at least four active agents.
●● Group 2 – amikacin is preferred because it is more readily available than 
kanamycin and capreomycin and MDR-TB strains are almost always 
1 Q = fluoroquinolone – moxifloxacin advised
2 IA = injectable aminoglycoside
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resistant to streptomycin. Amikacin-resistant isolates are always resistant 
to kanamycin, and should be treated with capreomycin. If possible, use 
amikacin in combination with pyrazinamide because the combination 
has good bactericidal activity. Give amikacin IV, usually via a peripherally 
inserted central catheter (PICC) because prolonged therapy is required.
●● Group 3 – moxifloxacin is the preferred fluoroquinolone agent.
●● Group 4 – prothionamide is the most widely used agent, PAS and cyclo-
serine less so. Adverse reactions are frequent with these agents so start 
with small doses of each of these drugs and increase to full doses (referred 
to as ‘ramping’) over 5–10 days.
Treatment duration
Treatment is divided into the intensive phase (when the injectable agent is given) 
and the continuation phase. The duration of the intensive phase is a minimum of 
6 months or for 6 months following culture conversion, and the total duration of 
treatment should be for a minimum of 18 months after culture conversion. Treat-
ment should be extended in cases of highly resistant infections, extensive disease, 
delayed microbiological response and (probably) coinfection with HIV.
The role of thoracic surgery
Surgery should only be undertaken in patients able to tolerate the procedure (a 
lobectomy or pneumonectomy) who have focal, usually cavitary, disease. General 
indications are:
●● Positive cultures beyond 4 to 6 months of treatment for MDR-TB
or
●● Extensive patterns of drug resistance that are unlikely to be cured with 
chemotherapy alone.
Surgery should be performed by an experienced surgeon.
Isoniazid and rifampicin resistance
Intensive phase: ZEQIA + Pro1
Continuation phase: ZEQ + Pro
Prothionamide may be omitted in selected cases of ‘low burden’ disease, espe-
cially if the patient has already responded well to standard four-drug therapy, e.g. 
isolated lymph node TB; pleural TB; smear negative, non-cavitary, localised pul-
monary TB.
1 Pro = prothionamide
46 Management of tuberculosis
Isoniazid and rifampicin and ethambutol resistance
Intensive phase: ZQIA + Pro (or PAS1) + Cs2
Continuation phase: ZQ + Pro (or PAS) + Cs
The combination of prothionamide plus PAS is associated with a high incidence 
of gastrointestinal side effects and is best avoided unless cycloserine cannot be 
given.
Isoniazid and rifampicin and pyrazinamide resistance
Intensive phase: EQIA + Pro (or PAS) + Cs
Continuation phase: EQ + Pro (or PAS) + Cs
The combination of prothionamide plus PAS is associated with a high incidence 
of gastrointestinal side-effects and is best avoided unless cycloserine cannot be 
given.
The dose of ethambutol may be increased to 25 mg/kg but retrobulbar neuritis is 
more common at this dose, and formal ophthamological monitoring is 
necessary.
Isoniazid and rifampicin and pyrazinamide and ethambutol resistance
Intensive phase: QIA + Pro + Cs + PAS
Continuation phase: Q + Pro + Cs + PAS
●● Extend the intensive phase to 9–12 months if possible.
●● Addition of a Group 5 (third-line) agent may be necessary.
●● Treatment should be continued for at least 24 months after culture 
conversion.
●● The combination of prothionamide and PAS is recommended in this situ-
ation because of limited treatment options.
●● The threshold for surgery should be lower than with lesser degrees of 
resistance.
Isoniazid and rifampicin and pyrazinamide and ethambutol and amikacin resistance
Intensive phase: Q + Capreomycin + Pro + Cs + PAS ± one or more third-line agents
Continuation phase: Q + Pro + Cs + PAS ± one or more third-line agents
1 PAS = para-aminosalicylic acid
2 Cs = cycloserine
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●● Give capreomycin if susceptible (there is some cross-resistance between 
amikacin and capreomycin).
●● Extend the intensive phase to 9–12 months if possible.
●● Treatment should be continued for at least 24 months after culture 
conversion.
●● The combination of prothionamide and PAS is recommended in this situ-
ation because of limited treatment options.
●● Surgery should be considered at an early stage because of the high level of 
resistance, especially if capreomycin cannot be given.
3.5 Monitoring MDR-TB treatment
3.5.1 Bacteriological status
It is mandatory to monitor bacteriological (smear and culture) status monthly 
from the second month until the sixth month, and then quarterly until the end of 
treatment. In contrast to drug-sensitive TB, patients with MDR-TB who are 
unable to expectorate sputum should undergo sputum induction to document 
conversion to culture negativity.
For a patient with a positive TB culture 3 months after starting treatment, there 
are two possible approaches.
1. If not acutely ill, and clinically stable, maintain on the ‘holding regimen’ 
until the new drug susceptibility results become available.
2. If acutely ill, or clinically deteriorating, add at least two (preferably three) 
new medications, based on an assessment of what remaining medications the 
organism is likely to be susceptible to. The original medications should be 
continued pending repeat drug susceptibility testing results. Never add a 
single antituberculosis medication to a failing regimen.
3.5.2 Drug toxicity
Close monitoring for drug toxicity of injectable and second-line agents is 
essential.
●● Aminoglycoside toxicity:
– warn (and subsequently enquire) about balance or coordination prob-
lems, hearing difficulty or tinnitus
– check renal function and electrolytes weekly for the first 2 weeks then 
2–4 weekly thereafter, and calcium and magnesium monthly
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– check trough amikacin levels weekly for first 2 weeks, then monthly, 
or at any time if significant changes occur in renal function
– perform baseline audiometry, and subsequently as advised by audiolo-
gist (usually 2-monthly)
– at baseline and at each follow-up visit, perform simple vestibular func-
tion testing (Rhomberg’s, doll’s eye manouevre, dynamic visual acuity) 
and refer for formal testing if any abnormalities are detected.
●● Liver function tests – check 1–2 weekly for the first 4 weeks then monthly.
●● Thyroid function tests – check 3-monthly for patients on PAS or 
prothionamide.
If the patient is experiencing a severe side-effect due to a specific drug that pre-
cludes its further use, such as ototoxicity from an aminoglycoside or gout from 
pyrazinamide, but the regimen is not failing (i.e. the patient has improved clini-
cally and cultures have converted from positive to negative) and it is too soon to 
discontinue any medications, options are:
●● Cease the medication responsible for the side-effect and continue on the 
remainder of the antituberculous treatment regimen
●● Substitute with a new, previously unused agent. This does not risk the 
emergence of resistance since the prior antituberculous regimen was not 
failing.
If the cause for the adverse reaction (e.g. hepatotoxicity, skin rash) cannot be 
identified readily, all medications should be discontinued and retested by 
 reintroduction singly into a regimen. In some instances of severe toxicity, hospi-
talisation for rechallenge with multiple drugs may be needed.
3.5.3 Therapeutic drug monitoring
Routine therapeutic drug monitoring (TDM) is generally not required, with the 
exception of measurement of aminoglycosides. Few Australian laboratories are 
able to measure TB drug levels (apart from aminoglycosides, and to a limited 
extent rifampicin). Although TDM has its proponents its value is uncertain, pri-
marily because there is lack of sufficient data to correlate in vitro drug therapeu-
tic ranges with clinical efficacy and response.
Peak serum levels of agents used for MDR-TB treatment are listed in Table 3.3.1. 
Serum TDM for drugs other than aminoglycosides should be considered if:
●● MDR-TB or XDR-TB patients develop symptoms that may be drug-related 
(e.g. CNS symptoms on cycloserine) and options for alternative agents are 
limited or non-existent
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●● The patient has a medical condition, such as malabsorption syndrome 
(chronic diarrhoea, short gut) or renal inpairment that affects pharma-
cokinetics and increases risk of treatment failure or toxicity.
3.6 Post-treatment evaluation
Patients who have completed treatment for MDR-TB should be followed up every 
6 months for at least 2 years. Clinical review includes symptom review, sputum 
examination for AFB smear, culture and DST, and CXR (if pulmonary TB).
3.7 Extensively drug-resistant tuberculosis (XDR-TB)
Extensively drug-resistant TB (MDR-TB, plus resistance to a fluoroquinolone 
agent and to one of the injectable agents amikacin, kanamycin or capreomycin) is 
an emerging problem. It was first described in HIV-positive patients in KwaZulu-
Natal in South Africa, where it was associated with person-to-person transmis-
sion and a high mortality. Approximately 44% of MDR-TB isolates have resistance 
to at least one second-line drug, and 9.9% have resistance to at least three second-
line drugs. Nearly 50% of XDR-TB isolates are also resistant to all first-line 
agents. Thus, XDR-TB may be resistant to at least seven TB drugs. This renders 
XDR-TB potentially untreatable because it may not be possible to construct a 
treatment regimen that consists of more than four drugs to which the organism 
is susceptible.
Countries and regions with high rates of XDR-TB include the Baltic states and 
some other countries of the former Soviet Socialist Republic (up to 15% of all 
MDR-TB tested, and up to 20% in some cities and districts), South Africa (10.5%) 
and China (7.2%). Data are unavailable for most high burden MDR-TB countries 
because of limited second-line drug susceptibility testing. Rates and numbers of 
cases of XDR-TB in most industrialised nations are low.
Treatment of XDR-TB should only be undertaken by a physician experienced in 
the management of drug-resistant TB and in close liaison with the state or terri-
tory mycobacterial reference laboratory and public health TB program.
The success rate of XDR-TB treatment varies from 57–66%, where cure is defined 
as > 5 consecutive culture-negative specimens during the final 12 months of 
treatment or completion of treatment regimen. Information about results of 
treatment in the longer term is limited.
The choice of antituberculous drugs follows the general principles of MDR-TB 
treatment and is based on results of drug sensitivity tests and prior treatment 
history; at least four active drugs should be used. As with cases of highly 
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drug-resistant MDR-TB, use of Group 5 (third-line) drugs such as linezolid, clo-
fazimine and amoxycillin–clauvulanic acid and consideration of surgical resec-
tion may be necessary. Treatment duration is for at least 24 months after culture 
conversion.
3.8 Alternative treatments for MDR-TB and XDR-TB
High-dose isoniazid
Strains of M. tuberculosis identified in the laboratory as isoniazid-resistant often 
contain mixtures of susceptible and resistant organisms. The use of high-dose 
isoniazid 16 to 20 mg/kg (i.e. 1–1.5 g/day) would eliminate susceptible organisms 
and those with low-level resistance. However, high-dose isoniazid is associated 
with hepatotoxicity, peripheral neuropathy and convulsions, and although the 
latter two adverse effects are preventable by large doses of pyridoxine, the role of 
this treatment remains undefined.
Rifabutin
Some rifampicin-resistant strains test susceptible to rifabutin, but as the MICs 
are just at or below the ‘breakpoint’ most authorities do not recommend use of 
rifabutin against these strains.
Clarithromycin
The drug has demonstrated poor in vitro activity against M. tuberculosis (MICs 
are generally above 16 mg/L) and (in contrast to its role in the treatment of M. 
avium complex infections; see Chapter 7) it has minimal value in the treatment 
of MDR-TB.
Clofazimine
There have been anecdotal reports of successful treatment of MDR-TB with 
regimens containing clofazimine; it may have some use when choices are limited, 
such as in the treatment for XDR-TB.
Cotrimoxazole
Some MDR-TB strains are susceptible in vitro using MIC cut-offs for conven-
tional bacteria, but clinical data are limited to case reports.
Amoxycillin–clavulanic acid
Beta lactam antibiotics penetrate the mycobacterial cell wall and in combination 
with a beta-lactamase inhibitor have proven bactericidal activity against 
M. tuberculosis. Clinical experience is limited, but drugs such as amoxycillin–
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clavulanic acid may have a role in treatment of highly drug-resistant MDR-TB or 
XDR-TB.
Linezolid
Linezolid has in vitro activity against M. tuberculosis, including MDR-TB and 
XDR-TB, and culture conversion has been documented in patients with MDR-TB 
and XDR-TB treated with linezolid. Significant side-effects, including bone 
marrow depression and irreversible peripheral neuropathy, often limit this drug 
to short-term use only.
Thioridazine
Thioridazine is a phenothiazine derivative, a class of neuroleptic drugs used for 
the treatment of psychosis. Thioridazine has in vitro antituberculous activity, but 
there is no reported clinical experience and phenothiazine side-effects are likely 
to be problematic.
Investigational agents
New nitroimidazoles (e.g. PA824) have been developed that have very promising 
in vitro and animal model activity against M. tuberculosis and have undergone 
phase I studies and are soon to begin phase II testing. Diarylquinolines (e.g. 
TMC207) are a novel drug class with potent activity against M. tuberculosis in 
vitro and in a murine animal model. Phase I studies of TMC207 have demon-
strated good tolerability and promising antituberculous activity, and a ran-
domised phase II study in patients with MDR-TB is in progress.
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4.1 Impact of pregnancy on TB
Pregnancy has no adverse impact on TB if there is no delay in diagnosis. Birth, 
puerperium and lactation also have no effect on TB or response to treatment. 
However, the diagnosis of TB may be delayed in pregnancy because pregnant 
patients with pulmonary TB are more likely to be asymptomatic at time of diag-
nosis compared with non-pregnant women with pulmonary TB. They are more 
likely to have non-specific symptoms and to experience a delay in obtaining a 
CXR than non-pregnant women with TB. The clinical manifestations of pulmo-
nary TB, if present, are the same as those in non-pregnant women.
The likelihood of extrapulmonary TB is more related to the demographic profile 
of the patient than to pregnancy itself. In Australia, the incidence of extrapulmo-
nary TB is greater among immigrants than those born in this country. The 
symptoms of extrapulmonary TB are frequently non-specific and may be mis-
takenly attributed to physiological changes of pregnancy. A high index of suspi-
cion is needed when pregnant immigrants develop symptoms.
4.2 Impact of TB on pregnancy
Maternal and fetal outcome in pregnancy vary with the site of the TB and the 
timing of diagnosis in relation to delivery. There seems to be no adverse outcome 
with lymph node TB. In other sites, the outcome of pregnancy is almost always 
unaffected provided TB is diagnosed early and treated, the exception being the 
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rare instances of congenital TB. In contrast, obstetric and perinatal morbidity is 
increased in patients with a late diagnosis of pulmonary TB and extrapulmonary 
TB involving sites other than lymph nodes.
For pulmonary TB diagnosed late in pregnancy, there is an increased incidence 
of pre-eclampsia, vaginal bleeding, early fetal death, prematurity, small-for-date, 
low birthweight, and low APGAR scores and perinatal death compared with 
pregnant women without TB. For extrapulmonary TB in sites other than lymph 
nodes, late diagnosis can lead to increased antenatal hospitalisation, poor 
APGAR scores and low birthweight infants compared with healthy controls. 
Untreated TB represents a far greater hazard to a pregnant woman and her fetus 
than does treatment of her disease.
Congenital infection may occur by transplacental spread or by aspiration or 
ingestion of infected amniotic fluid in utero or infected genital secretion during 
birth. These routes of infection are extremely rare. Most cases of neonatal TB 
occur as a result of airborne spread after delivery.
4.3 Antituberculous drugs in pregnancy
Treatment-related complications are reported but are less common than the 
reported rates of TB-associated complications as shown in Table 4.3.1 (adapted 
from Bothamly 2001). The oft-quoted increased risk of isoniazid-associated hep-
atitis during pregnancy and the post-natal period is the consequence of a single, 
retrospective and non-statistically significant study.
Isoniazid and ethambutol are both category A drugs, and are safe in pregnancy.
Rifampicin (category C)
Current consensus is that rifampicin is not teratogenic and that any risk to the 
fetus is small. Pregnancy is not a contraindication to use of rifampicin. Rifampicin 
can give rise to a haemorrhagic tendency in the newborn baby when adminis-
tered late in pregnancy. Some authorities therefore advise supplemental 
vitamin K (10 mg/day) for the last 4–8 weeks of pregnancy.
Streptomycin (category D)
Streptomycin is contraindicated in pregnancy as it is ototoxic to the fetus.
Pyrazinamide (category B2)
Pyrazinamide is little studied in pregnancy but is recommended by WHO and is 
routinely used in pregnancy at VIDS for all cases of TB.
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Pyrazinamide is strongly recommended in three situations:
1. When multidrug-resistance is suspected.
2. When the pregnant woman is HIV-infected.
3. In a pregnant woman with tuberculous meningitis, especially when isoniazid 
resistance is a possibility.
Pyridoxine
Supplement in pregnancy should be at a dose of 50 mg/day (instead of 25 mg/
day).
4.3.1 Agents used for multidrug-resistant TB (MDR-TB)
The treatment of MDR-TB is more complicated and difficult even in the absence of 
pregnancy, and overall care should always be under the direction of an individual 
with expertise in the management of patients with MDR-TB. For further details, 
refer to Chapter 3, Evaluation and treatment of drug-resistant tuberculosis.
Animal studies have observed teratogenicity with capreomycin, ethionamide 
and aminoglycosides, and patients who are taking these agents should be coun-
selled to avoid pregnancy. The possibility of teratogenicity should be emphasised 
and the patient should be advised to use two contraceptive methods. In the event 
of diagnosis of MDR-TB during pregnancy, expert advice should be sought 
regarding planning therapy for optimal maternal and fetal outcomes.
Table 4.3.1 TB-related complications in pregnancy: rates per 100 000 
pregnancies
Risk No TB TB Therapy related
Low	birth	weight 16 500 34 200
Premature 11 100 22 800
Small for date 7 900 20 200
Preeclampsia 4 700 7 400
Perinatal death 1 600 10 100
Fetal death 230 2 010
INH	hepatitis 1 600
All drug-related hepatitis 2 700
Fatal hepatitis 9.4–14
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4.3.2 Coinfection with HIV and TB
Coinfection with HIV and tuberculosis renders treatment regimens more prob-
lematic because of potential drug interactions and increase in frequency of treat-
ment-related side-effects. For further details, see Chapter 6, HIV and tuberculosis.
4.4 Breastfeeding and antituberculous drugs
TB drugs are excreted into breast milk. It is estimated that breastfeeding infants 
receive no more than 20% of the usual therapeutic dose of isoniazid for infants, 
and less than 11% of other antituberculous drugs. Potential toxic effects of drugs 
delivered in breast milk have not been reported.
Australian antibiotic guidelines recommend that breastfeeding infants of 
mothers taking isoniazid be given pyridoxine 5 mg daily (which must be crushed, 
and made into a suspension with water).
One way to minimise the level of antituberculous drugs in the baby is for the 
mother to take her antituberculous drugs immediately after feeding her child 
and substitute a bottle for the next feed, then go back to her usual feeding pattern 
till the next day.
4.5 Management of the newborn after delivery
Neonates exposed to TB during or after pregnancy should always be under the 
care of a paediatrician, but clinicians who look after adult TB patients need to be 
aware of the principles of management of exposed neonates.
The possibility of neonatal exposure may only become apparent in the early post-
partum period when the mother is referred to an adult clinic with possible dis-
seminated TB or smear-positive pulmonary TB. In such a case, it is essential that 
the treating physician recognises the potential for neonatal infection and organ-
ises immediate assessment of the baby at a major paediatric centre (for example 
in Melbourne at the Royal Children’s Hospital or Monash Medical Centre). Sub-
sequently, clinicians treating the mother and baby should maintain close contact, 
in conjunction with the public health TB program.
4.5.1 Withold BCG if HIV status is unknown
HIV status of the mother should be determined in all cases if not already known. 
If the mother is HIV-infected then HIV status of the newborn needs to be deter-
mined and appropriate HIV-related management initiated. Do not give BCG if 
the infant is HIV-infected.
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4.5.2 Management differs according to the routes and timing of exposure
Scenario 1: risk of haematogenous spread
Mother’s TB is likely to be associated with haematogenous spread (e.g. miliary 
TB, tuberculous meningitis during pregnancy or puerperium) or mother has 
active pelvic/genital TB during that time.
●● The infant has a definite risk of having or developing congenital TB. The 
onset of congenital TB averages 2–4 weeks (range a few days to a few 
months) after birth.
●● Keep the placenta and send for microscopy and culture, PCR and histo-
logical examination.
●● At birth, assess neonate for clinical evidence of congenital TB (e.g. fever, 
respiratory distress, hepatospenomegaly), and do CXR (clinical abnor-
malities are usually non-specific) and gastric washings for smear and cul-
ture. Culture is positive for M. tuberculosis in up to 80% of cases and 
provides important additional information of drug susceptibility. How-
ever, gastric washings are rarely smear-positive for acid-fast bacilli and 
therefore are not usually helpful in early assessment to confirm or exclude 
the diagnosis of TB. Lumbar puncture to exclude TB meningitis is indi-
cated if abnormalities suggestive of congenital TB are found.
●● Investigations should be done to detect other non-specific findings that 
can be found in congenital TB, including anaemia, altered liver function, 
raised inflammatory markers, and thrombocytopenia.
●● Treat with multiple drug therapy if any evidence of congenital TB is found.
●● In the absence of active disease:
– commence isoniazid (15 mg/kg/day) at birth
– perform careful clinical assessment frequently during the first 6 
months
– perform a TST (tuberculin skin test) at 4–6 weeks after birth (usually 
negative during the first few weeks), and repeat the TST at 12 weeks 
and 6 months; repeat the CXR at 4–6 weeks
– if the TST and CXR remain negative, continue isoniazid for 6 months
– if the TST is greater than 5 mm and there is no clinical or X-ray evi-
dence of TB, extend treatment to 9 months
– perform an interferon gamma release assay (e.g. QFN Gold In-Tube – 
QFN-GIT) on blood from the baby at birth and at follow-up as it may 
detect infection sooner and more reliably than TST.
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●● If there is any doubt about the diagnosis of congenital TB disease, have a 
low threshold for treating with a full course of antituberculous therapy.
●● Give BCG to the infant once congenital TB has been excluded or following 
the course of isoniazid therapy.
Scenario 2: active pulmonary TB in the mother
Mother has active pulmonary TB and is infectious at time of delivery.
●● Infection control procedures are required to reduce risk of transmission 
to baby, family, visitors and health staff. This would normally include 
admission to a well-ventilated isolation unit, education on cough hygiene 
and wearing of respiratory isolation face-mask while still infectious when 
in contact with others, e.g while handling or breastfeeding baby
●● There is no need to separate mother and infant if the infant is taking iso-
niazid and infection control measures are being used. There is no con-
traindication to infants rooming-in with their mother in hospital. Only 
separate mother and infant in highly exceptional circumstances, e.g. if 
there is a high suspicion of MDR-TB or if the mother is unable to care for 
her child.
●● Assess neonate for clinical, laboratory or radiological evidence of congen-
ital TB and treat with multiple drug therapy if it is present.
●● In the absence of active disease give isoniazid (15  mg/kg/day) to the 
newborn.
●● It is advised to withhold BCG immunisation. This is not because of evi-
dence of reduced effectiveness but because it may interfere with clinical 
diagnosis of TB disease in the baby.
●● After 6 weeks of isoniazid, do a TST and repeat CXR.
– If TST non-reactive (< 5  mm) and CXR normal, continue isoniazid 
and repeat these at 12 weeks and 6 months.
– If TST is reactive (≥ 5 mm) at 6 weeks, 12 weeks or 6 months of age, 
investigate thoroughly for pulmonary and extrapulmonary disease. If 
evidence of disease is present, treat with multiple drug therapy. If there 
is no evidence of pulmonary and extrapulmonary disease, continue 
isoniazid to complete a 9-month course.
●● After 6 months of isoniazid, do a TST and repeat CXR.
– If TST is non-reactive and the CXR is normal, discontinue isoniazid if 
the mother is now sputum smear-negative, and give BCG to the infant. 
The reason for repeating TST at 6 months and giving isoniazid up to 
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this time even if TST was non-reactive at birth is that tuberculin con-
version may be delayed for up to 6 months after infection at birth.
– If TST is non-reactive at 6 months of age but the mother is still sputum 
smear-positive, do not stop isoniazid. The mother needs investigation 
for treatment failure and possible drug resistance. The baby should be 
continued on isoniazid unless isoniazid resistance is thought to be 
likely or confirmed; if so, rifampicin would have to be given. A strong 
case exists for BCG in this situation.
●● If BCG is given to the baby (an option that some advocate at birth), watch 
for accelerated vaccine response.
– An accelerated response suggests that the baby has been infected. 
Follow the action outlined above; consider an accelerated response as 
you would a positive TST.
●● If there is no accelerated response, a tuberculin skin test can be done 2–4 
weeks later. A tuberculin reaction at this early stage suggests that it is due 
to a natural infection and not to the BCG.
Scenario 3: non-infectious pulmonary TB in the mother
Mother is on treatment for pulmonary TB but is no longer infectious (sputum 
culture is negative) at the time of delivery.
●● Assess neonate for clinical, laboratory or radiological evidence of congen-
ital TB (see above), and treat with multiple drug therapy if it is present.
●● No need for separation, but infection control measures such as wearing of 
respiratory isolation face-mask would be advised until mother has com-
pleted at least 8 weeks of TB treatment.
●● Examine the infant at monthly intervals.
●● Evaluate TB risk in family members.
●● Do a TST at 6 weeks, 12 weeks and 6 months (see above for further action).
●● There is a case for isoniazid preventive therapy for 6 months even if the 
mother is now sputum-negative because:
– the mother might have had haematogenous or genital spread resulting 
in infection of the infant
– the mother may still be infectious.
Scenario 4: mother’s treatment completed successfully
Mother completed antituberculous treatment during pregnancy and is no longer 
infectious.
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●● No separation of mother and baby is required.
●● Evaluate TB risk in family members.
●● Give BCG to the newborn, unless future risk of TB exposure is considered 
low.
Scenario 5: TB in the family
Another member of the family is being treated for TB.
●● If the family member with TB has completed treatment:
– evaluate the family member before the baby returns home
– give BCG to the newborn.
●● If the family member is on treatment:
– no contact with patient for at least 8 weeks after being culture negative
– give BCG to the newborn.
●● If the family member is infectious:
– the best course of action is to have no contact with the infectious 
person for at least 8 weeks after being culture negative
– if exposure is unavoidable or likely, give isoniazid until the index case 
is culture-negative for 8 weeks
– an alternative is to give BCG to the newborn before return to 
household.
Scenario 6: hospital exposure of baby to TB
Baby has been exposed to a healthcare worker with infectious TB while in the 
nursery.
●● Infection is rare under nursery conditions, but it can and does occur. 
Important information will include closeness and duration of contact, 
smear and culture result of index case and drug susceptibility pattern.
●● Investigate for TB, i.e. clinical features, TST and CXR. If no evidence of 
active TB disease is found, give isoniazid to the newborn for 6 months.
●● Follow up monthly.
●● If there is clinical suspicion of TB at any stage, then investigate for TB 
disease and treat as needed.
●● If the baby is well at 6 months, TST negative and CXR normal, discon-
tinue isoniazid and review at 12 months.
●● If the baby is well at 6 months, but TST reactive (≥ 5 mm), continue iso-
niazid until 9 months and review at 12 months.
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4.6 Screening for tuberculosis during pregnancy
Routine screening for tuberculosis during pregnancy is not necessary. However, 
screening should be considered for several groups of pregnant women.
4.6.1 Women at high risk
Women at high risk are those with possible active TB, or at high risk of latent TB 
and disease progression. These include:
●● Patients with symptoms suggestive of TB. Investigate for active disease; do 
not delay CXR.
●● HIV-infected patients (and other profoundly immunocompromised 
patients) – TST/QFN-GIT and CXR are indicated if not done previously 
or if the woman has had possible exposure to TB since the last test.
●● Recent close contact of infectious TB. Perform TST/QFT-GIT, followed by 
a CXR if this is positive.
4.6.2 Women at moderate risk
Women with moderate risk of disease progression include people with epidemi-
ology suggestive of previous but possibly remote TB exposure, such as recent 
arrival from a country with a high TB incidence. For these women, perform TST/
QFN-GIT, clinical assessment and CXR after the twelfth week of pregnancy.
4.7 Latent TB infection (LTBI) in pregnancy
For those with latent TB infection, including in HIV-infected women, there is no 
evidence that pregnancy increases the chance of TB reactivation. The TST 
reaction is not altered by pregnancy. The effect of pregnancy on QFN-GIT has 
not been evaluated; however it is recommended for use in all current circum-
stances in which TST is currently used.
There is no fetal toxicity from isoniazid (or rifampicin); however, the risk of iso-
niazid hepatitis is higher in women compared with men, and is possibly higher in 
the post-partum period. Treatment of LTBI is usually withheld until 3 months 
after pregnancy unless the patient has been recently infected (within the last 2 
years), is HIV-infected, or has medical conditions that increase the risk for reac-
tivation of inactive TB.
If women are to be treated during pregnancy, careful screening, patient educa-
tion about side-effects and monthly questioning for symptoms of toxicity (espe-
cially hepatitis) are recommended. Pyridoxine should be prescribed routinely, at 
a dose of 50 mg daily. Monthly hepatic enzyme testing should be performed if 
isoniazid therapy is given in pregnancy.
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4.8 Infertility related to tuberculosis
Genital tuberculosis is a well-known contributing factor to female infertility. 
While in-vitro fertilisation techniques can be successful in women with genital 
TB, it appears that outcomes are less favourable compared with other aetiologies 
of tubal infertility. A recent study evaluating the impact of LTBI in patients with 
unexplained infertility and previous unsuccessful IVF attempts suggests that 
improved outcomes may be obtained in women with latent infection who 
undergo treatment with antituberculous therapy.
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5.1 Decision-making in testing and treatment of latent 
TB infection
When deciding whether to treat for latent TB infection (LTBI), the first consid-
eration is to rule out active tuberculosis by taking a careful history, examining 
the patient and reviewing a recent CXR. When active TB is excluded, the follow-
ing questions must be considered.
●● How likely is it that the patient has LTBI, based on epidemiological 
grounds (pre-test probability)?
●● What is the probability that the patient will go on to develop active 
tuberculosis?
●● What are the test results and their interpretation?
●● What is the efficacy of treatment in this patient, taking into account like-
lihood of treatment adherence and completion?
●● What is the propensity for the patient to develop an adverse reaction 
(largely age-dependent hepatotoxicity) to treatment for LTBI?
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5.2 Pre-test probability of TB infection
Pre-test probability of TB infection must be assessed. Groups with a high proba-
bility of having TB infection include:
●● immigrants and refugees from countries with a high prevalence of TB – 
this is the most common risk factor for LTBI in Australia
●● those with a high degree of exposure – close contacts of smear-positive 
pulmonary TB cases (family members, household contacts and other con-
tacts with more than 8 hours of exposure), healthcare workers with expo-
sure to TB patients in high-prevalence countries
●● other specific high-risk groups – these may include the homeless, some 
Indigenous communities, some healthcare workers, travellers and expa-
triates who have spent prolonged periods of time in TB-endemic coun-
tries, and on occasions those in prisons and institutions.
5.3 Risk of TB disease progression following TB 
infection
Once a person has contracted LTBI, the risk for progression to TB disease varies. 
The greatest risk for progression to disease occurs within the first 2 years after 
infection, when approximately half of the 5–10% lifetime risk occurs. However 
this risk is age-dependent (see Table 5.3.1).
Numerous clinical conditions also are associated with increased risk for pro-
gression from LTBI to TB disease. These conditions can be divided into those 
with a more than 5-fold risk, and those with a 1–5-fold risk, relative to the risk in 
people who have acquired latent TB infection more than 2 years previously with 
no other risk factors. HIV infection is the strongest known risk factor.
Table 5.3.1 Risk of TB disease in 2 years following TB exposure and infection
Age group Risk (%)
Infants (≤ 1 year) 50
Children (1–2 years) 12–25
Children (2 to 5 years) 5
Children (5–10 years) 2
Adolescents and young adults 10–20
Older	adults 3–5
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5.3.1 More than five times relative risk
●● People with HIV infection
●● Infants and children aged < 5 years
●● People receiving tumour necrosis factor-alpha (TNF-a) inhibitors, e.g. 
infliximab, adalimumab
●● People who were recently infected with M. tuberculosis (within the past 2 
years)
●● People with a history of untreated or inadequately treated active tubercu-
losis, including people with fibrotic changes on chest radiograph consist-
ent with prior active tuberculosis (not just a granuloma)
●● People with medical conditions such as silicosis, chronic renal failure, leu-
kaemia, lymphoma, or cancer of the head, neck, or lung
●● People who have had a jejunoileal bypass
5.3.2 One–five times relative risk
●● People who have had a gastrectomy
●● People who weigh < 90% of their ideal body weight
●● Cigarette smokers and people who abuse drugs or alcohol
●● People with diabetes
●● People receiving immunosuppressive therapy such as > 15 mg predniso-
lone daily for more than 1–2 months, or etanercept (associated with a 
lower relative risk compared with the TNF-a monoclonal antibodies)
●● Recently arrived refugees from countries with a high TB prevalence.
If active infection does occur, those with HIV infection and children < 5 years 
old also have a greater risk of poor outcome, including meningitis and dissemi-
nated disease and death.
5.4 Interpretation of LTBI test results
The two most widely used tests for diagnosis of LTBI in Australia are the tuber-
culin skin test (TST) and the Quantiferon Gold-TB In-Tube (QFN-GIT) test, an 
interferon gamma release assay (IGRA). Neither test has perfect sensitivity or 
specificity, but the QFN-GIT has many advantages over TST that are elaborated 
below. In VIDS, QFN-GIT is the preferred test, but the TST is still widely used in 
other settings. It is not uncommon to see a patient who has had both tests, with 
results that are discordant (20%). The following subsections describe TST and 
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QFN-GIT, and their advantages and disadvantages and interpretation, including 
how to interpret discordant results.
5.4.1 Tuberculin skin test (TST)
Disadvantages of TST
Poor specificity: false positive TST results
TST is known to have high rates of false positives. Factors that lead to a false 
positive TST include:
●● Previous BCG vaccination. A single BCG vaccination at birth usually 
leads to a positive TST that wanes over the next decade. However, BCGs 
given after age 2 and repeat BCGs can lead to prolonged (false) positive 
TST.
●● Exposure to non-tuberculous mycobacteria (NTM). Geographically clus-
tered in tropical and sub-tropical regions, exposure to these environmen-
tal mycobacteria can lead to a false positive TST.
Poor sensitivity: false negative TST results
Immune dysfunction and other factors cause false negative TST results. Examples 
include:
●● HIV, and other immunosuppressive disease or therapy
●● inadequate nutrition
●● malignancy
●● active TB, especially severe/miliary TB
●● concurrent viral infection
●● children and elderly
Tuberculin reversion
Reversion from a previous positive to a negative reaction occurs in 2–20% of 
people over 2 to 20 years and is more likely in those with an initial reaction of 
10–14 mm, i.e. not a strongly positive reaction. With continuing TB exposure a 
large tuberculin reaction tends to be maintained.
Individual and interpreter variability
The TST response in an individual is highly variable. Two tests done at the same 
sitting by the same operator on different arms may show 15% discordance. The 
same tuberculin reaction in an individual measured by two different experienced 
operators may also show 15% discordance in the readings. Under-reading of a 
positive TST was common in one study: 33% failed to identify a positive reaction.
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Booster reactions
In patients with previous mycobacterial infection (either BCG vaccination, TB or 
NTM), an initial TST may be negative, but if this is followed by a second TST, the 
protein from the first TST boosts the immune response and can lead to a positive 
second test if performed from 1 week to 1 year (and possibly longer) later.
The implication of this is that when people have multiple TSTs (e.g. serial testing 
in high-risk healthcare workers, or screening before and after travel to a country 
with a high TB incidence), a positive result on a second or subsequent TST fol-
lowing an earlier negative result could be erroneously interpreted as indicating 
TB exposure and infection in the interval between the tests, whereas the result is 
really due to boosting of a waned immune response to a previous mycobacterial 
infection. This issue is not relevant if serial testing is performed with IGRA.
Interpretation of TST without IGRA
The current interpretation of TST results uses several cut-offs, with higher cut-off 
for those with low pre-test probability (≥ 15 mm) and lower cut-off (≥ 5 mm) for 
those with high probability of progression to tuberculosis. The intermediate 
cut-off (≥ 10 mm) is for those with epidemiological risk factors suggesting high 
pre-test probability and with those who have greater than average probability of 
progression to tuberculosis who do not fall into the high-risk group above.
Note that the choice of cut-offs is based on factors other than TST performance 
in these groups. This makes the interpretation very confusing, especially in the 
setting of discordant QFN-GIT results as discussed below.
5.4.2 Interferon gamma release assays (IGRA)
Interferon (IFN)-gamma release assays (IGRAs) are whole blood ex-vivo T cell-
based assays for the detection of LTBI. The principle of the assay is that T cells of 
individuals previously infected with M. tuberculosis will produce interferon-
gamma when they encounter TB-specific mycobacterial antigens. Thus, a high 
level of interferon-gamma production is presumed to be indicative of TB infec-
tion. The antigens used in IGRAs (ESAT-6, CFP-10 with or without TB 7. 7) are 
encoded by M. tuberculosis genes that are not shared with M. bovis-BCG or most 
NTM, and hence they are called ‘region of difference’ (RD) antigens.
There are two methods for detecting the IFN-gamma released by the T cell: an 
enzyme-linked immunosorbent assay (ELISA, e.g. QFN-GIT), and an enzyme-
linked immunospot assay (ELISPOT, e.g. T-SPOT.TB). The QFN-GIT is the more 
widely used of these tests in Australia. In both tests, a control mitogen and a nil 
sample are tested in parallel with the M. tuberculosis antigens. IGRA tests are 
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reported as positive, negative or indeterminate. Indeterminate tests may repre-
sent low response to the control antigen or high response to the nil control. Cur-
rently there is a single cut-off at which the test is regarded as positive.
Advantages over TST
●● Better specificity in the setting of BCG vaccination and NTM exposure 
(most common in tropical and subtropical regions).
●● Similar sensitivity to TST in most cases, although IGRAs may be more 
sensitive in the setting of immune suppression, e.g. in haematology and 
HIV-infected patients.
●● Simple, single blood test, not requiring return visit (hence definitely pre-
ferred in groups in whom follow-up TST reading may be difficult).
●● Automated interpretation of QFN-GIT eliminates problems with inter-
user reliability.
●● No booster phenomenon, as the individual does not encounter antigen in 
this in vitro test. (Results of studies of whether IGRA response can be 
boosted by TST are inconsistent.)
Disadvantages
●● IGRAs are more expensive than TST, so their use is not feasible in many of 
the countries in which TB incidence is highest.
●● The accuracy of IGRAs appears to be at least as good as TST in almost all 
settings. However, IGRAs may not perform as well in children as in adults, 
and currently the CDC suggest that in children < 5 years TST is preferred, 
although QFN-GIT is an acceptable alternative. Current practice at the 
Royal Children’s Hospital in Melbourne (February 2012) is still to per-
form TST for those under 16 years.
●● IGRAs require a phlebotomy and correct specimen handling and 
processing.
●● There is relatively limited data concerning the ability of a positive or nega-
tive IGRA test to predict the subsequent development or absence of TB 
(although such data are accumulating and indicate at least equivalent pre-
dictive performance to the TST).
Interpretation of QFN-GIT
●● A single cut-off value (TB antigen minus nil control ≥ 0.35 IU/mL) is used 
to define a positive result. Some experts have suggested applying different 
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cut-off values for high- and low-risk populations (as is done with TST), or 
defining a ‘borderline’ range, but this is not current practice.
●● An indeterminate result can be due to a low positive control or a high 
negative control (see section 5.4.4).
Factors affecting sensitivity
●● As with TST, IGRAs are less sensitive in the setting of significant immune 
suppression. However, studies in HIV infection indicate they are less 
likely to be falsely negative than TST.
Factors affecting specificity
●● False positives may occur in the presence of three NTM: M. marinum, M. 
szulgai, M. kansasii.
5.4.3 Interpretation of discordant TST and IGRA
Without a gold standard it is very hard to determine sensitivity and specificity, 
but the following considerations help guide interpretation.
●● In immune-competent adults, sensitivity of QFN-GIT and TST are both 
estimated to be around 70–80%. TST specificity is high (over 90% if 
15 mm used as cut-off) in those not vaccinated with BCG or exposed to 
NTM. QFN-GIT is 93–99% specific in immunocompetent people whether 
or not they are BCG vaccinated. In patients with a low risk of exposure, 
discordant TST+/IGRA– results are common, especially in those previ-
ously vaccinated with BCG.
●● In HIV-positive patients, TST is more likely than the T-SPOT.TB assay to 
produce a false negative result, and the lower the CD4 cell count the more 
likely this is to occur. QFN-GIT seems to have lower sensitivity than 
T-SPOT.TB but is more sensitive than TST. QFN-GIT has higher rates of 
indeterminate tests due to negative mitogen control response when the 
CD4 cell count is ≤ 100 per microlitre compared with when CD4 cell 
count is >100 per microlitre.
●● In the elderly TST is more likely to be falsely negative, whereas QFN-GIT 
is less affected by age.
●● Comparative studies are less common in children. QFN-GIT has been 
found to be less sensitive than T-SPOT TB in children with active TB.
●● Following treatment of active or latent TB, reversion from a positive to a 
negative result can occur with both TST and IGRAs. The significance of 
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this is unknown, in particular whether it indicates eradication of all M. 
tuberculosis organisms.
Meta-analyses have shown that IGRA specificity is consistently high in those 
with and without prior BCG vaccination, whereas TST specificity is diminished 
by prior BCG vaccination. A fully integrated statistical meta-analysis, which 
included latent class and mixed effects, estimated that sensitivity for IGRAs was 
64% and specificity was 99.7%. TST specificity was similar to IGRA in those 
without prior BCG but fell to 50% in those with prior BCG.
IGRA positive, TST negative
It is most likely that this discordance represents a falsely negative TST because 
data show that for groups such as the elderly and the immunocompromised 
IGRAs are more sensitive than TST.
IGRA negative, TST positive
This pattern of discordance is relatively common and is usually due to a falsely 
positive TST. If the patient has risk factors for a false positive TST, such as recent 
BCG, multiple BCGs, BCG at older age or exposure to NTM, the probability that 
this is a false positive TST is high.
If the TST reaction is large (> 20 mm) however, it is rarely a false positive. In such 
cases, the IGRA may be a false negative, particularly if the TB mitogen result is 
close to the positive cut-off.
5.4.4 Management of indeterminate QFN-GIT result
Indeterminate QFN-GITs should be repeated (once).
An indeterminate QFN-GIT due to a high nil control value (reflecting elevated 
background T-cell activity) may well lead to a more definitive result in the second 
test. An indeterminate result due to reduced mitogen activity is more likely to 
remain indeterminate. After two indeterminate results, judge the situation by epi-
demiology and risk of progression. A TST can be done in cases where: (i) the 
patient has no risk factors for false positive TST (no BCG and/or low likelihood of 
exposure to NTM); (ii) the TST is expected to be positive if LTBI exists (not sig-
nificantly immunosuppressed); and (iii) a positive TST would lead to a decision to 
treat the patient. Examples include recent significant TB exposure in an Austral-
ian-born person, or someone about to undertake TNF-a inhibition therapy.
5.4.5 IGRA testing in those who have had a TST
If a patient has already had a TST, an IGRA should only be done if interpretation 
of the TST result is unclear and the result of the IGRA would affect management. 
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The following guidelines will assist, but do not cover every conceivable situation. 
In practice, epidemiology (pre-test probability), risk of progression to disease 
and risk factors for false positives (especially prior BCG) and negatives all have to 
be taken into account.
●● If the TST is ≥ 15 mm, IGRA not indicated.
●● If the TST is ≥ 10 mm and < 15 mm:
(a) if the person has a history of TB exposure or has suggestive X-ray 
changes (e.g. > 1 calcified nodules, upper lobe fibrosis) or is immuno-
suppressed: regard TST as positive and IGRA not indicated. This rec-
ommendation is stronger if person has not had a BCG.
(b) if the person has none of risk factors in (a): regard TST as indetermi-
nate and IGRA indicated. This recommendation is stronger if person 
has had a BCG.
●● If the TST is < 10 mm, IGRA not indicated, unless the person has risk fac-
tors for LTBI and progression to active TB (e.g. patient from TB-endemic 
country with HIV, or patient with abnormal CXR about to start 
infliximab).
5.5 Treatment efficacy and adherence to therapy
Patients diagnosed with latent TB according to the recommendations discussed 
above should be considered for treatment with isoniazid monotherapy. Before 
recommending treatment in older patients and in those with complicating 
factors, consideration should be given to the probability of disease progression to 
active TB if untreated, likely compliance and treatment efficacy, and the risk of 
adverse drug reactions.
5.5.1 Treatment efficacy
Isoniazid is the recommended first-line treatment for LTBI at a dose of 300 mg 
once daily. The aim should be to treat for 9 months but in some cases therapy 
may be ceased at 6 months, for example if the patient is not motivated to continue 
therapy or is experiencing minor drug side-effects. HIV-positive and other 
immunosuppressed patients and those with fibrotic lesions on CXR should 
always be treated for for 9 months.
Studies have shown that both a 6-month and a 12-month course are effective at 
reducing progression of disease (RR 0.44 and 0.38 respectively), with no statisti-
cally significant difference between the progression rates to active TB in the two 
groups. However, in subgroup analyses of several trials the maximal beneficial 
effect of isoniazid is likely to be achieved by 9 months, and minimal additional 
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benefit is gained by extending therapy to 12 months. When compared with 
placebo, both 6-month and 12-month regimens are effective in HIV-positive 
patients, with no direct comparison available (see Table 5.5.1).
Rifampicin for 4 months is an acceptable alternative if there is significant toxicity 
to isoniazid or if the index case has known isoniazid-resistant TB. There are no 
head-to-head long-term efficacy studies comparing 4R with 9H.
Isoniazid and rifampicin given in combination for 3 months is another effective 
regimen; it is used in the United Kingdom but not commonly in Australia.
Rifampicin and pyrazinamide is effective and only has to be given for 2 months, 
but is not recommended because of high rates of hepatotoxicity.
Just as this handbook was in the final stages of its preparation, a regimen of 
directly observed weekly isoniazid and rifapentine (the latter is a rifamycin agent 
with a long half-life) for 3 months was reported to be as effective as a 9-month 
course of isoniazid. Rifapentine is currently not licensed for use in Australia.
5.5.2 Adherence
It is difficult to anticipate which patients will be compliant with therapy, but this 
is an important consideration in the final decision about treatment and treatment 
duration. Patients should ideally express a wish to take the medication and be 
willing to commit at the outset to daily medications for the duration of the pre-
scribed treatment, and to attend the outpatient clinic regularly for monitoring.
5.6 Risk of adverse effects from LTBI treatment
5.6.1 Hepatitis
●● Abnormal LFTs are common in patients following commencement of iso-
niazid therapy. Elevations of AST or ALT occur in 10% to 20% of people 
on isoniazid; however, clinical hepatitis is infrequent and is directly 
Table 5.5.1 Evidence for LTBI therapy
Drugs
Duration
(months) Interval HIV-negative HIV-positive
lsoniazid 9 Daily A(II) A(II)
6 Daily B(I) C(I)
Rifampicin 4 Daily B(II) B(III)
A	=	preferred;	B	=	acceptable	alternative;	C	=	offer	when	A	and	B	cannot	be	given.	I	=	randomised	
clinical	trial	data;	II	=	data	from	clinical	trials	that	are	not	randomised	or	were	conducted	in	other	
populations;	Ill	=	expert	opinion.
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related to increasing age – a very low risk below the age of 35, but a signifi-
cant risk in those over the age of 50, according to a study conducted in the 
1970s. A more recent study suggests the rate of symptomatic hepatotoxic-
ity may be one-fifth as common as previously believed in those over 35 
(see Table 5.6.1).
●● Another recent study of people over 35 years showed that of 335 patients 
commencing isoniazid for LTBI, 12% developed AST/ALT > 2× the upper 
limit of normal, but none developed symptomatic hepatitis and only one 
required temporary cessation of therapy.
●● The risk of hepatitis is increased in those with pre-existing liver disease 
and increased alcohol intake. Asymptomatic chronic carriers of hepatitis 
B (HBsAg+) do not have an increased risk of isoniazid hepatitis compared 
to other people of similar age, although caution is needed in patients with 
chronic HBV who develop abnormal LFTs. Several studies have also sug-
gested that being of white race and female trended towards increased risk, 
but these have not been statistically significant.
●● Isoniazid hepatitis can be fatal: the mortality rate is 6–8% and increases 
with age and alcohol intake.
●● While hepatitis is more common in the first 2 months of therapy, approxi-
mately 50% of elevated LFTs occur after this date. Seventeen severe isoni-
azid-associated liver injury events were reported by the CDC (years 
2004–08), of which 16 occurred after the first month of therapy.
5.6.2 Peripheral neuropathy
Peripheral neuropathy occurs in < 1% of people on isoniazid and is preventable 
with pyridoxine (vitamin B6) supplements of 25 mg/day. Pyridoxine is indicated 
for people older than 65 years of age, pregnant women, people with diabetes, 
daily alcohol users, people with chronic renal failure, poorly nourished people 
(frequent in recently arrived immigrants and refugees) and anyone with any 
other predisposition to peripheral neuropathy; otherwise we do not prescribe 
pyridoxine routinely.
5.6.3 Other isoniazid adverse effects
●● Allergic rash
●● Neuropsychological effects such as minor difficulties with concentration 
and dizziness – usually avoided by administering the dose at night
●● Acne and minor alopecia 
●● Gastrointestinal upset
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●● Drug interactions – increase in serum levels of phenytoin and 
disulfuram
5.7 Practical steps in management of LTBI
5.7.1 Who to screen for LTBI
Testing for LTBI should be targeted at those with risk factors for TB infection or 
progression to active TB. Groups for whom testing is recommended are:
●● Contact tracing of active TB cases.
This is undertaken by the public health TB program. In Victoria the 
DoH TB Control Program uses TST. A baseline TST is done at the time of 
contact tracing when a significant contact is established (> 8 hours contact 
in smear-positive pulmonary TB, and 24–48 hours if smear-negative pul-
monary TB). This is followed by a repeat test in 8–12 weeks after last 
infectious contact if the initial test is negative. An argument can also be 
made for just doing one test at 8 weeks, particularly in those with no prior 
exposure to TB.
●● Refugee screening.
Testing is recommended for all 12–35-year-old refugees except those 
with a known history of active tuberculosis, ideally within 12 months of 
arrival but later if not done earlier. Refugees have a high risk of recent 
infection or re-infection. Therefore, depending on the epidemiology, the 
age cut-off for routine testing may be higher in this group.
●● Immigrant and onshore visa applicant screening.
In Victoria, limited screening of selected recently arrived immigrants 
and visa applicants applying from within Australia – usually those with 
Table 5.6.1 Risk of hepatitis in patients treated with isoniazid by age, according 
to two different studies
Age
(years)
Hepatitis risk (%)
(from 1970s study)*
Age
(years)
Hepatitis risk (%)
(from 1990s study)**
< 20 Rare < 15 < 0
20–34 up to 0.3 15–34 0.8
35–49 up to 1.2 35–64 0.21
50–64 up to 2.3
≥ 65 4.6 > 65 0.28
* Kopanoff et al (1978)
** Nolan et al (1999)
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changes suggestive of inactive TB on the health check CXR – is done by 
the Migrant Screening Clinic, using TST.
●● Healthcare worker and student screening.
Guidelines recommend pre-employment screening for all employees 
with patient contact, and annual screening for employees at high risk of 
ongoing TB exposure. Healthcare students should also be screened prior 
to beginning clinical placements. Those born in a TB-endemic country 
are a particular priority for this testing.
●● Patients who are to undergo immunosuppressive treatment.
Testing for latent TB infection is recommended for patients treated 
with TNF-a inhibitors, high doses of corticosteroids and high-dose 
chemotherapy, and for organ transplant patients.
●● Patients with HIV infection.
●● Patients with silicosis.
●● Other groups.
Testing for latent TB may be considered in other groups at higher risk 
of TB infection or progression to active disease, such as the homeless and 
prisoners.
At VIDS, patients who require screening for latent TB undergo testing with 
QFN-GIT.
5.7.2 Exclude active infection
Active infection is treated with multiple drugs and must first be excluded.
●● Does the patient have any symptoms or signs? These may include consti-
tutional or respiratory symptoms, back pain (spinal disease) and enlarged 
lymph nodes.
●● Are there radiological changes? Are there old CXRs for comparison? If so, 
have these radiological changes been present for > 2 years? A CXR showing 
no abnormalities consistent with active tuberculosis is mandatory prior to 
initiating treatment. Stable chest films for at least 1 year would also be evi-
dence for inactive disease, but, if in doubt, sputum should be obtained. 
One or two calcified granulomas do not usually qualify as a significant TB 
abnormality. People with an isolated granuloma have a similar risk of 
developing active disease as those with completely normal films.
●● Collect sputum or bronchial specimens for culture in those with sus-
pected pulmonary tuberculosis.
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●● Even if all smears are negative and the patient is asymptomatic, the possi-
bility of asymptomatic TB disease remains. Consider bronchoscopy if 
radiographic changes are not typical for old scarred TB and cannot be 
proven to be stable, or if the patient has respiratory symptoms even in the 
absence of worrying CXR changes. Consider treatment for TB disease in 
the absence of X-ray changes suggestive of active disease if (i) the patient 
has constitutional symptoms such as weight loss or fever, or (ii) the patient 
has silicosis.
5.7.3 Determine if treatment of latent TB infection is indicated
Recommend treatment, regardless of age, for those patients at highest risk of 
progression to active TB:
●● Probable or confirmed recent infection following recent TB exposure
●● Conversion from negative to positive on serial LTBI testing
●● HIV infection
●● Significant immunosuppressive therapy – organ transplantation, TNF-a 
inhibitor therapy, high-dose chemotherapy
●● Silicosis
●● Children.
Consider treatment for patients at lower but still increased risk of progression to 
active TB:
●● Significant CXR changes indicative of past TB infection
●● Refugees < 45 years
●● Lesser degrees of immunosuppression
●● Some medical conditions such as chronic renal failure.
The decision to treat or not will depend on balancing the risk of TB progression 
against the risks of treatment (chiefly hepatotoxicity) and likelihood of 
adherence.
Treatment is generally not indicated for patients older than 35 years with no risk 
factors for TB progression. One exception is a healthcare worker, because of the 
potential for patient and staff exposure should that person develop TB.
Some people with LTBI are followed with serial CXRs, although this is an insen-
sitive way of detecting early TB reactivation. This approach can be taken if a 
patient declines a recommendation for LTBI treatment, if the risks of treatment 
outweigh the risk of reactivation of latent TB, or if a patient cannot be monitored 
adequately for adverse drug reactions and adherence.
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If serial CXRs are conducted, they are usually done 0, 6 months, 12 months and 
24 months after a person is believed to have been exposed to TB, and are there-
fore not required for those with LTBI likely to have been acquired >2 years prior 
to review.
5.7.4 Determine medical management
●● Isoniazid monotherapy is the preferred agent, with rifampicin monother-
apy an acceptable alternative in selected patients as discussed above.
●● Special groups:
– Children: as for adults, treat for 9 months with isoniazid.
– Pregnant women: usually defer treatment until after delivery except 
when the risk of TB developing during pregnancy is high; e.g. the 
patient is HIV-positive or has had a very recent exposure (within 
months). There is no risk of isoniazid to the fetus, but there may be a 
risk of flare of hepatitis in the mother following delivery.
– Suspected MDR-TB latent infection. Currently we do not change man-
agement based on concerns about rates of MDR-TB in the patient’s 
country of origin. However, this is under review as the epidemiology 
changes. If the case contact were known to have MDR-TB, the princi-
ple of management is to treat with at least two drugs to which the TB is 
known to be susceptible. Based on current evidence including local 
mycobacterial susceptibility data, we suggest moxifloxacin plus either 
ethambutol or pyrazinamide if empiric therapy is to be commenced 
while extended sensitivities are awaited. Optimal treatment duration 
is not established, but our current practice is for 6–9 months of 
therapy.
5.7.5 Baseline testing before starting LTBI treatment
●● Prior to initiating LTBI treatment, check LFTs, HBsAg, HCV  Ab and 
serum vitamin D level. It is important to document baseline LFTs to assess 
any abnormalities that may develop on treatment. Chronic hepatitis B and 
C affect the later interpretation of LFTs. Vitamin D deficiency is extremely 
common in TB clinic patients.
●● Provide patient with information sheets (in Victoria, these are produced 
by the TB Control Program and are available in several languages).
5.7.6 Monitoring during LTBI treatment
●● Patients should first be reviewed no later than 4 weeks after starting treat-
ment for LTBI. Subsequent appointments can be after 2 then 3 months so 
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the patient has an appointment at months 0, 1, 3, 6, and 9. (Note that this 
is less frequent than the monthly follow-up recommended in US guide-
lines.) The final appointment is useful to ensure and document full com-
pliance with therapy and to remind the patient of the small ongoing risk 
of active TB.
●● Those considered at high risk of adverse events or treatment non-comple-
tion should have monthly appointments and LFTs. These are patients:
– aged over 35 years
– with a history of daily alcohol intake, abnormal baseline liver function 
tests, known chronic liver disease or receipt of hepatotoxic medications
– where there are concerns regarding adherence
– with HIV infection and pregnant/post-partum patients.
●● At each outpatient clinic visit:
– Assess adherence.
– Evaluate for signs and symptoms of active TB and drug reactions.
– Remind patients of signs and symptoms of hepatotoxicity.
– Repeat liver function tests for patients listed above or for those with GI 
symptoms.
●● Routine CXR, TST and IGRA are neither necessary nor useful during or 
after treatment of latent infection.
●● If a patient misses one or more doses of medication:
– Interruption of < 1 month is probably not significant. Ensure the com-
plete course is taken.
– Interruption for > 1 month in the first 3 months of treatment: start the 
whole course again and ensure future compliance.
– Interruption for > 1 month after 3 months: ensure future compliance 
and complete the planned treatment course.
5.8 Key concepts
●● Testing for LTBI should be targeted at those with risk factors for TB expo-
sure or progression to active TB.
●● The TST is limited by its poor specificity, especially in BCG-vaccinated 
people, and by practical considerations relating to test administration and 
reading of the result.
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●● IGRAs have improved the specificity of testing for LTBI and offer consid-
erable practical advantages over the TST. In adults, IGRAs can be used in 
all situations in which TST is currently used, and IGRAs are preferred in 
BCG-vaccinated people.
●● Neither the TST nor the new IGRAs should be used for diagnosis of active 
TB disease.
●● Treatment of LTBI is targeted at those with a high risk of progression to 
active TB: close contacts of smear-positive pulmonary TB, recent TST or 
IGRA converters, young children, HIV-infected and other significantly 
immunosuppressed patients, recently arrived refugees from TB-endemic 
countries, and patients with significant CXR changes or silicosis.
●● Treatment of LTBI is with isoniazid for 9 months. For selected patients, an 
alternative is rifampicin for 4 months.
●● Combination therapy with isoniazid and rifapentine given weekly for 3 
months is a very promising treatment approach (but rifapentine is cur-
rently unavailable in Australia).
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6.1 Testing for HIV infection in TB patients
Globally, TB is the most significant infection complicating HIV infection. In 
Australia, there is relatively limited overlap between those at risk of HIV infec-
tion – predominantly men who have sex with men – and those at risk of TB, who 
are largely people born overseas in countries of high TB incidence. TB accounts 
for only 2–3% of AIDS-defining illnesses in this country. However, TB is the 
initial AIDS-defining illness in more than 20% of locally notified AIDS patients 
who were born in African and Asian countries. Late diagnosis of HIV infection is 
common in these patients, in whom tuberculosis is often the initial manifesta-
tion of previously unsuspected HIV infection.
The natural history of TB infection is profoundly altered by HIV infection: the 
rate of progression from latent to active TB infection is as high as 5–10% per year 
in people with HIV infection, compared with 5–10% over a lifetime in latently 
infected individuals without HIV infection.
The overall prevalence of HIV infection in the Australian population is 0.05–
0.1%. A minimum estimate of the prevalence of HIV infection among notified 
cases of TB is 1%. Therefore, all patients with newly diagnosed TB should be 
regarded in the same light as those belonging to ‘traditional’ HIV risk groups, 
and should be tested for HIV infection after appropriate discussion and provi-
sion of information about HIV testing.
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6.2 Screening for latent TB infection in HIV patients
All patients with newly diagnosed HIV infection should be tested for latent TB 
infection. The basis for this recommendation is that the incidence of TB in people 
living with HIV infection in Australia (66 per 100 000) is more than ten times 
higher than the incidence in the general population (5.8 per 100 000).
The sensitivity of the tuberculin skin test (TST) is reduced by advancing immu-
nosuppression, and a lower cut-off of 5 mm is used to define a positive result. 
Interferon gamma release assays (IGRAs) such as the QFN-GIT test are less 
affected by immunosuppression than the TST, and for this and other reasons are 
increasingly used as the preferred screening method for TB infection, as in other 
patient groups (see Chapter 5). The QFN-GIT test is used in the VIDS clinic, 
although this test also loses sensitivity and may be indeterminate (mitogen 
negative) with CD4 counts <100 per microlitre.
For patients with an initial negative or indeterminate test and a CD4 cell count < 
200 per microlitre, US guidelines recommend repeat TB infection testing when 
the CD4 cell count increases above 200 per microlitre after antiretroviral (ARV) 
therapy is started.
All patients, especially those born overseas, should have a baseline CXR as part 
of the initial assessment following HIV diagnosis.
Patients with a positive IGRA or TST should undergo a thorough clinical assess-
ment for evidence of active TB, and a chest radiograph, with further laboratory 
or radiological investigation if appropriate (see Chapter 5).
6.3 Treating latent TB in HIV patients
This is relatively straightforward and follows the principles outlined in Chapter 5.
●● A 9-month course of INH 300 mg once daily is given. The usual alterna-
tive to INH is a 4-month course of rifampicin but significant interactions 
occur between rifampicin and some antiretroviral agents (see below). If 
rifampicin cannot be used, an alternative is rifabutin, with appropriate 
dose modification of rifabutin and interacting antiretroviral agents.
●● INH hepatotoxicity is more common in HIV patients. LFTs should be 
monitored monthly, and patients counselled about symptoms of hepatitis.
●● Pyridoxine 25 mg daily should be prescribed routinely
●● INH should not be started at the same time as drugs with overlapping 
toxicity – there is less urgency about starting latent than active TB treat-
ment, and it is best to wait at least 4 weeks after starting ARV therapy or 
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cotrimoxazole in order to avoid the problem of trying to establish which 
drug caused side-effects such as skin rash or hepatitis.
A common clinical dilemma is the HIV patient from a high TB incidence country 
with a CD4 cell count < 200 per microlitre, a negative QFN-GIT or TST and a 
normal CXR: should this patient be treated for latent TB, given the possibility 
that the screening test may be falsely negative?
Studies of latent TB treatment in HIV infection, including those undertaken in 
high TB incidence countries, indicate that the greatest treatment benefit occurs 
in those with a positive baseline test (usually TST in these studies). Therefore 
presumptive treatment of ‘test negative’ latent infection is not generally recom-
mended, unless there are particularly compelling epidemiological circumstances 
indicating a very high risk of TB infection. As indicated above, patients with a 
negative or indeterminate TB infection test who start antiretroviral therapy 
when the CD4 cell count is < 200 per microlitre should have a repeat test when 
the CD4 cell count increases to > 200 per microlitre.
6.4 Diagnosing active TB in HIV patients
In contrast to most other serious HIV-related opportunistic infections, some 
cases of HIV-associated TB (a minority) occur at CD4 cell counts > 200 per 
microlitre. Most of these are cases of pulmonary TB, and usually present in the 
‘standard’ fashion with the expected respiratory and constitutional symptoms, 
typical X-ray findings of an upper lobe cavitating opacity, and AFB smear-posi-
tive sputum. Diagnosis is relatively straightforward.
Unfortunately, when the CD4 cell count is < 200 per microlitre, as it usually is, 
diagnosis of HIV-related TB is much more challenging. Patients have atypical 
manifestations of pulmonary infection and more than half have extrapulmonary 
or disseminated disease. Notable features of pulmonary TB include:
(i) non-productive or absent cough with negative sputum smears
(ii) non-classical CXR features such as mid or lower zone opacities, pleural effu-
sion or intrathoracic lymphadenopathy. At times, the CXR may even be normal.
Any form of extrapulmonary TB may occur so, in a patient with known HIV 
infection, TB must be part of the differential diagnosis of a wide range of HIV-
related syndromes. These include:
●● unexplained fever
●● meningitis
●● space-occupying intracerebral lesions
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●● choroidal and retinal lesions
●● regional lymphadenopathy
●● abdominal pain and diarrhoea
●● unusual forms of extrapulmonary disease, including pancreatic and 
splenic abscesses, and disseminated cutaneous disease.
Diagnosis of HIV-related TB usually requires a high index of suspicion. It begins 
with obvious clues such as the epidemiological background of the patient, 
followed by careful clinical assessment and standard investigations such as CXR 
and sputum examination. CT scanning should be undertaken early to look for 
evidence of disseminated pulmonary disease (specify high-resolution CT 
scanning), lymphadenopathy or localised organ disease (e.g. CNS tuberculoma). 
Tissue biopsy (preferred to fine needle aspiration) is usually necessary to diagnose 
extrapulmonary TB. Mycobacterial blood cultures are often positive, even in 
cases of apparently localised disease such as pulmonary or lymph node TB.
Molecular testing of AFB smear-positive specimens and culture isolates, prefer-
ably using primers that will detect rifampicin resistance mutations, will enable 
rapid identification of M. tuberculosis and provide information about drug sus-
ceptibility (see Chapter 3). Pending results of molecular testing, any HIV-infected 
patient with AFB smear-positive sputum or bronchial washings must be assumed 
to have TB, because AFB smear-positive MAC and other non-tuberculous myco-
bacterial respiratory infections are uncommon in HIV-infected patients.
6.5 Treating active TB in HIV patients
6.5.1 The role of empiric TB therapy
Mortality is high in the 1 to 2 months following presentation among HIV-
infected TB patients with a CD4 cell count < 200 per microlitre. Therefore, the 
threshold for giving empiric TB treatment to these patients should be much lower 
than it is for other TB patients. Empiric therapy is especially indicated for patients 
with suspected TB meningitis or miliary TB (just as it is in non-HIV patients), 
but should also be considered in other situations, including those entailing 
varying degrees of uncertainty about the diagnosis. Examples are:
(i) unexplained fever in a patient with a low CD4 cell count from a high TB inci-
dence country with non-specific investigation findings
(ii) a patient from a similar background with a chronic respiratory illness, non-
specific pulmonary opacities and AFB-negative smears (and negative studies 
for other pulmonary pathogens) on bronchoscopy.
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6.5.2 Drug interactions between rifampicin, rifabutin and antiretroviral agents
Rifampicin lowers blood levels of ARV agents from the protease inhibitor (PI) 
and (to varying degrees) non-nucleoside reverse transcriptase (NNRTI) classes 
by inducing cytochrome P450 (CYP) enzymes, chiefly CYP 3A4 and to a lesser 
extent 2C19. Rifampicin also lowers blood levels of the chemokine receptor 
antagonist maraviroc and the integrase inhibitor raltegravir, the latter via induc-
tion of UDP glucuronyl transferase. Rifampicin blood levels are unaltered by 
ARV agents. Recommendations for use of these ARV agents with rifampicin are 
given in Table 6.5.1.
Rifabutin is a less potent CYP inducer than rifampicin. In addition, its own 
levels are increased by PIs and decreased by efavirenz, but minimally affected by 
maraviroc and raltegravir. Recommendations for co-administration of rifabutin 
and relevant ARV agents are also given in Table 6.5.1.
There are no significant interactions between rifampicin or rifabutin and nucle-
oside/nucleotide reverse transcriptase inhibitors (NRTI), nor between any ARV 
agents and the other first- or second-line antituberculous drugs.
6.5.3 TB treatment regimens
TB treatment regimens are essentially the same as for non-HIV infected patients 
but some specific issues apply.
●● Patients should be managed by a physician experienced in management of 
both HIV and TB. If this is not possible, close liaison between the HIV 
and TB treatment teams is essential.
●● A rifampicin-containing regimen is preferred, but in situations where 
rifampicin is contraindicated because of interactions with ARV agents, 
rifabutin can be given (with dose modification, as above) and is of similar 
efficacy to rifampicin. Either rifampicin or rifabutin must be used 
throughout the treatment course unless the patient develops side-effects 
or the organism is resistant.
●● Most studies suggest a higher rate of side-effects from TB drugs, such as 
hepatitis, rash and neuropathy, although it is not always clear whether the 
TB drugs themselves are responsible. Patients should be counselled appro-
priately and monitored closely for signs of drug toxicity.
●● Patients should be reviewed 2 weeks after starting treatment then at least 
monthly and LFTs should be done at each visit.
●● Pyridoxine should be prescribed routinely.
86 Management of tuberculosis
Ta
b
le
 6
.5
.1
 
In
te
ra
ct
io
n
s 
an
d 
do
si
n
g 
w
it
h 
ri
fa
m
yc
in
s 
an
d 
se
le
ct
ed
 A
R
V
 a
ge
nt
s 
or
 c
la
ss
es
AR
V 
ag
en
t/
cl
as
s
Ri
fa
m
pi
ci
n
Ri
fa
bu
tin
 (R
BT
)
AR
V 
le
ve
ls
AR
V 
do
se
AR
V 
le
ve
ls
AR
V 
do
se
RB
T 
le
ve
ls
RB
T 
do
se
E
fa
vi
re
nz
↓
60
0
–8
0
0 
m
g 
d
ai
ly
→
60
0 
m
g 
d
ai
ly
↓
45
0 
m
g 
d
ai
ly
N
ev
ira
p
in
e
↓↓
R
el
at
iv
e 
co
nt
ra
in
d
ic
at
io
n
→
20
0 
m
g 
b
d
→
30
0 
m
g 
d
ai
ly
P
ro
te
as
e 
in
hi
b
ito
rs
↓↓
↓
C
o
nt
ra
in
d
ic
at
ed
↓
S
ta
nd
ar
d
 
d
o
si
ng
↑↑
15
0 
m
g	
da
ily
	3
	×
	w
ee
kl
y
E
tr
av
iri
ne
↓↓
↓
C
o
nt
ra
in
d
ic
at
ed
↓
20
0 
m
g 
b
d
→
30
0 
m
g 
d
ai
ly
R
al
te
g
ra
vi
r
↓
80
0 
m
g 
b
d
→
40
0 
m
g 
b
d
→
30
0 
m
g 
d
ai
ly
M
ar
av
iro
c
↓↓
60
0 
m
g 
d
ai
ly
→
30
0 
m
g 
d
ai
ly
→
30
0 
m
g 
d
ai
ly
K
ey
:
↑ 
b
lo
o
d
 le
ve
ls
 in
cr
ea
se
d
→
 b
lo
o
d
 le
ve
ls
 u
nc
ha
ng
ed
↓	
bl
oo
d	
le
ve
ls
	lo
w
er
HIV and tuberculosis 87
●● For drug-sensitive infections, standard recommendations for duration of 
treatment generally apply (see Chapter 1), but in situations where a 
6-month course of therapy is advised there should be a low threshold for 
continuing treatment for 9 months (that is, HR is given in the continua-
tion phase for 7 rather than 4 months), particularly when clinical or 
microbiological response is delayed. Some experts advise that a 9-month 
course should be given routinely.
●● Directly observed therapy is advised by WHO and other authorities. In 
Victoria, provision of DOT should be discussed with the DoH TB Control 
Program, especially for patients with suspected or documented adherence 
problems. If DOT is used it should be given at least 3 times per week.
●● Treatment of drug-resistant infections should follow the recommenda-
tions in Chapter 3, but should be extended to cover the maximum dura-
tions specified.
●● Corticosteroids should be used if the HIV-positive patient meets the 
standard criteria for use in TB, i.e. tuberculous pericarditis and meningi-
tis (see Chapter 2). If the risk of immune reconstitution inflammatory 
syndrome (discussed subsequently) is high, corticosteroids may also be 
considered for other indications, such as mediastinal lymph node enlarge-
ment, ureteric TB, and spinal TB with epidural involvement.
●● Education and support are essential. Being diagnosed with TB and start-
ing treatment are stressful enough at the best of times, but when this 
occurs in the context of HIV-related events (e.g. recent diagnosis of HIV, 
ongoing HIV-related complications like diarrhoea, starting ARV therapy), 
the patient can feel overwhelmed. Immigration status, inability to speak 
English, financial difficulties and employment or study concerns can add 
to the complexity of these cases. Special attention must be paid to adher-
ence, which can be a particular challenge. Intensive support from clinic 
staff, and involvement of the social worker, public health TB program 
nurses and community agencies is essential, as is use of a professional 
interpreter if necessary.
6.6 Antiretroviral regimens in patients being treated for 
tuberculosis
General issues concerning selection of an ARV regimen are covered in the Aus-
tralian commentary on the US Department of Health and Human Services 
antiretroviral treatment guidelines for adults and adolescents, available at <www.
ashm.org.au/aust-guidelines>.
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Most issues regarding coadministration of TB and HIV treatment relate to the 
potential for drug interactions between rifampicin or rifabutin and selected 
antiretroviral agents (see above). The initial ARV regimen should also be chosen 
on the basis of results of genotypic resistance testing.
No prior ARV therapy – fully drug-susceptible HIV
The preferred ARV regimen is:
tenofovir plus emtricitabine and efavirenz
(efavirenz is contraindicated in pregnancy)
UK guidelines recommend weight-based efavirenz dosing: 600  mg daily if 
< 60 kg (use the fixed dose combination Atripla) and 800 mg daily if > 60 kg (use 
Atripla plus efavirenz 200 mg). This is considered optional in US guidelines.
TB treatment:
The standard regimen containing rifampicin should be used.
No prior ARV therapy – resistance testing results not available, or documented NNRTI 
resistance
The preferred ARV regimen is:
tenofovir plus FTC (Truvada) and a ritonavir-boosted PI (either lopinavir or atazanavir)
TB treatment:
A regimen containing rifabutin 150 mg three times weekly instead of rifampicin should be 
used.
Patient currently being treated with ritonavir-boosted PI-based regimen
The preferred approach, especially if the regimen is well tolerated and the patient 
has a non-detectable HIV viral load, is:
continue ritonavir-boosted PI-based regimen, and use rifabutin 150 mg three times weekly 
instead of rifampicin.
An alternative approach in patients with no NNRTI resistance and no prior 
NRTI resistance is:
switch to an efavirenz-based regimen, and use rifampicin
Patients unable to take either efavirenz or PI-based regimen
Options are:
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●● Preferred (but limited experience)
tenofovir plus emtricitabine and double-dose raltegravir (800  mg twice daily), and use 
rifampicin 
●● Alternative:
tenofovir plus emtricitabine and nevirapine (providing CD4 criteria for initiating nevirapine are 
met – see antiretroviral guidelines), and use rifabutin
6.6.1 When to start ARV treatment
In HIV-infected patients diagnosed with TB who are not being treated with ARV 
therapy, treatment of TB takes precedence and must always begin before ARV 
therapy. Timing of introduction of ARV therapy has to balance those factors that 
favour delaying treatment, such as large pill burden if all drugs are introduced 
over a short period of time (with potential for poor tolerability and adherence), 
drug toxicities (with overlapping toxicities making it difficult to attribute side-
effects to a particular drug), and risk of immune reconstitution inflammatory 
syndrome (discussed below) against the one factor favouring early treatment, 
that is the well-documented increased risk of death in the first one to two months 
following TB diagnosis in those with a CD4 cell count < 200 per microlitre. Rec-
ommendations based on the findings of recent studies are summarised in Table 
6.6.2.
6.7 Immune reconstitution inflammatory syndrome 
(IRIS)
Two forms of TB immune reconstitution inflammatory syndrome occur in 
patients who start ARV therapy.
1. Paradoxical IRIS is the most common form. Typical patients have been 
recently diagnosed with TB, have a low CD4 cell count (< 100 per microlitre) 
Table 6.6.2. When to start ARV therapy in previously untreated patients being 
treated for TB.
CD4 cell count
(per microlitre) Timing of ARV initiation after starting TB treatment
< 100 Within	2	weeks
100–500 4–8	weeks
> 500 4–8	weeks,	or	wait	until	completion	of	TB	treatment
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and, within 2–6 weeks of starting ARV therapy, develop inflammatory mani-
festations related to TB in association with reduction in HIV viral load and 
restoration of immune function. These reactions also occur in non-HIV 
infected patients.
2. Incident TB IRIS refers to previously undiagnosed TB that is ‘unmasked’ 
soon after starting ARV therapy.
Clinical features of TB IRIS include fever, enlarging lymph nodes (cervical, 
intrathoracic or intra-abdominal), worsening pulmonary infiltrates, pleural 
effusion, intracerebral tuberculoma, and cold abscess formation.
The overall rate of IRIS ranges from 10 to 40%. Risk factors include low CD4 cell 
count (especially < 50 per microlitre), extrapulmonary or disseminated TB, ini-
tiation of ARV therapy within 4–8 weeks of initiation of TB treatment, rapid 
decline in HIV viral load and increase in CD4 cell count.
In vitro tests have shown that these reactions occur in association with improve-
ments in cell-mediated immunity against M. tuberculosis brought about by ARV 
therapy.
Management of these reactions comprises symptomatic treatment initially, but a 
short course of corticosteroids (e.g. prednisolone 40 mg initially, weaning over 
4–8 weeks) is often necessary. TB treatment should be continued. Occasional 
deaths have been reported but most patients recover uneventfully.
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7.1 Non-tuberculous mycobacteria
About 10% of mycobacterial infections seen in clinical practice are caused not 
by Mycobacterium tuberculosis but by atypical mycobacteria. Mycobacterium 
avium complex (MAC) and other nontuberculous mycobacteria (NTM) have 
distinctive laboratory characteristics, occur ubiquitously in the environment, 
are not communicable from person to person, and are strikingly resistant to 
antituberculous drugs.
The incidence of NTM varies in different studies between 0.7 and 1.8 per 100 000 
person-years. A recent Danish population-level survey of NTM confirms that 
MAC is by far the most common cause of confirmed NTM pulmonary disease (> 
50%) and M. gordonnae the most common colonising organism. M. abscessus 
was the next most common individual organism to cause pulmonary disease, 
although this was much less frequent (6.9%). The 5-year mortality after con-
firmed NTM pulmonary disease was high (40%). This distribution of disease due 
to NTM species is similar in a recent report from South Korea.
In immunocompetent persons the nontuberculous mycobacterial diseases are 
similar to tuberculosis in many ways, but they differ in several important respects:
●● the diseases tend to remain localised and progress extremely slowly
●● constitutional symptoms are less prominent
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●● isolation of a nontuberculous mycobacterium from pulmonary secretions 
does not always confirm a diagnosis.
7.2 Pulmonary Mycobacterium avium complex infections
The lungs are the most frequent site of involvement for MAC; however, all the 
NTM have been associated with pulmonary disease. Disease occurs more 
commonly in men, and there is a definite association with pre-existing lung 
disease, such as silicosis, bronchiectasis, or old tuberculosis.
The diagnosis of lung disease caused by MAC is based on a combination of 
clinical, radiographic and bacteriologic criteria, and the exclusion of other 
diseases that can resemble the condition. Complementary data are important for 
diagnosis because NTM organisms can reside in or colonise the airways without 
causing clinical disease, especially in patients with AIDS, and many patients 
have pre-existing lung disease that may make their chest radiographs abnormal.
7.2.1 Symptoms and signs
●● MAC causes a chronic, slowly progressive pulmonary infection resem-
bling tuberculosis in immunocompetent patients, many but not all of 
whom have underlying pulmonary disease such as COPD, bronchiectasis, 
previous mycobacterial disease, cystic fibrosis, and pneumoconiosis.
●● Most patients with MAC infection experience a chronic cough, sputum 
production, and fatigue.
●● Less common symptoms include malaise, dyspnoea, fever, haemoptysis, 
and weight loss.
●● Symptoms from the underlying lung disease may confound the evaluation.
●● Physical findings include fever and altered breath sounds, including rales 
or rhonchi, as well as signs of the underlying lung disease if present.
7.2.2 Clinical and radiological patterns of MAC lung disease
There are two typical clinical and radiological patterns of MAC lung disease in 
HIV-negative patients.
Fibrocavitary disease
The most common pattern of MAC lung disease is upper-lobe cavitary lung 
disease with clinical and radiological features that mimic TB. The cavities, 
however, are often thin-walled and have less surrounding parenchymal infil-
trate but more prominent pleural involvement than is commonly seen with TB. 
These patients are predominantly older (commencing in late 40s–50s) male 
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smokers with coexistent COPD or another underlying pulmonary disease. 
There may be a history of alcoholism. Patients present with cough, weight loss 
+/– haemoptysis. If left untreated, this form of disease is generally progressive 
within a relatively short time frame, 1 to 2 years, and can result in extensive 
cavitary lung destruction and respiratory failure. MAC disease is regarded as a 
superinfection.
Nodular/bronchiectatic disease
These patients are predominantly nonsmoking women over the age of 50 who do 
not have underlying lung disease, and have non-cavitary radiographic changes. 
They often have particular physical characteristics – a thin body habitus, some-
times with scoliosis, pectus excavatum, mitral valve prolapse, and joint hypermo-
bility. High-resolution CT (HRCT) scanning reveals (i) multifocal bronchiectasis 
and (ii) small, predominantly peripheral, nodular densities exhibiting a ‘tree-in-
bud’ appearance that reflects inflammatory changes, including endobronchial 
spread with bronchiolitis. The disease is often focused in the lingula and right 
middle lobe and in the lower zones. This combination of findings is highly sugges-
tive of MAC infection. In the absence of any past history, it is unclear whether 
bronchiectasis actually predates and predisposes to MAC infection, although 
once established, MAC infection clearly contributes to progression of bronchiec-
tasis. This form of MAC infection may progress, albeit far more slowly than the 
fibrocavitary form, to respiratory failure.
Shedding of MAC into respiratory secretions in these patients is less consistent 
than in the fibrocavitary form of the disease. Sputum may be intermittently 
positive and/or positive with low numbers of organisms. Bronchoscopy should be 
done if clinical suspicion of MAC infection is high in these patients.
7.2.3 Other forms of MAC disease
MAC may occur as a superinfection in patients with brochiectasis resulting from 
cystic fibrosis (CF), prior bacterial or viral infections, or previously treated TB. 
Patients tend to be > 50 years old (other than those with CF), of either sex, and 
there is no apparent relationship to smoking or smoke-related lung disease. They 
may have either no or minimal symptoms.
TFN-a inhibitor therapy is emerging as a risk factor for MAC infection as for TB. 
Patients with proven MAC pulmonary disease require therapy for this prior to 
commencing TNF-a inhibitor therapy.
HIV-infected patients with disseminated MAC infection uncommonly present 
with pulmonary involvement. When it is present it most typically presents as 
miliary disease.
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7.2.4 Diagnostic criteria
A combination of findings is required to diagnose pulmonary MAC disease. 
Sputum cultures positive for atypical mycobacteria do not in themselves prove 
infection because NTM may exist as saprophytes in the airways or as environ-
mental contaminants. All of the following criteria must be met before pulmonary 
disease can be ascribed to MAC. These criteria also apply to pulmonary disease 
caused by other nontuberculous mycobacteria.
Clinical criteria
●● There must be a compatible clinical illness: chronic cough, sputum pro-
duction, and fatigue; less commonly: malaise, dyspnoea, fever, haemopty-
sis, and weight loss.
Radiological criteria
●● There must be a compatible pulmonary process visible radiologically: 
nodular or cavitary opacities on chest radiograph, or an HRCT scan that 
shows multifocal bronchiectasis with multiple small nodules.
Microbiologic criteria
A significant isolate of MAC must be obtained from respiratory secretions or 
lung tissue.
A significant isolate is defined as:
●● positive culture results from at least two separate sputum samples
or
●● positive culture results from at least one bronchoscopy specimen – bron-
chial washings or BAL
or (less commonly)
●● lung biopsy with granulomatous inflammation or visible AFB and posi-
tive culture for MAC, or biopsy showing indicative histopathology and 
respiratory cultures positive for MAC. This is more likely to be present in 
HIV-infected patients investigated with bronchoscopy for a pulmonary 
infiltrate.
Exclusion of an alternative diagnosis
There must be reasonable exclusion of other diseases that could explain the con-
dition, in particular tuberculosis.
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Patients who are suspected of having MAC lung disease but who do not meet the 
diagnostic criteria should be followed until the diagnosis is firmly established or 
excluded.
7.2.6 Issues to consider in determining the significance of a respiratory isolate 
of MAC
Since MAC is present in the environment and water, a single isolation of MAC by 
culture from sputum may be a contaminant; the same may even apply with a 
single isolate from a bronchoscopy specimen, if not accompanied by typical 
clinical and radiological manifestations, because MAC and other NTM may con-
taminate bronchoscopes.
In general, multiple isolates are needed from non-sterile sites to establish disease, 
whereas one positive culture from a sterile site, particularly where there is sup-
portive histopathology, is usually sufficient.
In establishing a diagnosis of MAC, the clinical presentation and any predispos-
ing factors are also helpful. Patients with pre-existing lung disease or impaired 
immunity (especially cell-mediated immunity) are more prone to these infec-
tions than those without such predisposing conditions.
In patients with a more chronic presentation and a radiograph that is difficult to 
interpret, the diagnosis of disease, as opposed to colonisation of previously 
damaged lung, may be difficult to make. Indeed, sometimes disease may develop 
after a period of colonisation.
Making the distinction between ‘colonisation’ and ‘disease’ is not as simple as it 
once was. With the wider use of high resolution chest CT scanning, it is clear that 
many patients previously considered to be ‘colonised’ on the basis of a normal 
CXR and stable symptoms actually have slowly progressive lung disease.
7.2.7 Management
Because therapy of MAC lung disease is often poorly tolerated and is not always 
effective, there will be patients who have MAC isolated from a respiratory 
specimen but who might not benefit from medical therapy.
Patients for whom treatment may be withheld
●● Patients with a normal CXR do not require therapy if they have transient 
or self-limited respiratory symptoms with a single smear-negative, MAC 
culture-positive sputum specimen, who on follow-up have multiple 
smear- and culture-negative specimens. They should have ongoing clini-
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cal follow-up, including further CXR, to confirm the lack of significant 
lung disease.
●● Certain patients with established MAC lung disease might not benefit 
from MAC medications. These include patients who have severe co-mor-
bidities that will limit life expectancy.
●● A few patients who have significant hypersensitivity responses to either 
macrolides or rifampicin should not receive these drugs.
Patients for whom treatment is indicated
●● Patients who meet previously described diagnostic criteria for pulmonary 
MAC infection and who have no contraindications to anti-MAC 
medications.
Patients for whom treatment decision is to be deliberated.
●● A risk–benefit approach needs to be considered in patients with slowly 
progressive disease who demonstrate intolerance of therapy or who are 
likely to be intolerant of therapy, as side-effects can manifestly reduce the 
quality of a patient’s life.
●● Some elderly patients with non-cavitary MAC lung disease will have 
slowly progressive disease that is not especially bothersome from a symp-
tomatic standpoint and is not likely to affect life expectancy. These 
patients require assessment over a prolonged period in order to be sure 
that they have indolent disease and that they have few and relatively stable 
symptoms due to MAC disease. If there is acceleration of the patient’s 
MAC disease, on either a symptomatic, microbiological or radiological 
basis, then the decision to withhold treatment should be revisited.
Patients for whom treatment of MAC lung disease may be modified
●● Some patients, especially elderly patients, will simply decide that the 
adverse effects of the medication are less tolerable than the symptoms 
associated with MAC lung disease, regardless of the symptoms associated 
with MAC disease, or the rate of progression or the extent of the disease 
on CXR.
●● If patients on a standard MAC treatment regimen (discussed in more 
detail below) develop gastrointestinal side-effects, it may be possible to 
continue therapy with a modified regimen by omitting rifampicin and 
using a standard or a lower dose of the macrolide agent and continuing 
ethambutol. Although the efficacy of this approach is unproven in MAC 
lung disease, clarithromycin (given at standard doses) and ethambutol is 
an effective regimen for disseminated MAC disease in HIV infection.
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7.2.8 Treatment of MAC lung disease
VIDS generally follows the ATS recommendations on drug treatment of MAC 
disease. These utilise the newer macrolides as the cornerstone of therapy. The 
ATS guidelines recommend macrolide susceptibility testing for all new, previ-
ously untreated MAC isolates, but currently this is not standard practice in 
Victoria; instead such testing is reserved for those with recurrent disease.
The preferred empirical combination regimens of the ATS include a macrolide 
agent (clarithromycin or azithromycin) plus ethambutol plus rifampicin. With 
these regimens sputum conversion rates for pulmonary MAC infection in adults 
able to tolerate the medications are about 90%. Rifampicin is preferred over 
rifabutin because there is no difference in clinical response between these agents 
and rifabutin may cause more problematic, treatment-limiting, adverse effects 
(uveitis, leucopenia), especially in the elderly.
American Thoracic Society recommendation for MAC disease (Griffith et al. 2007)
For fibrocavitary disease
Clarithromycin 500 mg twice daily
or
Azithromycin 250 mg daily
plus
Ethambutol 15 mg/kg daily
plus
Rifampicin 600 mg daily
The ATS also discuss the option of adding amikacin (25  mg/kg two to three 
times a week) as a fourth drug for the first 8 weeks for patients who have a sub-
stantial burden of extracellular organisms, e.g. extensive or cavitary disease with 
strongly positive sputum smears. (Streptomycin has been used in the past but its 
unavailability limits current use.) We rarely follow this approach in VIDS, 
although it could be considered in the very occasional patient who is critically ill, 
or as part of a retreatment regimen.
Intermittent dosing may be used for patients with nodular/bronchiectatic 
disease consisting of:
Clarithromycin, 1000 mg three times a week
or
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Azithromycin, 500 mg three times a week
plus
Ethambutol, 25 mg/kg three times a week
plus
Rifampicin, 600 mg three times a week
Lower doses of clarithromycin (500  mg/day) or azithromycin (250  mg three 
times a week) may be better tolerated in patients over the age of 70 years who 
have a low body mass, especially if the creatinine clearance is reduced. In these 
patients, regular doses may lead to high drug levels which may be associated with 
intolerable side-effects.
The duration of treatment is typically 18–24 months total with treatment contin-
ued for 12 months after monthly sputum cultures convert to negative. Most 
patients do not clear MAC from their sputum for between 6 and 12 months. 
Patients in whom sputum cultures remain positive at 9–12 months must be 
assessed for non-compliance.
Progression of pulmonary infiltrates during therapy or lack of radiographic 
improvement over time are poor prognostic signs and also raise concerns about 
secondary or alternative pulmonary processes.
Patients need to be reviewed monthly with repeat sputum samples done until 
cultures are negative. CXRs should be done at regular intervals (3-monthly). 
Clearing of pulmonary infiltrates due to MAC is slow.
As patients will be on long-term rifampicin and ethambutol it is important that 
special attention is paid to side-effects of these agents. Regular monitoring of 
LFTs is required for rifampicin toxicity (monthly initially then 2-monthly if well 
tolerated). Visual acuity and colour vision should be measured at each monthly 
visit, and the patient referred to the ophthalmology clinic if abnormalities are 
present at baseline or develop during ethambutol therapy or if the patient com-
plains of visual symptoms.
The BTS’s view appears to differ from the ATS. The 1999 BTS recommendation 
for HIV-negative patients with disease due to MAC is that first-line treatment 
should be with rifampicin and ethambutol for 24 months, plus or minus isonia-
zid. The British opinion is also presented here as it is useful on occasions when 
macrolides cannot be used. With this regimen there was 72% microbiological 
clearance and disease-free follow-up at 3 years.
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7.2.9 Points relevant in risk-benefit considerations for treatment of MAC lung 
disease
●● Macrolides (clarithromycin, azithromycin) should not be used as mono-
therapy because of the risk of developing macrolide-resistant MAC 
isolates.
●● The toxicity of clarithromycin and azithromycin is related to dosage and 
serum concentration. Doses greater than clarithromycin 1000  mg/day 
and azithromycin 300 mg/day are poorly tolerated.
●● The regimen with the highest sputum conversion rates comprises daily 
clarithromycin, a rifamycin agent (VIDS follows ATS recommendations 
and uses rifampicin) and ethambutol.
●● In multidrug regimens for MAC lung disease, dosage adjustments are fre-
quently necessary because of adverse events.
●● Close toxicity monitoring is required for all patients receiving treatment 
for MAC lung disease.
●● In patients with localised pulmonary disease, resective lung surgery with 
lobectomy should be considered when there is failure of sputum conver-
sion after 4–6 months of antimycobacterial therapy.
●● Where macrolide resistance is present as in relapsed disease, the regimen 
most frequently used consists of rifampicin, ethambutol, moxifloxacin, 
and amikacin. There are limited data regarding the benefit of moxifloxa-
cin other than animal models, but few other options are available. As 
Table 7.2.1 Adverse events associated with medications for MAC
Medication Adverse event
Clarithromycin and 
azithromycin
Bitter taste, diarrhoea, anorexia, nausea, vomiting, 
abnormal	LFTs	with	hepatitic	picture,	decreased	auditory	
acuity, hypersensitivity reactions
Rifampicin Nausea, vomiting, anorexia, abnormal hepatitic enzymes, 
hypersensitivity reactions, flu-like syndrome, 
thrombocytopenia, renal failure
Ethambutol Optic	neuritis	with	loss	of	red-green	colour	discrimination	
and/or loss of visual acuity
Rifabutin Nausea,	vomiting,	anorexia,	abnormal	LFTs	with	hepatitic	
picture, polyarthralgia, polymyalgia, hyperpigmentation, 
leucopenia, anterior uveitis, hypersensitivity reactions 
(thrombocytopenia, renal impairment, fever)
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there is cross-resistance between the macrolides there is no benefit in 
switching between them in this situation.
●● If patients are intolerant of an initial daily regimen, intermittent therapy 
can be tried with clarithromycin, 1000  mg; ethambutol, 25  mg/kg and 
rifampicin 600 mg, all given three times weekly. It may also be worthwhile 
changing from clarithromycin to azithromycin or vice versa in a daily 
regimen to rule out intolerance to a specific macrolide.
7.3 Treatment of MAC extrapulmonary disease
MAC extrapulmonary disease occurs predominantly in the cervical lymph nodes 
of children < 3 years of age. The treatment of choice is complete excision of the 
affected nodes. Antimycobacterial chemotherapy with clarithromycin, ethambu-
tol and rifampicin for up to 2 years should be considered in those patients where 
disease recurs or where surgical excision is incomplete or impossible because of 
involvement or proximity of vital structures. The default diagnosis in a child 
from a TB-endemic area with granulomatous inflammation of a lymph node 
should be TB. In sites other than lymph nodes ATS recommends chemotherapy 
for 6–12 months with surgical excision for localised disease.
7.4 MAC hypersensitivity-like disease
A MAC pulmonary disease syndrome with a presentation similar to hypersensi-
tivity lung disease has recently been recognised. This syndrome has previously 
been termed ‘hot tub lung’. Non-tuberculous mycobacteria other than MAC also 
have the potential to result in this condition. MAC, like other mycobacterial 
organisms, has a predisposition for growth in indoor hot tubs as these bacteria are 
relatively resistant to disinfectants and may be able to grow at high temperatures.
Treatment requires recognition of the condition and avoidance of exposure to 
the hot tub. Maintenance and disinfection of the spa according to the manufac-
turer’s instructions may be insufficient to eradicate MAC. Special disinfection 
measures may be successful, but most experts advise affected patients to avoid 
exposure to the spa completely. The role of short courses of MAC therapy and 
corticosteroids is not proven.
7.5 Mycobacterium kansasii
7.5.1 Characteristics
●● Pulmonary disease is the most frequent clinical presentation of M. 
kansasii infection. Most patients are middle-aged to elderly men, over half 
of whom have chronic bronchitis and emphysema, old healed tuberculo-
sis, or both.
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●● M. kansasii is found in tap water. Pulmonary disease is not transmissible 
from person to person.
●● M. kansasii isolated from respiratory cultures is generally regarded as a 
pathogen. Isolation of M. kansasii from respiratory cultures is usually cor-
related with invasive pulmonary disease, unlike most other NTM.
●● Unlike MAC, M. kansasii primarily causes pulmonary disease, only occa-
sionally disseminating in both immunocompromised and immunocom-
petent hosts.
●● The illness presents acutely or subacutely in a way that is clinically and 
radiologically similar to TB, although patients may be asymptomatic.
●● The characteristic radiological presentation of thin-walled cavitary lesions 
(70–90%) is seen in both HIV and non-HIV patients.
●● Less frequently, M. kansasii can produce non-cavitary, nodular/bronchi-
ectatic disease similar to MAC.
●● Culture techniques and drug susceptibility testing similar to that used 
with M. tuberculosis can also be performed in patients with M. kansasii 
infection.
●● In untreated patients with pulmonary disease caused by M. kansasii, 
sputum positivity generally persists and the disease progresses clinically 
and radiologically. Clinical data suggest that patients do better with ear-
lier therapy.
●● M. kansasii produces proteins including CFP-10 and ESAT-6 that are 
detected by IGRA testing, thus a false positive test for M. tuberculosis 
infection may result.
7.5.2 Treatment
Recommended treatment of M. kansasii infection, with or without concurrent 
HIV infection (ATS recommendation 2007) is a combination of the following 
agents:
Isoniazid (INH) 300 mg daily
Rifampicin 600 mg daily
Ethambutol 15 mg/kg daily
●● Duration of treatment is at least 12 months following negative cultures.
●● This treatment regimen is the same for both extra-pulmonary and pulmo-
nary disease.
●● For patients with rifampicin-resistant M. kansasii disease, a three-drug 
regimen is recommended based on in vitro susceptibilities including 
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clarithromycin or azithromycin, moxifloxacin, ethambutol, sulfameth-
oxazole, or amikacin.
●● Pyrazinamide is not used to treat M. kansasii infections because this 
organism is resistant to this agent.
7.6 Rapidly growing mycobacteria (RGM)
RGM are mycobacteria that produce visible non-pigmented colonies by 7 days 
when subcultured onto growth media. They will often have grown by 3–5 days 
but may take longer to grow during primary isolation.
RGM are ubiquitous in the environment, and there are approximately 50 species. 
The three clinically relevant species are M. fortuitum, M. abscessus (formerly M. 
chelonae subsp. abscessus) and M. chelonae. Other potentially pathogenic species 
include M. smegmatis, M. peregrinum and M. chelonae-like organisms, but these 
rarely cause human disease.
RGM grow well on both standard mycobacterial media and routine bacterial 
media (e.g. 5% sheep’s blood or horse blood agar). In cutaneous disease RGM are 
isolated in more than 50% of cases via routine bacterial media. Nevertheless, in 
suspected cases, specimens should be inoculated onto mycobacterial media, and 
in addition cultured at both 30°C and 37°C, as some strains require lower tem-
peratures to promote growth. Further species identification is achieved via bio-
chemical methods and drug susceptibility patterns. M. abscessus and M. chelonae 
differ by only a small number of base-pairs.
RGM predominantly infest skin/soft tissue and contiguous structures, e.g. bony 
infection. They less commonly cause pulmonary infection.
7.6.1 M. fortuitum
M. fortuitum causes human infection primarily by direct inoculation, including 
primary skin and soft tissue infections, surgical wound infections, and catheter-
related sepsis. Rarely, other infections occur such as keratitis, pulmonary disease, 
prosthetic valve endocarditis, and cervical lymphadenitis. M. fortuitum causes 
less than 20% of lung disease due to RGM.
7.6.2 M. abscessus
There is a wide clinical spectrum of disease due to M. abscessus. It is most fre-
quently associated with cutaneous disease. This may be primary, such as following 
soil- or water-inoculation injury, or nosocomial, involving surgical wound infec-
tions. Other nosocomial infections include post-injection site abscesses, bone and 
joint disease, prosthetic valve endocarditis, and keratitis. It is an uncommon but 
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well recognised cause of pulmonary disease. It is responsible for over 80% of RGM 
lung disease, but accounts for less than 5% of NTM pulmonary disease.
Disseminated infections occur, but usually in the setting of immune compro-
mise. About 20% of cases developed in people without an identified immune 
defect in one review.
7.6.3 M. chelonae
Disseminated skin lesions involving the lower extremities (pseudo erythema 
nodosum) due to RGM are almost always due to M. chelonae and occur in patients 
on chronic corticosteroid therapy. In addition, surgical wound infections follow-
ing augmentation mammoplasty and heart surgery have been described. M. 
chelonae is an extremely uncommon cause of RGM pulmonary disease (< 1%).
7.6.4 Antimicrobial susceptibility
RGM are uniformly resistant in vitro to the standard antituberculous drugs, and 
this is mirrored by clinical in vivo resistance. The exception is M. smegmatis, 
which is susceptible to ethambutol. Sensitivity studies should not be undertaken 
with antituberculous agents, but rather with the following antibacterial agents:
●● amikacin
●● cefoxitin
●● imipenem
●● doxycycline
●● clarithromycin
Table 7.6.1 Published susceptibilities for RGM (expressed as percentage 
sensitive)
Drug M. abscessus M. chelonae M. fortuitum
Amikacin 90 50 100
Cefoxitin 70 0 50
Imipenem 50 60 100
Tobramycin 60 100
Clarithromycin 100 100 80
Doxycycline 4 25 50
Ciprofloxacin 0 0 100
Sulfamethoxazole 0 3 100
Linezolid Some activity 90
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●● erythromycin
●● ciprofloxacin/moxifloxacin
●● sulfamethoxazole
●● linezolid.
7.6.5 Skin and contiguous structure disease due to RGM
●● Some minor infections will resolve spontaneously or after surgical 
debridement. However, several studies of injection site abscesses in which 
no therapy was given revealed disease that persisted in most patients for 
8–12 months before resolving spontaneously.
●● In two outbreaks of sternal wound infections caused by M. abscessus in 
the era when little was known of chemotherapy or surgery for these organ-
isms, approximately one-third of the patients died of uncontrolled infec-
tion. Drug therapy or combined surgical and medical therapy clearly 
produces better results than these historical controls.
Treatment of skin and contiguous structure RGM diseases
●● No controlled clinical trials of treatment for disease caused by M. fortui-
tum, M. abscessus, or M. chelonae, comparing one form of treatment with 
another or with no drug treatment at all, have been performed.
●● Because of variable drug susceptibility among species and even within 
species and subgroups, susceptibility testing of all clinically significant 
isolates is essential for good patient management.
●● Use at least two active agents initially. For M. abscessus and M. chelonae, 
an initial phase of combination parenteral therapy is usually given fol-
lowed by oral therapy, whereas M. fortuitum infections, unless severe, can 
generally be treated with an oral regimen from the outset.
Parenteral therapy
●● For M. abscessus, use a combination of amikacin 10–15 mg/kg IV daily 
and cefoxitin 200 mg/kg IV per day in divided doses; the lower amikacin 
dose (10 mg/kg) should be used in patients over the age of 50. Once-daily 
amikacin dosing is unproven clinically but appears to be adequate.
●● For M. chelonae use tobramycin 4–6  mg/kg IV daily and imipenem 
500 mg IV four times daily due to resistance to amikacin and cefoxitin.
●● This combination is recommended for initial treatment (minimum 2 
weeks) until clinical improvement is evident.
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Oral therapy
●● For M. chelonae, clarithromycin, linezolid (and in 20% of isolates cipro-
floxacin and doxycycline) are the only oral drugs to which the organism is 
susceptible in vitro.
●● For M. abscessus, the only oral agents available for treatment are clarithro-
mycin (500 mg twice daily) and azithromycin (250 mg daily).
●● Milder M. fortuitum infections can be treated with trimethoprim/sul-
famethoxazole 1–2 double-strength tablets per day and doxycycline 
200 mg per day if the organism is sensitive.
Duration of treatment
It is not certain how long chemotherapy should be continued for these infections 
as there is no evidence from controlled clinical trials. For serious disease, a 
minimum of 4 months of therapy is necessary to provide a high likelihood of 
cure. For bone infections, 6 months of therapy is recommended.
Surgery
Surgery is generally indicated for both extensive disease and abscess formation 
where drug therapy is difficult. Removal of foreign bodies such as breast implants, 
percutaneous catheters etc. is essential for recovery.
7.7 Pulmonary disease due to rapidly growing 
mycobacteria
●● Pulmonary disease due to RGM is well described and most commonly 
occurs in the elderly or those with an underlying predisposing condition.
●● The largest group of patients with this lung disease are elderly (> 60), 
white, female nonsmokers with no predisposing conditions or known 
lung disease.
●● Underlying disorders that are associated with the disease include lung 
damage produced by prior mycobacterial infection (usually tuberculosis or 
MAC), gastro-oesophageal disorders with chronic vomiting, lipoid pneu-
monia, cystic fibrosis, and bronchiectasis due to prior respiratory infection.
●● The distinguishing feature of patients with underlying disease is that their 
rapidly growing mycobacteria lung disease occurs at a younger age, usu-
ally < 50. Almost all patients < 40 have one of the above disorders.
●● Overall, M. abscessus appears to be a more virulent respiratory pathogen 
than M. fortuitum.
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●● Careful clinical evaluation and follow-up, as for pulmonary MAC infec-
tion, is always necessary to determine the significance of an RGM respira-
tory isolate.
●● Interestingly, approximately 15% of patients with M. abscessus will also 
have M. avium complex, suggesting the close relationship of the disorders. 
Some patients have positive sputum cultures for Pseudomonas aeruginosa, 
further evidence of bronchiectasis.
7.7.1 Clinical features
●● The usual presenting symptoms are cough and easy fatiguability, often 
attributed for months or years to bronchitis or bronchiectasis.
●● Fever, night sweats, and weight loss occur, but they are much less common 
and less severe than with M. tuberculosis.
●● Haemoptysis and dyspnoea are also common.
●● The constellation of typical presenting symptoms in an elderly nonsmok-
ing patient with no underlying lung disease, a compatible chest radio-
graph, and multiple culture positive sputum specimens is sufficient to 
make a diagnosis.
●● The presence of other diseases or unusual features may necessitate obtain-
ing a lung biopsy to be certain of the diagnosis.
●● The diagnosis of RGM pneumonia tends to be delayed. (It was usually not 
established until > 2 years after the onset of symptoms in one series.)
7.7.2 Natural history
●● The natural history of this disease depends primarily on the presence or 
absence of underlying disorders.
●● For most patients with M. abscessus and no underlying disorder, the dis-
ease is indolent and slowly progressive. Some patients show little radio-
graphic change over years.
●● More fulminant, rapidly progressive disease can occur, particularly in 
association with gastro-oesophageal disorders. Death occurs as a conse-
quence of M. abscessus in 20% of cases.
7.7.3 Imaging
●● In patients with no apparent risk factors, the chest radiograph usually 
shows multilobar, patchy, reticulonodular or mixed interstitial–alveolar 
infiltrates with upper lobe predominance.
Mycobacteria other than tuberculosis 109
●● Cavitation occurs in only approximately 15% of cases.
●● The CXR is usually not typical of or suggestive of reactivation pulmonary 
tuberculosis, which likely accounts for a delay in ordering sputum for 
AFB analysis and therefore a delay in diagnosis.
●● HRCT of the lung frequently shows associated cylindrical bronchiectasis 
and multiple small (< 5 mm) nodules, a pattern also seen in nonsmokers 
with MAC lung disease.
7.7.4 Treatment of RGM pulmonary disease
●● RGM pulmonary disease must be treated because the natural history usu-
ally involves slow progression, and, without treatment, death. Spontane-
ous resolutions may occur, but rarely.
●● Appropriate therapy relies on accurate species identification and the 
results of susceptibility testing to the drugs listed above. Susceptibility 
testing should be performed on each clinically significant isolate as there 
may be interspecies and intraspecies variability.
●● If surgery is possible it should be employed as surgical resection of local-
ised disease is the only possible means of cure.
M. abscessus
●● M. abscessus isolates are usually susceptible in vitro only to the parenteral 
agents amikacin, cefoxitin, and imipenem, and to the newer oral 
macrolides.
●● Microbiological and clinical cure may not be possible and therapy may 
need to aim at symptomatic and radiological improvement.
●● Prior to the availability of clarithromycin, medical therapy alone was 
largely unsuccessful for disease due to M. abscessus. Cure was only 
achieved in those where antibiotics were combined with localised surgical 
resection of the involved lung.
●● Combination therapy of low-dose amikacin plus high-dose cefoxitin for 
2–4 months along with clarithromycin should be used. Successful therapy 
consists of a 12-month period of negative sputum cultures.
●● Quinolones, sulfonamides, amikacin, cefoxitin, imipenem, linezolid and 
newer agents such as tigecycline and telithromycin (not available in Aus-
tralia) may have a place in treatment.
●● Surgical resection for limited disease related to prior localised lung dis-
ease can also be curative.
110 Management of tuberculosis
M. fortuitum
●● M. fortuitum isolates are usually susceptible to multiple oral antimicrobial 
agents including quinolones, doxycycline and minocycline, and 
sulfonamides.
●● Inducible resistance to clarithromycin and azithromycin may be present 
so these agents should be used cautiously.
●● Drug susceptibilities for this species are essential for effective therapy.
●● Six to twelve months of therapy with two oral agents to which the M. for-
tuitum isolate is susceptible in vitro usually results in clinical cure.
●● For serious M. fortuitum infections, a combination of intravenous amika-
cin 10–15  mg/kg IV per day, plus cefoxitin 200  mg/kg IV per day in 
divided doses is recommended in the initial phase of treatment.
7.8 Mycobacterium marinum
7.8.1 Disease characteristics
●● M. marinum predominantly affects the skin and subcutaneous tissue.
●● Infection is acquired after exposure to water, commonly from relatively 
stagnant water, such as in fish tanks. The disease present as slowly grow-
ing nodular–ulcerating lesions of the extremities. The lesions may be soli-
tary but may ascend along the limbs, resembling sporotrichosis. The 
lesions may be extremely long-lived, up to 50 years.
●● Diagnosis is made by biopsy of affected tissue for histopathological exam-
ination and culture of the organism.
By susceptibility testing, these isolates are:
●● susceptible to rifampicin, ethambutol, clarithromycin, sulfonamides or 
trimethoprim–sulfamethoxazole
●● susceptible or intermediately susceptible to doxycycline and minocycline
●● intermediately susceptible to streptomycin
●● resistant to isoniazid and pyrazinamide.
M. marinum produces proteins including CFP-10 and ESAT-6 that are detected 
by IGRA testing, thus a false positive test for M. tuberculosis infection may result. 
As the skin lesions of M. marinum are not typical of cutaneous TB there should 
be no reason for ordering QFN-GIT in these patients.
7.8.2 Treatment
●● Superficial skin infections due to M. marinum may heal spontaneously, 
but deeper infections and bone involvement require definitive treatment.
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●● Surgical debridement, cryosurgery, or electro-dessication may be all that 
is required for small, superficial lesions.
●● If the lesions are more extensive, then one of the following treatment regi-
mens can be used:
Clarithromycin 500 mg twice daily
or
Minocycline or doxycycline 100 mg twice daily
or
Trimethoprim–sulfamethoxazole (cotrimoxazole) 160/800 mg twice daily
●● For extensive disease, use a combination of:
Clarithromycin 500 mg daily
and
Ethambutol 15 mg/kg daily
●● Rifampicin may also be added for osteomyelitis.
●● The rate of response to antimycobacterial treatment is variable and 
response may not occur for up to 3 weeks. A minimum of 4 to 6 weeks of 
therapy should be given before considering that the patient may not be 
responding. Therapy is typically continued for a minimum of at least 3 
months. Very longstanding lesions require a longer course of therapy.
●● If a lesion is excised surgically, many clinicians provide drug coverage 
during the perioperative period. It is not clear if longer duration of drug 
treatment after surgery offers any additional advantage.
7.9 Mycobacterium ulcerans
7.9.1 Disease characteristics
Mycobacterium ulcerans causes skin and soft tissue infections, referred to 
as Bairnsdale or Daintree ulcers in Australia or Buruli ulcers (BU) 
internationally.
Its major virulence factor is a lipid toxin, capable of causing necrosis of fat and 
subcutaneous tissue. Significant morbidity is caused by chronic ulceration and 
potential disfigurement if left untreated.
Patients typically present with a slowly progressive skin papule that evolves to 
become an undermined ulcer over months. There is usually minimal pain, and 
112 Management of tuberculosis
an absence of systemic symptoms. A single arm or leg lesion is most common, 
but buttock, abdominal wall, and face or head lesions have all been reported in 
Australia. BU should be considered in cases of unresolving cellulitis or necrotis-
ing skin lesions. Rarely, the disease can present as acute limb swelling and 
oedema with or without the classic ulceration or skin lesion.
7.9.2 Distribution
In Australia, M. ulcerans is distributed in the environment in coastal Victoria in 
the Bellarine and Mornington peninsulas, and the Western Port and Gippsland 
Lakes areas. In northern Australia, active foci are found near Rockhampton and 
in Far North Queensland.
Overseas, M. ulcerans is endemic in sub-Saharan Africa, particularly in West 
Africa where point prevalence studies estimate BU rates in Ghana and Benin are 
similar to local rates of tuberculosis or leprosy. While more than 30 countries 
have reported cases of BU, in the Asia–Pacific region M. ulcerans is endemic in 
parts of Papua New Guinea and Malaysia. Molecular typing suggests that strains 
differ across geographic regions.
Residents of endemic areas are at greatest risk of infection; however, it is thought 
that visitors with only brief environmental contact can become infected.
7.9.3 Diagnosis
Microbiological diagnosis from wound swabs or tissue samples can be made if 
acid-fast bacilli are seen, particularly in a patient who has not travelled abroad. 
Polymerase chain reaction (directed at IS 2404) is highly sensitive and specific if 
sufficient material is obtained for analysis.
Samples should be collected deep to the undermined ulcer edge using standard 
cotton-tipped swabs in either dry or standard non-charcoal transport medium. 
Requests should be made for AFB microscopy, culture and PCR.
7.9.4 Treatment
A combination of surgical and medical therapy is usually required.
●● Surgery is generally recommended to debride necrotic tissue. Small lesions 
may be completely cured by surgery alone. Case series evidence suggests 
that AFBs or granulomas present in resection margins predict treatment 
failure and the need for adjuvant medical therapy.
●● Large lesions may require additional preoperative antibiotics for 2–4 
weeks.
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●● Indications for combination antibiotics include:
– resection margins with AFBs or granulomas present
– large lesions requiring grafting
– complex, recurrent disease
– disease which cannot be complete debrided.
Oral-only regimes include:
Rifampicin 10 mg/kg per day up to 600 mg daily for 3 months
plus either
Clarithromycin 500 mg twice daily for 3 months
or
Ciprofloxacin 500–750 mg twice daily for 3 months
or
Moxifloxacin 400 mg daily for 3 months
7.9.5 Indications for intravenous therapy
WHO recommend oral rifampicin in conjunction with injectable streptomycin 
(interchangeable with amikacin in Australia). Oral therapy alone using two 
agents has been shown to have some success in Australian case series, but in 
animal models, oral-only therapy is less effective at killing M. ulcerans.
Intravenous amikacin (for 4–8 weeks) with oral rifampicin (for 3 months) should 
be considered for:
●● severe or extensive disease
●● when deep structures (bone, tendon, nerves, vessels) are involved
●● large lesions that could not be fully resected
●● major relapses
●● osteomyelitis
●● where trying to minimise surgery (e.g. eye or face lesions)
●● initial therapy of acute oedematous disease.
Amikacin regimen
Amikacin 15 mg/kg (ideal body weight, maximum 1000 mg) intravenously daily on 5–7 days 
each week for 4–8 weeks
114 Management of tuberculosis
●● Trough drug levels and renal, auditory and vestibular function need close 
monitoring in accordance with treatment guidelines described earlier for 
resistant M. tuberculosis (see Chapter 3).
Prolonged follow-up for recurrence after surgery and/or medical therapy is 
advised as late relapses can occur.
7.9.6 Prevention
●● There is no immunity developed from previous BU infection, so re-infec-
tion is possible.
●● There are no public health interventions known to date to remove M. 
ulcerans from the environment.
●● Personal protection including arm and leg covering and insect repellent to 
avoid insect bites is recommended when outdoors in endemic areas.
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8.1 BCG vaccine and its efficacy
BCG (Bacille Calmette-Guérin) vaccine is a suspension of live attenuated M. 
bovis, derived from the strain developed by the Institut Pasteur and first tested in 
humans in 1921. BCG strains differ genetically from the original strain of M. 
bovis and from each other. Compared to M. bovis, all BCG strains lack the RD1 
region, which contains the antigen coding genes ESAT6 and CFP10. Another 
deletion, RD2, occurred at the Institut Pasteur between 1927 and 1931. A third 
deletion, RD14, occurred between 1938 and 1961. Other deletions, duplications 
and polymorphisms vary between strains. These genetic differences enable the 
distinction of infections due to M. bovis from those due to BCG vaccine strains, 
using either culture or PCR. The genetic deletions are also associated with varia-
tions in susceptibility of BCG strains to antimycobacterial drugs and 
antibiotics.
The vaccine was initially administered orally, but intradermal vaccination was 
introduced in 1927, and percutaneous administration in 1939. Oral administra-
tion ceased in 1979. The original vaccine was distributed to a number of labora-
tories worldwide, with subsequent propagation of a number of strains, described 
by the location of their production. The BCG vaccine currently in use in Aus-
tralia is the Connaught strain manufactured by Sanofí Pasteur Ltd.
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BCG is protective against TB and leprosy. There has been much debate on the 
efficacy of BCG vaccine against TB. Since 1975, case-control studies and pro-
spective clinical trials using different BCG strains indicated that vaccine effica-
cies ranged from 0 to 80%. Immunity induced by the same vaccine may vary 
appreciably between populations.
Vaccine-induced immunity differs in degree against different forms of tuberculo-
sis, and in particular it may be more effective against meningitic and miliary 
disease than against pulmonary disease. A meta-analysis found that the average 
protective effect of BCG was 50% against TB infection, 78% against pulmonary 
and disseminated TB, 64% against TB meningitis, and 71% against death from 
TB. That analysis also determined that higher BCG vaccine efficacy rates were not 
associated with the use of particular vaccine strains. Most of the variability in 
results arose from geographic latitude of the study site, with greater efficacy at 
higher latitudes.
The important point is that BCG vaccination does not consistently prevent 
tuberculous infection. It primarily reduces the risk of death from tuberculous 
meningitis and disseminated disease in young children. The duration of 
efficacy wanes over time. Several studies have shown the protective effect to 
last up to 15 years, although it may persist beyond 50 years. Subsequent revac-
cination with BCG has not been shown to confer any additional protection 
against TB.
BCG is the most widely used vaccine in the world. While it is given to most 
children in the developing world, its use in the developed countries is limited to 
selected populations. The major objection to its use is that it makes interpretation 
of TST difficult. There is no correlation between the presence or strength of reac-
tivity to tuberculin and protective effect of BCG.
8.2 Recommendations for BCG vaccination
8.2.1 Australia
In Australia BCG is recommended for:
●● Aboriginal and Torres Strait Islander neonates living in regions of high 
incidence
●● neonates born to parents with leprosy or with a family history of leprosy
●● children under the age of 5 years who will be travelling to live in countries 
of high tuberculosis prevalence for longer than 3 months (countries with 
an annual incidence over 100 per 100 000 population: see <http://who.int/
tb/en>)
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●● embalmers
●● healthcare workers conducting autopsies
●● healthcare workers who may be at high risk of exposure to drug-resistant 
cases of TB.
Victoria
Victorian Department of Health Guidelines also recommend BCG for:
●● children under the age of 5 years who will be travelling to live for more 
than 4–6 weeks in countries of high TB prevalence
●● infants and children under the age of 5 years who live in a household that 
includes immigrants or unscreened visitors who recently arrived from 
countries of high TB prevalence. This group includes infants and young 
children in families that travel frequently to visit or stay in the homes of 
relatives in countries of high TB prevalence.
Additional recommendations
BCG should also be considered for:
●● children and adolescents aged less than 15 years who continue to be 
exposed to an index case with active smear- and/or culture-positive pul-
monary TB, and who cannot be placed on isoniazid therapy
●● children, adolescents and young adults to the age of 25 to 30 years who 
have been exposed to an index case with active MDR-pulmonary TB 
(where the organisms are resistant at least both rifampicin and isoniazid), 
after exclusion of TB infection with TST or IGRA
●● persons aged over 5 years through to young adulthood who are living or 
travelling for extended periods (more than 2–3 months) in countries of 
high TB prevalence.
8.2.2 International recommendations
●● US guidelines recommend BCG for a narrower range of groups than those 
of Australia (children with continued exposure to pulmonary TB, who 
cannot be removed from the infectious contact and cannot be given pri-
mary therapy for latent TB, and healthcare workers working in areas with 
a high prevalence of drug-resistant TB, without effective TB infection 
control procedures).
●● The UK guidelines recommend BCG for a wider range of groups than do 
those of Australia (a wide range of children and adults with risk of social 
or occupational exposure to TB).
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8.3 Contraindications to BCG
8.3.1 Contraindications
BCG is contraindicated for:
●● individuals with TST of greater than 5 mm or positive IGRA at any time 
in the past
●● patients who are immunocompromised by HIV infection, corticosteroids, 
other immunosuppressive drugs, irradiation, or malignancies involving 
bone marrow or lymphoid systems (because of the high risk of dissemi-
nated BCG infection in these individuals)
●● individuals with a high risk of HIV infection where HIV antibody status 
is unknown
●● individuals with any serious illness, including the malnourished
●● individuals with significant fever
●● individuals with generalised skin diseases (e.g. eczema, dermatitis, 
psoriasis)
●● pregnant women and those who may become pregnant soon
●● individuals who have previously had tuberculosis.
8.3.2 Defer vaccination
BCG should be deferred for the following:
●● neonates with birth weight < 2.5  kg or who may be relatively 
malnourished
●● neonates of HIV-infected mothers (until HIV infection has been excluded 
in the infant)
●● children currently on isoniazid therapy for latent TB infection (since iso-
niazid may inactivate the vaccine)
●● recent vaccination (within past 4 weeks) of another live vaccine such as 
measles-mumps-rubella, varicella, or yellow fever (but not oral polio vac-
cine). However, BCG can be given concurrently with another live 
vaccine.
8.4 Practical issues in BCG administration
A TST must be carried out before BCG immunisation except in infants <  6 
months old who may be immunised without a prior test unless exposure to infec-
tious TB has occurred. If exposure to infectious TB has taken place, such infants 
should be tested and considered for preventive therapy rather than BCG.
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BCG should not be given to individuals with a TST reaction ≥ 5 mm.
BCG can be given at the same time as live viral vaccines, measles-mumps-
rubella or yellow fever. If it is not done at that time, it is necessary to wait 4–6 
weeks after these live vaccines before administering BCG, as the immunogenic-
ity of BCG may be impaired if it is given earlier. Oral polio vaccine does not 
affect the immunogenicity of BCG because the oral polio vaccine virus repli-
cates in the intestine to induce local immunity and serum antibodies, and three 
doses are given.
No further immunisation should be given for at least 3 months in the arm used 
for BCG vaccination because of the risk of regional lymphadenitis.
BCG vaccine can be given only by an accredited vaccinator. The names and 
addresses of accredited BCG vaccinators in Victoria can be obtained from the 
Tuberculosis Control Section, Department of Health (telephone 03 9096 5114).
BCG is administered intradermally into the upper arm in the region of the inser-
tion of the deltoid into the humerus. By convention, the left arm is used in order 
to enable subsequent identification of individuals who have received BCG vacci-
nation. The BCG vaccine must not be given subcutaneously.
Protective eye wear should be worn by the person administering the vaccine, the 
patient, and the parent holding the patient (if the patient is a small child requir-
ing restraint). Eye splashes may ulcerate. If an eye splash occurs, wash the eye 
immediately with saline or water and seek expert advice.
Dose: 0.1 mL for children and adults over 12 months old; 0.05 mL for infants under 12 
months of age.
8.5 Expected response following BCG vaccination
The normal local response to BCG vaccination occurs within 2–3 weeks. Indura-
tion with erythema appears, and a small papule (5–6 mm diameter) is usually 
present after 2 weeks. This is followed by a pustule or an ulcer with scab. Local 
reaction is maximum at 4–6 weeks. Tuberculin reactivity appears at 6–10 weeks 
in 95% of BCG vaccine recipients.
In the great majority resolution takes place after 3–4 months leaving a scar of 
4–8 mm, although up to 25% of children may not have a typical scar after vacci-
nation in infancy. In 50,000 individuals vaccinated with BCG, less than 2% had 
an ulcer of 10  mm or more when examined 6–14 weeks after vaccination. In 
15,000 individuals examined up to 6 months later, only 0–0.56% had ulcers larger 
than 10 mm.
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Survival of living BCG in tissues has been demonstrated as long as 517 days after 
inoculation.
8.6 ‘Accelerated response’ and its significance
When tuberculin reactors or those in the pre-allergic phase of TB infection are 
vaccinated a pronounced reaction frequently occurs at the site of vaccination. A 
nodule with induration is formed on the 1st or 2nd days (within 72 hours). Scab 
formation and healing may be completed by 10–15 days. The intensity of the 
reaction, which represents Koch’s phenomenon, varies between individuals and 
vaccine strains.
8.7 Management of local reactions
Local reactions occur in approximately 5% of vaccinated individuals. Abscesses 
at the primary inoculation site occur in about 2.5%, lymphadenitis in about 1%, 
and severe local reactions in about 1.5% of vaccinated individuals. Erythema 
nodosum occurs occasionally. About 1% of individuals require medical attention 
(including surgery) following vaccination. Reactions are more severe when the 
vaccine is injected subcutaneously.
Lymphadenitis may appear early (within 2 months of vaccination) and late 
(between 2 and 8 months following vaccination). Lymphadenitis with ‘softening’ 
(fluctuance with abscess formation) does not usually appear before the 3rd 
month, sometimes as late as 6th or 7th month and exceptionally after 2–3 years. 
Small children are more liable to lymphadenitis with softening than older 
children and adults. If the enlargement is rapid (within 2 months) spontaneous 
drainage is more likely to occur compared to the slowly progressive form. 
Abscesses in lymph nodes do not always coincide with large reactions at the 
inoculation site.
The management of local ulceration and abscess formation at the inoculation site 
is controversial. In the vast majority, follow-up without specific treatment is all 
that is required, and this should be the mainstay of the management in BCG-
related local reactions. Non-suppurative lymph nodes usually improve spontane-
ously, although resolution may take several months.
8.7.1 Treatment modalities
If specific treatment is required, options for medical treatment are:
●● oral erythromycin 500 mg 4 times daily for 3–4 weeks
●● isoniazid
●● isoniazid plus rifampicin.
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Medical treatments may speed the resolution of inoculation site reactions and 
lymphadenitis, but none of these regimens has clearly demonstrable efficacy over 
another, or in preventing progression to local abscess formation.
Options for surgical treatment (which may be combined with medical therapy) 
are:
●● surgical incision and drainage – with or without installation of isoniazid 
into the abscess cavity (50 mg single dose in 0.5 mL solution)
●● surgical drainage and excision of abscess cavity.
8.7.2 General approach
●● Recognise that ulcers may take 2–3 months to heal. Reassure the patient. 
Take culture for secondary invaders (rare), and for BCG if the ulcer is 
long-lasting.
●● Leave the ulcer uncovered and exposed to air. If it is moist, dab the ulcer 
gently with cotton wool soaked in methylated spirit, as often as required, 
to dry the lesion.
●● Use dry dressing over the ulcer if there is a discharge.
●● Patients with large discharging ulcers beyond 2–3 months, especially if 
associated with lymphadenitis, are likely to demand that something be 
done. Oral erythromycin for up to 4 weeks is a reasonable first choice. (No 
work has been done with the newer macrolides, but they can be used.)
●● Non-adherent lymphadenitis will heal spontaneously without treatment. 
For adherent or fistulated lymph nodes the WHO suggests drainage and 
direct instillation of antituberculous drug into the lesion.
●● If the node is very large (greater than 30  mm in diameter or enlarging 
rapidly), total excision is the treatment of choice because the recurrence 
rate after incision and drainage is high, and scarring is often prominent.
●● If the response is an accelerated one (see section 8.6), first exclude pres-
ence of active disease. Then consider the use of isoniazid preventive ther-
apy for M. tuberculosis infection. The exaggerated response itself is not 
expected to respond to isoniazid.
8.8 Other complications of BCG vaccination
Disseminated BCG infection is very rare, but has a case fatality rate of up to 70% 
despite antituberculous therapy. The incidence of fatal disseminated disease is 
estimated at 0.19 to 1.56 per million vaccines, and has occurred almost exclu-
sively in those with severely compromised cellular immunity. Disseminated 
infection may occur decades after the vaccination. One 31-year-old HIV-infected 
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person developed disseminated BCG infection 30 years after BCG vaccination. 
Treatment as for disseminated TB may be successful in some cases, noting that 
BCG (like other strains of M. bovis) is not susceptible to pyrazinamide.
BCG in patients on corticosteroid therapy may result in an excessively large BCG 
lesion with regional adenopathy and failure to develop tuberculin sensitivity. 
Hypertrophic scars occur in an estimated 28–33% of vaccinated persons taking 
corticosteroids, and keloid scars occur in approximately 2–4%.
The incidence of osteitis varies from 0.01 per million in Japan to 300 per million 
in Finland.
8.9 BCG and bladder cancer
Intravesical installation of BCG is used in the adjuvant treatment of intermediate 
and high-risk non-muscle-invasive bladder cancer, to reduce the risk of local 
recurrence and disease progression.
Intravesical installation of BCG suspension leads to a delayed-type hypersensi-
tivity reaction in the bladder wall, but the mechanism by which BCG therapy acts 
against tumour recurrence and progression is not well understood.
Lower urinary tract symptoms such as dysuria, frequency, urgency, haematuria 
and suprapubic pain are common with intravesical BCG therapy but the severity 
of these symptoms does not correlate with efficacy.
Acid-fast bacilli may be visible or detectable by PCR in the bladder wall several 
years after installation of BCG, but viable organisms cannot usually 
be cultured from urine after a week or two. Mycobacteraemia (detected by 
PCR) following intravesical BCG is uncommon in patients without clinical 
side-effects.
8.9.1 Dosage and administration
Intravesical BCG is given according to a standard protocol. The original protocol 
used by Morales et al. consisted of 120 mg of BCG-Pasteur suspended in 50 mL of 
normal saline. The dose was repeated weekly for 6 weeks. The need for a mainte-
nance phase of therapy was subsequently demonstrated by Lamm et al. and the 
Southwest Oncology Group. The optimum dose and frequency of maintenance 
treatment have not yet been established, but a minimum of three cycles (each 
cycle comprising weekly installations for 3 weeks) at 3, 6 and 12 months is cur-
rently thought necessary.
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Induction therapy with intravesical BCG should commence a minimum of 2 
weeks following transurethral resection of bladder tumour, to allow re-epitheli-
alisation of the bladder and reduce the risk of systemic side-effects.
Indications to defer treatment
Intravesical BCG should be deferred in the presence of:
●● traumatic catheterisation (defer 1 week)
●● gross haematuria (defer until urine clears)
●● bacterial urinary tract infection (defer 1 week, until treated)
●● symptomatic cystitis (depending on severity)
●● contracted bladder (defer until resolution of symptoms)
●● local side-effects, i.e. symptomatic granulomatous prostatitis, epididymo-
orchitis (suspend installations until treated)
●● mild or transient fever and malaise (≤ 48 hours)
●● mild allergic reactions (defer until resolution of symptoms).
Indications to discontinue treatment
Intravesical BCG should be permanently discontinued in the presence of:
●● persistent high-grade fever (> 38.5°C for > 48 hours)
●● systemic BCG reaction
●● severe allergic reaction.
8.9.2 Side-effects of intravesical BCG therapy of bladder cancer
Side-effects of intravesical BCG are usually seen during induction therapy and in 
the first 6 months of maintenance therapy.
Cystitis
Cystitis is the most common side-effect, occurring in 80% of patients. It is fre-
quently accompanied by haematuria and is the most common reason for delayed 
installation of therapy. The severity of lower urinary tract symptoms does not 
correlate with the efficacy of BCG therapy against tumour recurrence.
Initial management should include urine culture to exclude bacterial cystitis, 
and symptomatic treatment. If symptoms persist beyond 48 hours, the next 
installation should be postponed. If a bacterial infection is identified, treat 
according to culture and sensitivity testing results. Note that chemical cystitis 
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due to intravesical chemotherapy is also common, in which case antimicrobial 
therapy will be of no benefit.
For subsequent installations, doses of BCG may be reduced and use of peri-
installation antibacterial prophylaxis directed against coliform organisms can be 
considered.
Haematuria
Gross haematuria occurs in up to 90% of patients and frequently occurs with 
cystitis. Management includes culture of urine to exclude bacterial cystitis and 
postponement of intravesical therapy until urine clears. Persistent gross haema-
turia (>  48  h) may warrant further investigation, e.g. cystoscopy to exclude 
tumour recurrence, and treatment, e.g. bladder irrigation. Haematuria is also 
commonly due to intravesical chemotherapy.
Granulomatous prostatitis
Granulomatous prostatitis is common, but only 1–3% of patients have local or 
systemic symptoms. Up to 5% of cases will need treatment. Digital rectal exami-
nation may reveal an indurated prostate. Prostate specific antigen may be elevated. 
Ultrasound may show hypoechoic areas in the transition zone of prostate.
Initial management includes culture of urine to check for bacterial cystitis and/
or prostatitis.
If symptoms are severe or persist beyond 48 hours, specific therapy is indicated, 
using antimycobacterial drugs for 3 months. The suggested initial regimen is:
Rifampicin 10 mg/kg (up to 600 mg) orally, daily
plus
Isoniazid 10 mg/kg (up to 300 mg) orally, daily
Corticosteroids are often used initially, and their dose is tapered once symptoms 
improve. An antibiotic active against coliforms may be added if bacterial infec-
tion cannot be excluded.
Response to treatment may be monitored clinically, with PSA and ultrasound. 
Failure of biochemical and radiological abnormalities to resolve suggests a need 
to exclude prostatic malignancy. Subsequent installations should be postponed 
until treatment is completed and symptoms resolved.
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Epididymo-orchitis
Early epididymo-orchitis is usually bacterial, while later onset suggests mycobac-
terial infection by BCG. Estimates of the frequency of its occurrence range from 
0.2–10% of patients treated with intravesical BCG.
Early management includes urine culture for bacterial pathogens and antibiotic 
therapy directed against coliforms. Lack of response to antibacterial therapy 
suggests a need for treatment directed against BCG. Antimycobacterial therapy 
as for granulomatous prostatitis (in combination with an antibiotic active against 
coliforms if bacterial infection cannot be excluded) is recommended for a period 
of 3 months. Corticosteroids may be used if symptoms are severe or persist.
Severe, persistent symptoms or development of an abscess may require orchidec-
tomy. Further intravesical therapy should be postponed until treatment is com-
pleted and symptoms resolved.
Malaise and fever
If symptoms are mild and short-lived, only symptomatic treatment is needed. If 
high-grade fever (>  38.5°C) and malaise are persistent >  48  h, evaluation for 
systemic BCG infection should be undertaken, and intravesical BCG therapy 
should be permanently discontinued (unless BCG has been excluded as a cause).
Disseminated BCG infection
Disseminated BCG infection is rare but life-threatening granulomatous inflam-
matory process. Diagnosis is often difficult. Onset may be rapid, following instal-
lation of BCG, or may occur many years after completion of therapy. The course 
may be indolent and subacute, or fulminant with septic shock and multi-organ 
failure. Although there are theoretical concerns about the risk of systemic BCG 
infection in immunocompromised patients receiving intravesical BCG therapy, 
the risk of systemic BCG infection has not been shown to be higher for individu-
als with haematological malignancies or those on treatment with low-dose corti-
costeroids. Published experience with other immunocompromised patients is 
limited. Symptoms may be generalised and non-specific, or related to particular 
organs, as are those of other disseminated mycobacterial infections. Infections of 
prosthetic joints have been reported, as have mycotic aneurysms, endophthalmi-
tis, osteomyelitis and lymphadenitis. Diagnosis may be confirmed by identifica-
tion of M. bovis-BCG in blood, urine, bone marrow or other tissues, through 
culture or specific PCR. Often, granulomata are seen on histology of biopsy 
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specimens but acid-fast bacilli cannot be identified. Diagnosis in these cases is 
presumptive.
Management requires treatment with antimycobacterial drugs for 6 months. 
Bone and joint infections may need a longer course of therapy (12 months). The 
suggested regimen is:
Rifampicin 10 mg/kg (up to 600 mg) orally, daily
plus
Isoniazid 10 mg/kg (up to 300 mg) orally, daily
plus
Ethambutol 15 mg/kg (up to 1200 mg) orally, daily
The rationale for addition of ethambutol to HR is discussed in section 8.10. Mox-
ifloxacin 400 mg daily should be used if ethambutol is contraindicated. High-
dose corticosteroids should also be used until symptoms have resolved. 
Intravesical BCG therapy should be discontinued permanently.
Systemic granulomatous disease
Without isolation of M bovis it is difficult to distinguish clinically between a 
systemic BCG infection and a noninfectious granulomatous BCG reaction, 
which also occurs. The distinction may be somewhat artificial. Treatment 
requires both antimycobacterial drugs and systemic corticosteroids, with subse-
quent permanent discontinuation of intravesical BCG therapy.
Noninfectious systemic reactions
A seronegative and culture-negative reactive polyarthritis may occur following 
BCG installation. Joints most commonly affected include knees, ankles and 
wrists, but other joints may be involved. Conjunctivitis or uveitis may occur con-
currently. Fever is common. ESR and CRP are raised. Aspirated joint fluid shows 
inflammatory changes with a predominance of polymorphonuclear cells. Culture 
and PCR for M. bovis-BCG are negative. Treatment with NSAIDs is usually suc-
cessful. If there is no response to NSAID treatment, treatment for disseminated 
BCG infection should be commenced. Intravesical BCG therapy should be per-
manently discontinued.
Allergic reactions
Allergic reactions with skin rash and arthralgia are rare. If symptoms are mild, 
treatment with antihistamines and NSAIDs is sufficient, and intravesical therapy 
BCG vaccination 127
may be continued. If symptoms persist >  48  h, further installations should be 
postponed until clinical resolution of allergic symptoms.
Severe, persistent allergic symptoms may need to be treated as disseminated BCG 
reactions, with antimycobacterial drugs, corticosteroids and cessation of intra-
vesical BCG therapy.
8.9.3 Occupational exposure to BCG infection during intravesical therapy
Healthcare workers are at risk for occupational exposure to BCG during prepara-
tion and installation of BCG suspension. Splashes to the eye can result in ulcera-
tion. Percutaneous exposure may result in localised cutaneous or deep tissue 
infections with M. bovis. A combination of surgical resection and prolonged 
antimycobacterial therapy may be necessary to cure such infections.
8.10 Antimycobacterial drugs and BCG
The susceptibility of BCG to antimycobacterial drugs varies with the strain. All 
strains of BCG, like all strains of M. bovis, are intrinsically resistant to 
pyrazinamide.
A study comparing susceptibility of BCG strains to first- and second-line antitu-
berculous drugs found all were susceptible to rifampicin, rifabutin, ethambutol, 
ciprofloxacin, ofloxacin, streptomycin, amikacin, kanamycin and capreomycin. 
Strains BCG-Connaught (the strain used in Australia) and BCG-Denmark 
showed low-level isoniazid resistance and resistance to ethionamide. The clinical 
significance of low-level isoniazid resistance in BCG strains is unclear. Although 
this form of resistance in M. tuberculosis is not thought to impair the response to 
standard antituberculous therapy, emergence of rifampicin resistance has been 
described in a case of disseminated BCG-Denmark infection in an HIV-infected 
infant treated with a two-drug combination of rifampicin plus isoniazid.
Susceptibility of BCG strains to macrolides is difficult to test, but in vitro evidence 
suggests that strains with a deletion in the RD2 region of the genome (such as 
BCG-Connaught) are susceptible to macrolides, while those that retain this 
region (such as BCG-Japan, BCG-Russia, BCG-Sweden and BCG-Moreau) are 
resistant.
These results suggest that selection of antimycobacterial drugs for BCG infec-
tions will be made easier by the clear documentation of the specific BCG strain 
used for intravesical BCG therapy, and by the isolation, culture and strain-spe-
cific identification of acid-fast bacilli from clinical specimens obtained from 
patients with suspected infectious complications of intravesical BCG therapy.
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In keeping with current urological guidelines, we recommend that localised 
BCG reactions such as granulomatous prostatitis and epididymo-orchitis should 
be treated with a combination of rifampicin and isoniazid. For disseminated 
BCG infections, the larger organism burden may lend more weight to the theo-
retical concern about low-level isoniazid resistance, so addition of ethambutol as 
recommended by the guidelines (or moxifloxacin if ethambutol is contraindi-
cated) to prevent emergence of resistance is reasonable, albeit unproven.
The additional benefit of adding adjunctive corticosteroids to antimycobacterial 
drugs for localised and disseminated BCG infection has not been examined in a 
prospective study, but has a sound theoretical basis and is supported by clinical 
experience.
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